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Abstract
The blood transcriptome in tuberculosis (TB) has been well described, it is distinct
from healthy controls and other diseases, and is being developed as a biomarker for risk
of disease progression, disease severity and treatment response. But TB patients, espe-
cially those from high TB-burden countries, often have comorbidities, so the described
transcriptomic signature may not be an accurate representation of a typical population.
Whether this signature remains constant in different patient phenotypes is an important
question.
The effect of HIV-1 and also type 2 diabetes (T2DM) on the transcriptomic profile
of TB was investigated, using microarray and RNA-seq technology, respectively. Both
comorbidities increase the risk of developing active TB, but the underlying mechanism in
T2DM is unknown. The potentially beneficial effects of the anti-diabetes drug metformin,
on the transcriptome of healthy donors, were also investigated, as existing reports indicate
it could behave as an adjuvant for TB therapy.
The effect on the TB blood transcriptome signature of HIV-1 coinfection was studied
in collaboration with the PanACEA consortium, and T2DM (HbA1c > 6.5) and pre-
diabetes (HbA1c > 5.7 & < 6.5) in the TANDEM consortium. It was found that the
TB treatment response transcriptomic signatures could still be observed with HIV-1
coinfection. Both T2DM and pre-diabetes affected the blood transcriptome: increased
inflammatory profile with down-regulated type I interferon response genes. This could be
indicative of an enhanced immunopathological response in TB/DM and of the important
role of type I interferons in susceptibility to TB. Because patients with pre-diabetes
i
had similar transcriptomes to TB/DM, albeit of lower magnitude, it shows that even at
intermediate levels of hyperglycaemia there is an immune dysfunction. Metformin had an
anti-inflammatory effect in healthy donors in the context of M. tuberculosis stimulation,
indicating its potentially beneficial role in TB/DM treatment.
ii
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1Introduction
1.1 Tuberculosis
1.1.1 A natural history
Tuberculosis (TB) has long anguished humankind, reports in mummies indicate the rela-
tionship has been around for thousands of years, with paleopathological evidence dating
back 8000BCE.1 The bacterium responsible for causing tuberculosis disease, typically in
the lungs, is Mycobacterium tuberculosis, which was discovered by the German bacteri-
ologist Robert Koch in 1882.2 Prior to this, in Ancient Greece, it was known as phthisis
(phthiein = to waste away), first described by Hippocrates, the Greek physician known
as ’the father of medicine’. He described a disease of ’weakness of the lung’, which came
with a fever and a cough and was often fatal. It was hypothesised that it was a hereditary
disease, rather than an infectious one, due to it occurring throughout families.3 It was
first recognised as infectious by Galen of Pergamon, who described symptoms of a ’hectic
fever’, bloody sputum and small hard swelling in the lungs he named phuˆma.
1
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In the 19th century, tuberculosis or consumption as it was known, was responsible for
25% of deaths in Europe. One of the most famous was George Orwell, who succumbed
to TB just after completing 1984, of which a lot of his suffering was reflected in the
protagonist; Winston. In the 20th century however, the death toll started to decline as
living standards and nutrition began to improve. Mortality continued to decrease with the
discovery of the antibiotic streptomycin in the 1940s, and again with the introduction
of the BCG vaccine in the 1980s. Tuberculosis was almost eradicated in the West in
the late 20th century, although continued to decimate the developing world. But now,
tuberculosis has made a comeback worldwide.4
M. tb is primarily a pulmonary pathogen, although it can assert itself all over the body,
causing skeletal, pleural and lymph node tuberculosis amongst others. M. tb spreads
through bacilli-infected air droplets, which are then inhaled into the lungs. The bacilli
can either be eliminated by the host’s immune response, or remain persistent in a latent
state. This latency is where the bacilli have been contained so do not cause disease; it
is asymptomatic and non-infectious. Approximately 10% of individuals latently infected
go on to progress into active, symptomatic tuberculosis disease at some point in their
lives. Of course, the M. tb infection to disease is a dynamic spectrum, but for clinical
simplicity, individuals are characterised as either latent or active. Such clinical symptoms
of active tuberculosis disease include coughing, fatigue, loss of appetite, haemoptysis, and
more classically: weight-loss. Symptoms vary from individual and overlap with other
respiratory diseases like pneumonia, or even lung cancer.5
Comparatively, M. tb is not as infectious as other pathogens, like smallpox or measles.
This is measured by a ’reproductive number’ or R0. It equates to the average number
2
CHAPTER 1. INTRODUCTION
of secondary infectious cases generated when one infectious case is introduced into an
uninfected population. In the case of M. tb, its R0=2. For perspective, measles virus is
R0=12. That being said, the average infectious period of M. tb can be over a year and it
is also frequently fatal. Without proper treatment, 45% of active TB patients die.
1.1.2 A global healthy issue. Again
Due to a multitude of reasons, TB has now become a global health issue. It began
its resurgence in the 1990s, strongly correlating with the acquired immunodeficiency
syndrome (AIDS) epidemic and human immunodeficiency virus (HIV) prevalence. Im-
migration, an ageing population and overcrowding have contributed to its revival. This
revival is evermore dangerous than before because of its acquired drug resistance to the
current antituberculosis therapy, caused by poor health care services and infrastructure,
and poor treatment adherence.
TB is now the leading cause of death from an infectious disease in 2015, overtaking
HIV. The World Health Organisation (WHO) reported that globally in 2015, there were
10.4 million new cases (56% were men, 34% women, 10% children). Only six countries
accounted for 60% of these new cases; India, Indonesia, China, Nigeria, Pakistan and
South Africa, with China and India contributing 45% (Figure 1.1). Within this, almost
half a million cases were multi-drug resistant TB (MDR). Together with this, there were
1.4 million deaths worldwide caused by TB. Although the number of deaths has fallen
since 2000, TB continues to be one of the top ten causes of death worldwide. These new
cases are defined as symptomatic active disease, but the majority of people infected with
M. tb remain latent. Current estimates of global latent infection are at 2-3 billion people.
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As approximately 10% of infected people go on to develop active TB, this means that the
many people with latent TB are acting as a reservoir of potential TB disease. A number
of factors contribute to the activation of disease, including smoking, HIV-1 coinfection,
malnutrition, diabetes mellitus, male gender and age.6
Figure 1.1: Global incidence of TB in 2015. New cases per 100,000 population per year.
Data from WHO.
Progression to active TB can occur from months to years after initial infection, and
can vary considerably depending on the individual. Progression can be effected by a
myriad of factors, with most associated with an immunodeficiency. Immunocompromised
individuals, like transplant patients or cancer patients undergoing chemotherapy are more
susceptible to active TB disease progression. This is also the case with intravenous drug
users and smokers. On the other hand, individuals in prison due to overcrowding, the
homeless, and healthcare workers are at increased risk of infection because of higher
exposure.
Malnutrition is a big risk factor, as it is also coupled with confounding risks, like
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poverty, inequality, poor housing, and inadequate access to health services. This is of
course a problem in low income countries that have high incidence of TB. Another large
risk factor in the progression to active disease are comorbidities, especially HIV-1 coin-
fection. This is one of the most detrimental associated risk factors on the individual level.
An HIV-positive individual is 10 fold more likely to progress to active TB compared to an
HIV-negative individual. As well as HIV-1, other comorbidities increase susceptibility,
for instance, diabetes, kidney disease, and some autoimmune disorders like lupus and
rheumatoid arthritis. These comorbidities, especially diabetes, can end up being a larger
risk factor on the population level. This is because a much higher number of people are
exposed.5
1.1.3 Current actions in TB control
Vaccines
Currently there is only one licensed vaccine available against M. tb; the Bacillus Calmette-
Gue´rin (BCG) vaccine. The BCG vaccine was introduced in 1921, and was heavily
promoted by the WHO which lead to worldwide use during the 1950s. Now, more people
have been vaccinated with BCG than any other vaccine,7 although it has not come
without its controversy, in that its impact on TB control is unclear.
The efficacy of the vaccine against adult pulmonary TB has been questionable. A
meta-analysis revealed that the efficacy of BCG was highly variable, ranging 0-80%, with
lower efficacy the closer one gets to the equator. The reason behind this variability
is unknown, but it has been hypothesised that people in low efficacious regions have
been exposed to environmental non-tuberculosis mycobacteria.8 To further this, a meta-
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analysis of paediatric BCG showed the duration of protection was up to ten years, which
waned over time.9
Another vaccine candidate, the MVA85A vaccine recently underwent its phase II
trial, which was designed to enhance the efficacy of the BCG vaccine in a prime-boosting
strategy. Unfortunately however, the vaccine did not induce protection superior to BCG
on its own.10 There are several other vaccine candidates at various stages of clinical
development, but none are likely to be licensed in the short-term.11
Diagnostics
When a patient enters a clinic with an unexplained persistent cough for two weeks, they
are investigated for TB. Currently, the cornerstone of diagnosis is sputum culture, which
is highly specific; able to differentiate M. tb from other non-tuberculosis mycobacteria
(NTM). The liquid culture method is even more sensitive, which uses the Mycobacterial
Growth Indicator Tube (MGIT) from BACTECTM . The main caveat of culture meth-
ods however is time; it can take a median of four weeks before a result is obtained as
mycobacteria are notoriously slow growing. Another classical method is sputum smear
microscopy using Ziehl-Neelson staining. This technique also has high specificity, but
lower sensitivity than sputum culture (∼50%) because of the need for relatively high
bacilli load to be detected. This presents a problem in HIV-positive patients who tend
to have reduced numbers of bacilli because of the fewer cavitations.12
From microbiological methods, there are also molecular methods to diagnose TB
based on polymerase chain reaction (PCR), including the Gene Xpert MTB/RIF. This
technique is very fast and has high sensitivity and specificity. One of its outstanding
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features is its ability to test for drug resistance to one of the principal first-line antibiotics;
rifampicin. The locus that is responsible for rifampicin resistance; rpoB remains fairly
conserved which means it can be successfully amplified and therefore detected. This is
invaluable in the early detection of hard to treat cases, but comes at a high monetary
cost which is not always feasible in low resource countries.
Contrasting to diagnostics that detect the presence of bacteria, methods exist to
detect changes in the host, the most traditional being chest X-rays. Radiography is
sensitive and has the advantage of detecting latent or asymptomatic TB. Again though,
sensitivity is lower in HIV-positive patients and equipment is expensive. It is also of
lower specificity, and radiologists require substantial training to accurately diagnose TB.
Another class: immunodiagnostics, detect the immune response to the pathogen
rather than the pathogen itself. This includes the tuberculin skin test (TST) and the
inteferon-gamma release assay (IGRA). They are both indicators of infection, not disease.
The IGRA is superior in specificity to the TST in that IGRA measures the presence of
M. tb specific antigens like early secreted antigen-6 (ESAT-6), so there are fewer false
positives in for example BCG-vaccinated individuals.5,13
Treatment
Before the age of antibiotics in the 19th century, TB patients were prescribed rest and
’appropriate’ nutrition, as TB caused significant weight-loss. Sometimes, patients would
be sent to a sanatorium in the countryside for the fresh air. Times quickly changed with
the discovery of the first antibiotic, penicillin by Alexander Fleming in 1928. However,
this was not effective in M. tb because of its non-porous cell wall. Then, Selman Waksman
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discovered streptomycin, which had a different spectrum of activity and was effective
against M. tb,14 resulting in him winning the Nobel Prize in 1952. Drugs currently used
in TB treatment were discovered shortly afterwards; isoniazid in 1952, and rifampicin in
1965.4
The current TB regimen is six months of first-line chemotherapy drugs (Table 1.1).
This is split into two phases; the intensive phase of two months, and then the continua-
tion phase of four months. Bacteria exist in different populations within a tuberculosis
lesion, and therefore have different characteristics like multiplying speed.15 This means
that a combination of drugs which also possess different characteristics is needed for suc-
cessful treatment. For instance, isoniazid is particularly effective against rapidly growing
bacilli. The first two weeks of chemotherapy reduces the bacilli by 90%, and sustained
chemotherapy is required in order to kill the remaining 10%. Failure to do so can lead
to recurrence or drug resistance. The intensive phase comprises four drugs; isoniazid, ri-
fampicin, ethambutol and pyrazinamide, and kills most of the bacilli. Typically, patients
are culture negative after the two month intensive phase, and this phase often determines
the outcome of the regimen. The continuation phase is then the remaining four months
with isoniazid and rifampicin, where the remaining persistent bacilli are killed.5
Antibiotic Mechanism of action
Rifampicin Inhibits bacterial RNA polymerase
Isoniazid Inhibits mycolic acid synthesis
Pyrazinamide Disrupts synthesis of ATP
Ethanbutol Inhibits lipid and cell wall metabolism
Table 1.1: The first-line anti-tuberculosis drugs and their mechanism of action.
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This standard six month regimen has a good success rate, with a recurrence rate
of around 5%. But, problems arise with the regimen, centering around the treatment
duration. With prolonged treatment, patients can develop drug toxicity particularly
in the liver. This can undermine adherence, which in turn leads to treatment failure,
relapse, development of drug resistance and ongoing transmission. Strategies have been
put in place to aid drug treatment and adherence. Directly Observed Therapy-Short
course (DOTS) was put in place by the WHO and involves standardised treatment with
health worker visits to witness administration and provide patient support. It is part of
a wider response including political commitment and sustained financing, case detection
through quality-assured bacteriology, ensuring effective drug supply and management
and implementing monitoring and evaluation systems.
Antibiotics have been, in a way, victims of their own success. As TB incidence fell
in high income countries, the need for new drugs was neglected. There has been a lack
of public and private investment in research and development since the 1970s, reflected
in the lack of any new antibiotics. So, as a solution, other already available drugs are
being optimised. These include traditionally second-line drugs; fluoroquinolones like
moxifloxicin and gatifloxicin. These types of drugs have shown excellent in vitro activity,
but in trials using fluoroquinolone-based treatment for four months have not achieved
similar cure rates as the standard six month regimen.
One of these recent trials; ReMox involved shortening the regimen to four months
and administering moxifloxicin instead of either isoniazid or ethanbutol. The result was
there was an increase in time to culture negativity, but there was no difference in re-
lapse rate compared to the standard six month regimen.16 This showed that the culture
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results at month two were insufficient in predicting TB treatment outcome. Another
fluoroquinolone based trial, OFLOTUB also shortened TB treatment to four months and
administered gatifloxacin instead of ethambutol during the intensive phase of treatment.
They found that there was high variability across different populations and ultimately
were unable to show non-inferiority, with more treatment failures, compared to the stan-
dard six month regimen.17 These results show that being culture negative at two months
does not always lead to sterile cure at the end of treatment, and shows why we need
better ways to predict treatment outcome and relapse-free cure.
Treatment monitoring
Treatment monitoring is important because it provides information that would be used to
make inferences regarding treatment success. Also, if monitoring showed that treatment
was unsuccessful, it would allow for the appropriate alteration of regimen, ultimately
reducing reactivation rates and drug resistance. Treatment monitoring is incredibly valu-
able in clinical trials involving new drugs and regimens, and also vaccine trials. In trials,
drug efficacy is measured by the rate of relapse after two years post treatment. The two
year relapse rate is 5%, so any new compounds need to be non-inferior. Currently the
WHO recommends the two month sputum smear status as an indicator of poor treatment
outcomes, however there is loss of sensitivity and risk of contamination.
Sputum conversion rate lacks precision in reliably predicting the long term clinical
outcome of a regimen. The early bactericidal assay (EBA) is able to evaluate the patient’s
response to anti-tuberculosis medication within the first few days. The EBA is when anti-
TB drugs cause significant reductions in sputum colony forming unit counts (CFUs) in
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the sputum of a TB patient, measured during the first two days of treatment.18 But, even
though CFU is often used to detect bacterial load, it is not always representative of the
total population of M. tb present. Barer et al noted that resuscitation-promoting factors
were able to detect previously undetected viable M. tb cells, which had been invisible
in standard culture demonstrating that there is a presence of non-replicating cells in
sputum.19
A new method of measuring viable M. tb in sputum is the molecular bacterial load
(MBL) assay which detects M. tb 16S rRNA. The culture-free method is incredibly rapid
and accurate in quantifying the bacillary load.20,21 A study comparing three different
treatment monitoring methods; CFU, time to positivity (TTP) and MBL showed that the
MBL assay was able to detect subpopulations of M. tb which were not detected by CFU
or TTP methods.22 It demonstrates that a molecular signatures have many advantageous.
A molecular surrogate end point for TB treatment is much needed; a rapid and reliable
predictor of potential poor treatment outcomes. Such a signature would be used across
human populations and would therefore need to include information from different ethnic
groups, geographical locations and also different comorbidities. Such a test that would
reflect successful and continued cure would be beneficial in the clinical management of
TB patients
1.1.4 Immunology of Tuberculosis
The immune response to M. tb can be complex and involves a medley of immune cells
and responses, summarised in Figure 1.2. Studies have also shown that there is a fine
balance between protection and pathogenesis and M. tb has adapted to persist in its host
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through the construction of a granuloma. The fundamental control of M. tb, as shown
in human and animal studies, involves CD4+ T-cells, IFN-γ and TNF-α. The immune
response to M. tb starts when the bacterium enters the respiratory tract via inhalation,
where it encounters the first-line of defence; alveolar macrophages. The macrophages
are able to internalise the bacterium via receptor mediated phagocytosis. This is done
through Toll-Like Receptors (TLRs), manose receptors (MR), Fcγ receptors (FcγR) and
complement receptors. These receptors behave as Pattern Recognition Receptors (PRRs)
to the mannosylated lipoarabinomannan (ManLAM) present on the bacterial cell surface.
Dendritic cells (DCs) also interact with M. tb in the early stages as an antigen presenting
cell (APC) through Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing
Non-integrin (DC-SIGN) receptors.
12
CHAPTER 1. INTRODUCTION
Figure 1.2: The immune response to M. tb. Following infection with M. tb, lung alveolar
macrophages, neutrophils and DCs become infected, leading to the production of cytokines
and chemokines.M. tb infected DCs migrate to the lung-draining lymph nodes 8-12 days post
infection under the influence of IL-12, which then drive naive T-cells towards Th1 phenotype.
Antigen specific Th1 cells migrate back to the lungs and produce IFN-γ, leading to macrophage
activation and further cytokine production.23
The phagocytosed bacillus is then transported to the lysosome for degradation, but,
M. tb can inhibit the phagosome-lysosome fusion and therefore prevent acidification and
its killing. The infected macrophage can then induce necrosis, allowing the spread of
bacilli, or apoptosis. Virulent strains of M. tb are able to manipulate macrophages and
evade apoptosis. Infected DCs then transport M. tb to the lymph node for T-cell priming.
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The naive T-cells are activated, start to proliferate and become effector cells able to
migrate towards the lung tissue. They are driven towards a Th1 response by IL-12, so are
able to secrete IFN-γ which is central in the killing of M. tb. Primed CD4+ T-cells migrate
to the lung, secreting IFN-γ, IL-2 and TNF-α, leading to macrophage activation. There
becomes an influx of phagocytic cells causing the formation of a granuloma to contain
the bacilli, like a prison. This physical barrier consists of macrophages, neutrophils and
later CD4, CD8 T-cells and B-cells. But, as bacteria replicate, an imbalance can occur,
causing necrosis, caseation and rupture of the granuloma, causing M. tb to leak into the
airway.24
For the maintenance of the granuloma, TNF-α is crucial, the importance of which
is seen in humans and animals. TNF−/− mice and patients on anti-TNF therapy for
rheumatoid arthritis are highly susceptible to M. tb. Those on anti-TNF therapy are at
5 fold higher risk of developing TB.25 Formation of the granuloma does occur in absence
of TNF-α but at a slower rate and with higher bacillary numbers.
The adaptive immune response is also important in the maintenance of the granuloma.
For example, CD4+ T-cell deficient mice are unable to control bacterial growth because
of the absence of IFN-γ. The significance of CD4+ T-cells was witnessed during the
HIV/AIDS epidemic, where patients were severely immunocompromised because of a
depletion of their CD4+ T-cell population.
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1.2 HIV-1
1.2.1 The AIDS epidemic
AIDS was first recognised in 1981, and its cause; HIV was discovered not long afterwards.
The HIV/AIDS epidemic was devastating, and so far 35 million people have died globally
from HIV/AIDS. The world has committed to end the AIDS epidemic by 2030, but still
in 2015, there were 2.1 million new HIV infections worldwide, and 1 million people died
from HIV related diseases in 2016, leaving 36.7 million people living with HIV globally.
There are large disparities across regions and within countries (Figure 1.3), with the
majority of cases in eastern and southern Africa (19.1 million living with HIV).26
Figure 1.3: Global HIV prevalence in 2008. Data from WHO.
There was huge stigma surrounding HIV/AIDS because it is sexually transmitted and
was associated as a ’gay disease’. This prudish mentality only added to the epidemic,
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as there was such little awareness and reluctance in being diagnosed. Attitudes slowly
started to change, and HIV prevention adverts were being shown on the TV and on
posters, an example of which is shown in Figure 1.4. Now, fewer and fewer people are
progressing to AIDS due to the development and rollout of highly active anti-retroviral
therapy (HAART), also known as anti-retroviral therapy (ART).
Figure 1.4: HIV prevention advert
in 1991.
In the absence of treatment, the progression of
AIDS from HIV can take 10 years, but of course
varies considerably. The hallmark of HIV infection
is the progressive depletion of CD4+ T-cells, and
AIDS is defined as a CD4+ count of below 200 cells
per µl. AIDS patients succumb to opportunistic in-
fections, like M. tb, pneumonia and certain cancers.
Upon infection with the virus, 50-90% of individ-
uals develop influenza-like symptoms, and due to
the nonspecific nature, it is often not recognised as
HIV. So, it has been recommended that people in
high-risk groups that present with an unexplained
fever should be tested for HIV.
1.2.2 HIV treatment and diagnosis
Diagnosis of HIV has come along way and now there is a point of care test that takes
minutes, which detects HIV antigens. However, this has comparatively low specificity
and sensitivity, so a PCR is used to confirm results. This detects genomic material; HIV
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RNA and DNA, and also measures viral load. Serological assays are also used, namely
enzyme-linked immunosorbent assays (ELISA) which detect antibodies to the virus.
Currently, there is no cure or vaccine, but ART has enabled HIV-infected individuals
to have a normal quality of life. HIV can remain latent in subpopulation of cells or in
reservoirs which current therapy cannot yet eliminate, so it is possible the HIV infection
will reactivate. At the moment, therapy is based on a functional cure; the suppression of
the virus to sub-clinical levels. ART is becoming a global success, and has reached 46%
global coverage.
There are a few classes of ART drugs; reverse transcriptase inhibitor (RTI) like zi-
dovudine, protease inhibitors (PI) like saquinavir, non-nucleoside reverse transcriptase
inhibitor (NNRTI) like nevirapine and nucleotide reverse transcriptase inhibitors (NtRTs)
like tenofovir. Within each class, there is variability in potency, toxicity and drug-drug
interactions. For example, saquinavir interacts with rifampicin, so its use is limited in
TB patients. Treatment regimens tend to follow triple therapy; two nucleoside RTIs and
one NNRTI. Ongoing work involves optimising combination regimens to minimise side
effects and improve adherence.27
Pre-exposure Prophylaxis (PrEP), commonly known as Truvada, and post exposure
(PEP) prophylaxis are also available. PrEP is taken by those at substantial risk of HIV-
infection and can stop the virus from establishing an infection. PEP involves taking
ART after potentially being exposed to HIV in order to prevent becoming permanently
infected, and is administered daily for 28 days. Although neither of these are 100%
effective, both offer valuable options in the prevention of HIV.28,29
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1.2.3 Immunology of HIV
HIV is transmitted across the genital epithelium, commonly through damage to the said
epithelium, and transferred to mucosal DCs, macrophages and T-cells. HIV enters these
cells through the CCR5 and also the CXCR4 receptors. The DCs then migrate to the
lymph nodes to present the virus to T-cells, initiating the adaptive immune response.
A curious case; the ’Berlin patient’ has been ’cured’ of HIV. He was HIV-infected
and underwent a bone marrow transplant for leukaemia in 2008. The donor had a CCR5
mutation so the receptor was defective, preventing HIV entry into cells. His viral load
has remained below detection limits without ART.30 This case demonstrated the central
role for the CCR5 receptor and the potential for the development of CCR5-targeted
treatment.
During infection, the HIV ssRNA activates the TLR7/8 receptor in DCs, increasing
the production of type I IFNs which impair viral replication and recruit immune cells.
The type I IFN: IFN-α recruits natural killer (NK) cells which are able to recognise
and kill infected cells, however, HIV has evolved mechanisms to dysregulate NK cell
function. As mentioned, HIV-1 depletes CD4+ cells, causing loss of the cellular arm of
the immune response. HIV-1 selectively infects CD4+ cells and causes the cells to lyse
and apoptose. These CD4+ T-cells provide cytokines for proliferation and differentiation
so progressive depletion of CD4+ causes great immune function impairment. The other
arm of the adaptive immune system also generates a response. Antibodies from B-cells
can be detected and used in diagnostics. In vivo, neutralising antibodies are able to limit
viral replication, but HIV quickly mutates to overcome it.31 To add, the conserved regions
of the virus are shielded or hidden from the immune system, so an antibody response is
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not capable of killing the virus.
1.2.4 TB and HIV coinfection
M. tb is the most common opportunistic infection in HIV-positive individuals, and HIV
was partly responsible for the resurgence of TB in the 1990s. TB is the leading killer of
HIV-positive people; in 2015, 35% of HIV deaths were due to TB. In 2015 there were
1.2 million global new TB cases in HIV-positive individuals and 390,000 people died
of HIV-associated TB. HIV is one of the largest risk factors of developing active TB
with HIV-positive patients are 10 times more likely to progress to active TB disease.
Considering an estimated quarter of the worlds population is latently infected with M. tb
and 36.7 million people globally live with HIV, it is a huge amount of potential disease
and also death.6
HIV and M. tb share a biological synergy; cell-mediated immunity, specifically CD4+
T-cells, which are essential in the control of M. tb, and a depletion of this arm of immunity
is the hallmark of HIV infection. This is discussed in more detail in Chapter 2.
1.3 Diabetes Mellitus
1.3.1 A history
Diabetes is a progressive chronic disorder characterised by abnormalities of metabolism.
Its overriding feature is the inability to control glucose appropriately, resulting in a myriad
of problems throughout the body. There are a number of type of diabetes, mainly type
1 (T1DM) and type 2 (T2DM) which differ in causation and pathogenesis.
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Reports of diabetes date back centuries, it was first described in Egypt 1500BC in
reference to ’a medicine to drive away the passing of too much urine’. After which the
hindu physician Sushruta noted a disease of honey urine, echoed in Persia by Avicenna
who detailed an account of diabetes including ’a melting down of flesh and limbs into
urine’.32 Ancient diagnosis for such a thing involved tasting the urine, or seeing if ants
congregated around it. It was not until 81-133AD when a Greek physician Aretaeus
of Cappadocia coined the term diabetes, from the Greek ’to pass through’, describing
the excessive urination in which the condition is associated (the Latin word for sweet;
mellitus was later added). It was in this time that diabetes was thought of as a disease
of the kidney, ’diarrhoea of the urine’, a theory put forward by Galen (AD 129-210),
which remained in Europe throughout the Renaissance. Later discoveries proved the
diabetic urine was caused by sugar33,34 and unravelled the role of the liver and then the
pancreas. The role of the pancreas was notably discovered by Mering and Minkowski
in 1889 when they performed a pancreatectomy in dogs which resulted in a condition
similar to diabetes.
Diabetes had been a relatively uncommon disease before the 20th century and was clas-
sically associated with the wealthy, but changes in lifestyle meant prevalence increased,
as Robert Saunby put it, ’there is no doubt that diabetes must be regarded as one of
the penalties of advanced civilisation’. The first reference of diabetes as an epidemic was
made in the 1920s by Eliot Joslin, one of the most prominent diabetes specialists of the
20th century. He espoused that six people in a row of houses had died from diabetes,
and had the cause of death been cholera, the health authorities would have been round
instantaneously.35
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In the search of a treatment for diabetes, Banting and Best won the Nobel Prize
in Physiology or Medicine for the isolation of insulin in 1921. The results of the use of
insulin in humans were published the next year, with patients experiencing a reduction in
blood glucose and no glycosuria. Finally, after centuries, a treatment for diabetes could
be administered and mass-produced.35 In the decades that followed, hyperbolic headlines
in the mainstream media alluded to a ’cure for diabetes’, and it has become an almost
mundane, manageable condition, but the reality is it remains a pernicious disease.
1.3.2 A disease of the West
T2DM accounts for 90% of the diabetic population, the prevalence of which has been
rising exponentially. The number of people with diabetes had risen from 108 million in
1980 to 422 million in 2014. Current projections estimate 552 million cases by the year
2030.36 The top burden countries are China, India and the United States of America
(Figure 1.5). In addition to this it has been estimated that diabetes directly caused 1.5
million deaths in 2012.37
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Figure 1.5: Estimated total number of adults living with diabetes in 2015. IDF
Diabetes Atlas, 2015.36
This current and projected increase is a result of urbanisation, dietary changes and
a rise in life expectancy. There is a strong genetic predisposition, but over time, hu-
mankind’s lifestyle has become almost unrecognisable, now risk factors for T2DM like
physical inactivity and obesity have become commonplace. The majority of T2DM pa-
tients are overweight (80-90%) and obesity, defined as a body mass index (BMI) > 30, is
strongly correlated with T2DM. Obesity is one of the largest risk factors in developing
T2DM, and in itself has become an epidemic. Cases of obesity have more than doubled
since 1980 and in 2014, 600 million adults globally were classed as obese.38
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1.3.3 Diagnosis and management of diabetes
Although often diabetes patients can be asymptomatic, they present the classical symp-
toms of frequent urination, excessive thirst, weight loss and blurred vision. In clinics,
patients are screened for T2DM if they are over the age of 45, or have two or more
risk factors; physical inactivity, a first-degree relative with diabetes, hypertension, high
cholesterol, obesity or history of cardiovascular disease (CVD).
Current diagnostic tests are random plasma glucose (RPG), glycated haemoglobin
A1c (HbA1c) and fasting plasma glucose (FPG). A RPG reading of ≥ 200mg/dl is
positive for diabetes, and is confirmed using HbA1c (≥ 6.5%), or FPG (≥ 126mg/dl).
RPG is highly variable depending on when the subject last ate, so it not always reliable
which is why subsequent testing is needed. HbA1c is more expensive and slightly less
sensitive than FBG, but is much more convenient as the patient does not need to fast.39
In more detail, HbA1c is a form of a haemoglobin; the oxygen carrying protein in
erythrocytes, that is bound to glucose. It is also referred to as glycated haemoglobin.
Haemoglobin can assess glucose concentration because intracellular erythrocyte glucose
concentrations are in equilibrium with glucose plasma levels. A reaction occurs between
glucose and the amino groups in haemoglobin, forming glycated haemoglobin. This
glycated haemoglobin builds up in erythrocytes, and is able to reflect the average level
of glucose to which the cell has been exposed to over its life time of 120 days. HbA1c is
therefore used as a longer term gauge of blood glucose levels.
Before the pharmaceutical era, management of diabetes was principally diet and exer-
cise, and even starvation therapy. This was effective, but the rising prevalence demanded
more advanced medical treatments. The implementation of pharmacotherapy was in full
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swing in the 1990s. Different therapeutics with different effects are available including
injectable insulin. Also available are biguanides, like metformin, which act on the liver
and enhance the effects of already present insulin, and sulfonylureas, like glibenclamide
which act directly on the pancreas to augment the supply of insulin. Each have pros
and cons, but metformin is the most favoured as it does not induce severe hypogly-
caemia. Commonly, anti-diabetes drugs are administered in combination; insulin and
metformin together lower glucose more effectively, and adverse effects such as weight
gain are avoided.39 It should be noted that pharmaceutical intervention is an adjuvant,
rather than a substitute for dietary modification and exercise.
Still, exercise therapy has remained an effective treatment for the prevention of T2DM
as well as having other benefits. In a clinical trial in the USA, non-diabetic patients who
had elevated fasting plasma glucose were administered either metformin twice daily, a
placebo, or lifestyle modifications (weight-loss goals and physical activity). The follow-up
was over two years, and they found that lifestyle intervention reduced the incidence of
T2DM by 58%, compared to metformin by 31%.40
Complications resulting from uncontrolled T2DM is a major cause of disability, and
even early death. These disease manifestations include kidney disease, blindness and
CVD. T2DM is the leading cause of new cases of blindness in adults, and also increases
the risk of CVD by 3-6 times. Therefore it is imperative diabetes patients receive that
appropriate support and treatment to control their glucose levels.
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Mechanism of glucose control
Glucose control is tightly regulated by two hormones, insulin and glycogen which work
in antagonism of one another. Dysregulation causes severe negative effects on the body,
including death, so regulation is paramount. Diabetes is a chronic disease that is charac-
terised by pancreas either not producing enough insulin or the body not using the insulin
it produces effectively. T1DM has a strong genetic component and is where the insulin-
secreting cells in the pancreas have been destroyed by the immune system, leading to an
absolute deficiency of insulin. On the other hand, T2DM is where inadequate amounts of
insulin are secreted relative to the blood glucose concentration, while the insulin-secreting
cells remain intact.
The insulin-secreting cells are located in the pancreas; an endocrine secreting tissue,
comprised of groups of cells called the Islets of Langerhans. The Islets of Langerhans
contain a number of cell types; primarily α cells which secrete glucagon, and β cells
which secrete insulin. The regulator of these two hormones is the amount of glucose
in the blood. Insulin is a small peptide protein: it is anabolic and stimulates glucose
uptake through plasma membrane receptors into the tissues allowing for glucose to be
metabolised and stored as glycogen and fat.41
When blood glucose levels rise, the glucose transporter GLUT2 transports the glucose
into the β-cells, where it is converted to glucose-6-phosphate by hexokinase IV and en-
ters glycolysis. Because of the increase of glucose catabolism, ATP increases, causing the
closure of ATP-gated K+ channels in the plasma membrane. This causes a reduced eﬄux
of K+, which in turn depolarises the membrane. The closing of these channels increases
the intracellular positive charge and decreases the membrane potential. Membrane depo-
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larisation opens voltage gated Ca2+ channels, resulting in the increase in cytosolic Ca2+
concentration. This increase triggers the release of insulin via exocytosis, summarised in
Figure 1.6. The subsequent reduction in blood glucose levels are detected by the β-cells,
which slows or halts the release of insulin, initiating the feedback regulation.42
Figure 1.6: Glucose regulation of insulin secretion by pancreatic β cells. When blood
glucose levels are high, metabolism in the β cells raises ATP, closing K+ channels in the plasma
membrane, depolarising the membrane. In response to the change in membrane potential,
voltage-gated Ca2+ channels open, causing an influx of Ca2+ into the cytoplasm, which triggers
the release of insulin.42
Diabetes pathogenesis
T2DM is characterised by the failure of the body to respond appropriately to insulin,
coupled with impaired secretion and insensitivity of target cells to insulin. This is known
as insulin resistance and occurs to some extent in all obese individuals and T2DM pa-
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tients. It is where there is a decrease in the ability of insulin to alter the metabolism in
target tissues. This occurs when there is an oversupply of nutrients relative to energy ex-
penditure, so more insulin is secreted to compensate. The pancreas has to continuously
secrete more insulin. In time, the β-cells become exhausted from the continual extra
insulin secretion needed, and start failing to secrete sufficient insulin to obtain normal
blood glucose levels leading to impaired glucose tolerance and uptake in skeletal muscle.39
Chronic exposure to high glucose concentration is toxic and raises reactive oxygen
species (ROS) levels. The pancreatic β-cells have low levels of anti-oxidative enzymes
so are vulnerable to oxidative stress, therefore constantly elevated glucose levels leads to
β-cell failure and loss via apoptosis.43 The progressive β-cell death contributes further
to a decrease in adequate insulin secretion.
Overabundance of free fatty acids (FFAs) also majorly contribute to adverse metabolic
effects such as insulin resistance. An increase in FFAs is tightly linked with obesity, where
there is an excessive growth of adipose tissue. FFAs add to insulin resistance by impairing
glucose uptake in muscle because of competitive inhibition and also reduces the inhibition
of glycogenolysis. With elevated adipose tissue mass, higher levels of FFAs can leave the
adipose cell and enter the circulation to be taken up by other organs like the liver and
skeletal muscle.
1.3.4 Diabetes as an inflammatory syndrome
T2DM has been linked to inflammation for some time; back in the late 1800s it was
found certain non steroidal anti-inflammatory drugs (NSAIDS), salicylates and aspirin
improved hyperglycaemia in diabetes patients.44 This was again noted in the 1950s, when
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a diabetic patient was administered high dose aspirin to treat their arthritis, and they no
longer required daily insulin infections.45 Fifty years later, it was found that salicylates’
molecular target was to inhibit the phosphorylation action of the IκB kinase (IKK) com-
plex, a central regulator of NFκB activation.46 However, even though anti-inflammatories
exhibited desirable effects like increased insulin sensitivity and reduced HbA1c values, the
focus of medications was targeted on insulin secretion rather than any anti-inflammatory
properties, so did not gain momentum.
T2DM has now been described as an immune dysfunction disorder, with patients
displaying persistent low grade inflammation. This is down to the relationship between
T2DM and obesity. In obesity, there is increased adiposity, and adipocytes are an en-
docrine organ which secrete fatty acids, hormones, cytokines and chemokines (Figure
1.7). Several cytokines, namely TNF-α, IL-6 and IL-1β are secreted by adipocytes. This
was first noted in a study by Hotamisligil et al, where TNF-αmRNA was found in adipose
tissue from rodent models of obesity and diabetes. Then, when TNF-α was neutralised
in the obese rodents, there was an increase in the peripheral uptake of glucose in response
to insulin.47 In a separate study, TNF-α−/− mice were resistant to the development of
insulin-resistance in diet-induced obesity.48 TNF-α seems to play a role in inflammation-
induced insulin resistance and demonstrates how inflammation and insulin resistance are
connected.
Dysfunction of some components of the immune system in T2DM has been illus-
trated, including altered concentrations of cytokines and chemokines, and changes in
absolute number of immune cell subsets. For instance, not only TNF-α, but other pro-
inflammatory cytokines are reported to be elevated in obese subjects; serum IL-6 has been
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reported to be higher in T2DM patients than in healthy controls, and also positively cor-
related with HbA1c levels.49 Also, IL-6 expression is elevated 10-fold in the adipose tissue
of obese individuals than in lean individuals.50–52 These pro-inflammatory cytokines in
turn recruit macrophages, which are present in higher numbers in the adipose tissue of
obese individuals.53 Together, this causes a feedforward process; activation of NFκB and
the chronic activation of pro-inflammatory pathways within insulin target cells, leading
to further insulin resistance. With the association of obesity and T2DM, inflammation
and insulin resistance, this shows the tie between inflammation and metabolism.
Figure 1.7: Inflammation development in type 2 diabetes. Excessive levels of glucose
and FFAs stress the pancreatic islets and insulin-sensitive tissues like adipose tissue. This leads
to the production and release of pro-inflammatory cytokines and chemokines resulting in the
recruitment of immune system cells and inflammation.54
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It is also possible for FFAs to trigger inflammation, through the stimulation of TLR
signalling, Figure 1.8. A hypothesis for this is that FFAs behave as a ligand for TLRs due
to their structural similarity with bacterial cell wall lipopolysaccharides (LPS).55 Stim-
ulation of TLR4 by FFAs for example leads to the activation of NFκB and downstream
production of pro-inflammatory cytokines.56,57 This mechanism further contributes to the
subclinical inflammation displayed in T2DM patients.
Figure 1.8: Inflammation induction by glucose and FFAs in islets of patients with
type 2 diabetes. High concentrations of glucose promote the secretion of pro-inflammatory
cytokines through NF-κB. FFAs can also directly induce activation of TLR2 or TLR4, also
activating NF-κB and enhancing inflammation.54
Bearing in mind that T2DM is an inflammatory syndrome, it is possible that fu-
ture therapies for diabetes would target inflammation. A proof-of-concept trial entitled
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Targeting INflammation Using SALsalate in T2DM (TINSAL-T2DM) recently investi-
gated the effect of administering anti-inflammatories on glycaemia in T2DM patients.
They found that the salsalate group had reduced HbA1c compared to the placebo group
demonstrating that modulating inflammatory pathways is a possible therapy for T2DM
patients.58
1.3.5 TB and diabetes
A link between TB and diabetes was first noted centuries ago, but the comorbidity did not
come into the spotlight. Diabetes represents a risk factor for active TB progression, and
also for poor treatment outcomes. T2DM patients are 3.1 times more likely to develop
active TB than non-diabetic individuals.59 Considering the vast growing number of cases
of T2DM globally, it serves as a potential reservoir for active disease. T2DM has been
described as a chronic inflammatory metabolic syndrome, but the exact mechanism of
how T2DM causes elevated TB susceptibility is unclear. TB/DM is discussed in more
detail in Chapters 4 and 5.
1.4 Transcriptomics
The transcriptome is the complete set and quantity of gene RNA transcripts present
in a cell. Analysing the transcriptome can determine and quantify the amount of gene
activity in for example a certain cell type, developmental stage or physiological condition.
Analysis of the transcriptome has become a decisive tool in the characterisation and
understanding of the molecular basis in biological variation. What is key however, is
that it shows the relative abundance of the transcripts between two physiological states.
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It is used heavily in investigating the gene expression changes in diseases, for example, it
is able to quantify the immune response to a disease.
Large scale gene expression studies first started in the 1990s when the microarray
was invented, prior to which, gene expression analysis was investigated using RT-PCR
on an individual gene basis. Microarrays are able to measure over 40,000 mRNA tran-
scripts at the same time, in an unbiased approach. Over the years it has become a very
popular, robust and informative method, which has seen the biological advancement of
many investigations between disease and health, or pharmaceutical effects. Microarray
technology is based on hybridisation of a sample onto a chip with pre-existing probes,
which is discussed in more detail in the following chapter.
Microarrays have been widely used, but recently RNA-sequencing (RNA-seq) has
become an attractive alternative and is slowly replacing them. In RNA-seq, an RNA
sample is enriched for mRNA (or depleted for rRNA) and fragmented. The fragments
are converted to a library of cDNA, with adapters attached to either end. The inserts are
also tagged with a barcode and sequenced in a high throughput manner. This produces
millions of short reads (30-400bp) which can then be mapped to a reference genome, or,
with a method called de novo assembly, where reads can be overlapped into sections of
sequence without the aid of a reference. Once the alignment is complete, the number of
reads mapped within a genomic feature are counted. The number of reads mapped to a
gene is used as the measure of its abundance in that sample.60,61 Transcript abundance
can then be compared in samples from different conditions in order to show the differences
in expression levels.
There are several advantages of RNA-seq over microarray. Firstly, RNA-seq has
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a larger dynamic range with less background noise, so it can detect lower abundance
transcripts.62 Because there is more background noise in microarrays, which is then sub-
tracted, genes expressed at low levels are lost. Studies have compared the two tech-
nologies, and it has been found that RNA-seq is more accurate at calculating absolute
transcript abundance.63,64
Limitations in RNA-seq do exist. The analysis and normalisation is more complex
as there tends to be more variation within and between samples, specifically in library
size and transcript length. Length of transcripts differ greatly, so longer genes have a
higher total number of mapped reads than a short transcript which needs to be taken into
account. Complex algorithms have been and continue to be develop in order to tackle
these issues, but there is still no gold standard.
1.4.1 Transcriptomics in TB
RNA expression analysis by microarray, and now by RNA-seq has become a powerful tool
for understanding disease biology, namely in cancer, but now also in infectious disease
including TB. Now there is a plethora of literature on transcriptomics in TB. The first
studies showing TB was detectable in blood were in 2007, where it was found that pa-
tients with TB were distinct from healthy controls and latently infected individuals,65,66
paving the way to a possible blood biomarker. A principal study followed in 2010 by
Berry et al used a much larger cohort with more detailed characterisation. Using mi-
croarray technology, a 393-gene active tuberculosis signature was found, relative to latent
tuberculosis infected individuals and healthy controls. This signature was strongly asso-
ciated with interferons, of which the magnitude correlated with radiographs and disease
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severity. The active TB signature cleared throughout anti-tuberculosis treatment, dimin-
ishing after six months which allowed the construction of a ’molecular distance to health’,
quantifying the response to treatment. To add, it was also reproducible in two different
populations; South Africa and the UK, and further analysis showed the TB signature
was distinct from other inflammatory diseases (sarcoidosis).67 This TB-specific distinct
signature has been shown in several other studies, Table 1.2. Not only does it divulge
important information regarding biological mechanisms, but a biosignature could behave
as a much-needed diagnostic.
Further on from this, Cliff et al conducted a longitudinal study to investigate the
changes in the transcriptome throughout anti-tuberculosis treatment. Within the first
week of therapy, there was large-scale down-regulation in the transcriptomic profile, and
moderate changes later in treatment.68 Another independent study confirmed these find-
ings with strikingly similar results, despite samples being collected from different popu-
lations and the use of different technology platforms. It does indeed seem that the signal
is treatment related, hinting at a possible method for monitoring treatment and clinical
management and potentially the efficacy of new anti-TB drugs.
Previous RNA expression studies have excluded HIV co-infected patients, which is
not ideal as it does not accurately represent a typical TB endemic population. In order
for a biosignature to be useful, it must be applicable across populations, other ethnic
groups and different geographical regions. To address this, Kaforou et al performed a
study involving a large cohort of TB patients with other diseases, including HIV coin-
fection. They also mixed different populations as they wanted to create a signature that
was as inclusive as possible. They found that the signature developed was significantly
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more powerful at discriminating active TB from healthy controls if all the TB patients
(with and without other diseases) from different populations were combined than if they
were analysed separately.69
Reference Year Population Study design Sample Findings
Mistry et al66 2007 South Africa TB versus
LTBI
Whole blood 22 gene pat-
tern
Jacobsen et al65 2007 Germany TB versus
LTBI
PBMC Fcγ-receptor
signalling
Berry et al67 2010 UK and
South Africa
TB versus
LTBI, HC,
OD
Whole blood IFN signalling
Maertzdorf et al70 2011 The Gambia TB versus
LTBI, HC
Whole blood JAK/STAT,
IFN signalling
Maertzdorf et al71 2011 South Africa TB versus
LTBI, HC
Whole blood -
Bloom et al72 2012 South Africa TB treatment Whole blood -
Ottenhoff et al73 2012 Indonesia TB versus
HC, TB
treatment
PBMC IFN signalling
Kafarou et al69 2013 South Africa,
Malawi
TB versus
LTBI, OD
(HIV+/-)
Whole blood -
Bloom et al74 2013 UK TB versus
OD, TB
treatment
Whole blood IFN signalling
Cliff et al68 2013 South Africa TB treatment Whole blood Complement
Anderson et al75 2014 South Africa,
Malawi,
Kenya
TB versus
OD, LTBI
Whole blood -
Table 1.2: TB transcriptomic studies and their findings. Eleven different studies investi-
gated TB blood transcriptomes, varying in population, study design and sample type. Latent
TB (LTBI), other diseases (OD), or healthy controls (HC).
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A more recent study demonstrated that a correlate of risk signature, likely an early
indicator of active tuberculosis, could be predicted 18 months prior to clinical diagno-
sis, by blood transcriptomics. This was pivotal because patients at risk of progressing
into active disease potentially can be predicted, permitting the possibility of interven-
tion. Healthy latently-infected adolescents were recruited in South Africa. During the
two year follow up, patients who developed active tuberculosis disease were classified
as progressors. Using RNA-seq technology, a 16-gene signature was developed, differ-
entiating progressors from matched controls. The predictive signature achieved 71.2%
sensitivity in detecting tuberculosis 0-180 days before diagnosis. The expression of the
genes in progressor samples increased as tuberculosis diagnosis approached, relative to
matched controls. The signature was validated in household contacts of smear positive
TB patients recruited in the Gambia and South Africa. Potentially, once validated in
additional propective clinical trials, such as the Cortis trial, clinicians will be able to
target preventative therapies to at-risk individuals identified by a blood test.76
So far, transcriptomic studies have involved quite simple populations; South Africa
has been heavily studied. As mentioned, for a signature to be effective, it needs to be
more inclusive. So, more complex situations need to be investigated to include different
comorbidities and different populations.
1.4.2 Transcriptomics in diabetes
In comparison, blood transcriptomic studies in T2DM are few whereas more studies have
been conducted with tissues such as muscle. A blood-based study in Brazil by Manoel-
caetano et al measured the gene expression in PBMCs of T2DM patients, and found that
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T2DM had a distinct profile from non-diabetic subjects. In more detail, T2DM exhibited
up-regulation of genes involved in inflammation, responses to hypoxia, oxidative stress
and fatty acid processing compared to non-diabetic controls. Gene ontology analysis
confirmed that the most significantly differentially expressed genes were involved in the
immune response and fatty acid metabolic processing.77
To add, Grayson et al compared the peripheral blood gene expression profiles of pa-
tients with metabolic syndrome, coronary artery disease and T2DM. They also found that
the gene expression profile of T2DM was distinct from healthy controls, with many signifi-
cantly differentially expressed genes involved in the activation of T-cell signalling.78 These
results complement the hypothesis that T2DM is indeed a chronic pro-inflammatory dis-
order and start to uncover the molecular mechanisms of T2DM pathogenesis and potential
susceptibility. Transcriptomics in TB/DM comorbidity patients had not yet been per-
formed until very recently by Prada-Medina et alPrada˙sytems˙2017 where they found that
the blood transcriptome did not distinguish TB/DM from non-diabetic TB patients and
noted more quantitative differences rather than qualitative.
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1.5 Aims and Objectives
Aims
I To investigate the effect of comorbidities on the TB blood transcriptome
and its resolution through TB treatment
II Investigate the potential for metformin to be used as host-directed ther-
apy
Objectives
I To investigate the effect of HIV coinfection on TB gene expression before
and during treatment, using microarrays
II To examine the effect of diabetes on TB gene expression before and
during treatment, using RNA-seq technology
III To investigate the potential mechanisms of action of metformin in re-
sponse to Mycobacterium tuberculosis using RNA-seq
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2Transcriptomic changes through TB treatment in HIV
patients
2.1 Introduction
2.1.1 TB and HIV coinfection
TB has become such a global health issue, it was listed as one of the top ten causes of
death worldwide, and caused more deaths than HIV/AIDS in 2015. It was estimated
there were 1.4 million deaths from TB across the globe in 2015. Amongst them, 0.39
million deaths were among HIV-positive people. This coinfection has gained track from
both diseases sharing an overlap of high incidence countries, particularly sub-saharan
Africa, Figure 2.1. TB/HIV together has presented such a problem, so much so that 12%
(1.2 million) of new TB cases (9.6 million) and 25% of TB deaths in 2014 were among
HIV-infected patients. TB is the most common opportunistic infection associated with
HIV, and remains a leading cause of death among people with AIDS.6
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Figure 2.1: Prevalence of HIV in new TB cases. WHO Global TB report (2015).
Ever since the beginning of the AIDS epidemic in the 1980 and 1990s, the link between
TB and HIV has played a substantial role in the resurgence of TB, and has contributed
to the spread and pathogenesis of both diseases. Not only are HIV-infected patients more
vulnerable in progressing to active TB disease with an increased relapse rate, but TB
also accelerates the progression to AIDS.
HIV-1 is a potent risk factor of active TB disease; in general, people latently infected
with M. tb have a 10% life-long chance of progressing to active TB disease, but this
increases dramatically when patients are co-infected with HIV-1 to 10% per year. This
increased risk is down to the biological synergy between HIV-1 and M. tb, in which both
infections potentiate each other to deteriorate the immune function. This synergy can be
attributed to CD4+ T-cells, which were proven to play an integral role. HIV-1 infection
causes CD4+ lymphocytes to progressively decline in number and function, which are
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crucial in the containment of M. tb.79,80 So, HIV-1 infection can dramatically increase
the rate of active TB disease. ART works at dampening HIV replication and restores
CD4+ T-cell counts.81 However, even HIV patients who retain normal CD4+ T-cell levels
are still five times more likely to develop active TB than HIV-uninfected individuals.82
All in all, the coinfection is a huge problem in the control of both diseases.
2.1.2 TB and HIV Immunology
HIV first comes into contact with macrophages at the mucosal surface. It enters the cell
using the CCR5 or CXCR4 receptor. Recent studies have shown that HIV is able to
disrupt aspects of the innate response. For example, HIV causes a dysfunction in the
macrophage responses; studies have shown that it reduces the viability of macrophages
and causes impaired levels of TNF-α.83
There is evidence that HIV and TB potentiate each other. HIV infection of macrophages
increases M. tb growth. In turn, the TB induced pro-inflammatory response, including
TNFα, IL-1β and IL-6 and decrease in IL-10, then drives HIV replication.84
HIV also causes the loss of the cellular arm of the adaptive response. As discussed,
HIV primarily infects CD4+ T-cells, and replicates, causing accelerating apoptosis and
viral-mediated cell lysis. This progressive CD4+ depletion restricts Th1 responses, which
produce IFN-γ, IL-2 and TNF-α; key cytokines in the control of M. tb. This has been
shown in in vitro studies where T-cell responses to M. tb in HIV-infected cells are signif-
icantly lower as well as a reduction in IFN-γ production.85
M. tb granulomas formed in HIV-positive individuals differ in their architecture com-
pared to in HIV-negative individuals. There are fewer immune cells and defective for-
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mation of the granuloma, Figure 2.2. This is particularly the case for CD4 T-cells; the
lower the CD4 count, the fewer pulmonary cavities and poorer granuloma formation and
containment. This inevitably results in an increase in dissemination of M. tb. This is
why HIV causes reactivation of latent M. tb and faster progression to active TB disease.
Conversely, HIV-positive patients are less likely to transmit M. tb because fewer bacilli
are able to replicate extracellularly inside granulomas prior to rupture and release via
aerosol through coughing.
Figure 2.2: The effect of HIV on M. tb granuloma formation. How HIV-induced CD4 T-
cell depletion impairs the immune control of M. tb infection. In HIV-positive individuals there
are reduced numbers of CD4 T-cells in the lungs at the air-tissue interface. Reduced numbers
result in defective granuloma formation ultimately leading to dissemination of the bacilli.85
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2.1.3 Diagnosis and treatment of TB/HIV
Diagnosis of active TB in HIV-1 co-infected patients can be a challenge. This is because
in HIV-infected patients, there tends to be a lower concentration of M. tb in sputum
due to the fewer cavity formations. The GeneXpert is a valuable diagnostic tool as
it demonstrates high sensitivity whilst also can detect rifampicin resistance. In some
countries, like South Africa, it is replacing sputum smear microscopy as the first assay
in diagnosing TB. The Xpert MTB/RIF was endorsed by the WHO in 2010, although it
is still expensive. However, in HIV co-infected patients, the GeneXpert MTB/RIF had
significantly lower sensitivity than HIV-negative TB patients.5 Diagnosis of TB in HIV-
infected individuals is difficult as the HIV immunosuppression reduces T-cell responses,
which causes false negative TST and IGRA results.
A relatively new test for M .tb that uses urine detects lipopolysaccharide liboarabino-
mannan (LAM) on the cell wall of M. tb has proven effective (66.7%) in HIV co-infected
patients with advanced immunosuppression i.e. CD4+ count of < 50/µL. The TB-LAM
is able to act as a rapid-diagnostic for those most at risk of mortality for TB disease so
it is very much useful tool. However, new and better diagnostics are needed, which is
where a biomarker could have much potential.86
Treatment of TB/HIV coinfection can be complex, due to the potential drug interac-
tions between ART and anti-tuberculosis medication. The current treatment regimen for
TB/HIV patients is the same as for HIV-uninfected patients: the standard six months
of combination antibiotics. ART restores the immune depletion caused by the virus, re-
ducing the progression into AIDS, and it also drastically reduces the incidence of active
TB in HIV-positive patients.87 However, there has been little research on treatment out-
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comes, and rates of TB among HIV-positive patients remain very high even when they
are on ART.
Treatment with ART in TB/HIV patients can develop into a serious condition; im-
mune reconstitution inflammatory syndrome (IRIS). This is when the immune system
starts to recover, and there is a rapidly normalising CD4+ T-cell poopulation, which can
lead to an overwhelming inflammatory response which is ultimately detrimental to the
host. It occurs in 10-40% of HIV-positive patients and can be life threatening.
A number of randomised control trials have investigated different therapy regimens for
TB/HIV patients. One involved administering 12 months of standard anti-tuberculosis
therapy to HIV-1 co-infected individuals, and found patients had lower relapse rates than
patients who were administered the standard six months of treatment.88 Another involved
administering HIV-1 patients isoniazid prophylaxis for one year after the standard TB
treatment, which also found a slight reduction in relapse or reinfection.89 A meta-analysis
summarising several studies found similar results; an increase in treatment length slightly
reduced relapse rate, and also patients were three times more likely to fail treatment if
they were not on ART. They recommended at least 8 months of therapy, daily dosing
and concurrent ART, as these were associated with better outcomes, but a randomised
trial would need to confirm this.90
2.1.4 Microarrays in TB
Microarray analysis can be used to monitor genome wide expression levels of many genes
under a particular condition. Microarrays work using a probe based method. Thousands
of probes are bound to a chip, and are used to measure the relative concentration of
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specific DNA sequences in a solution. These probes represent the genes in a genome,
so one can analyse the ’genome wide’ expression, of known genes, however. In gene
expression studies, the RNA is extracted from a sample of interest, and fluorescently
labelled. The probes hybridise to the labelled nucleic acids in the mixture, and can
therefore quantify the relative nucleic acid sequences. The fluorescence at each probe
spot is detected by a laser and the fluorescence intensity directly corresponds to the
measure of expression of the probe associated gene.5
Microarrays have been used extensively in cancer research, but now also in infectious
diseases research. So far, a number of microarray experiments have been done on patients
with uncomplicated TB, and have shown their expression profile is distinct compared to
the profiles of latently infected patients, other inflammatory diseases and also healthy
controls.67 However, TB patients co-infected with HIV-1 have mostly been excluded from
such studies.
Kaforou et al characterised blood transcriptome signatures in active TB disease in
both HIV-positive and HIV-negative individuals. This was a large microarray study with
mixed populations and coinfection status. When HIV-positive patients were included in
the analysis, the biosignature generated was more powerful than without them. Including
coinfection patients in such studies is important as it is a more realistic representation
of a typical high TB burden population, like in sub-saharan Africa, where the TB/HIV
burden is the greatest.69
Longitudinal studies have shown that in non-complicated TB patients, rapid large-
scale changes are seen in blood gene expression in the initial stages of treatment, specif-
ically within one week.68 Such changes could act as a marker for drug efficacy as it may
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correlate with rate of relapse.91 Again though, these longitudinal studies have excluded
HIV-1 co-infected patients. So, if these early changes also occur in patients with HIV-
1 coinfection, biomarkers could be developed for populations with a high prevalence of
HIV-associated TB, facilitating drug development and clinical management.
This study was conducted in collaboration with the Pan-Africa Consortium for the
Evaluation of Antituberculosis Antibiotics (PanACEA consortium). To add context, re-
cent publications using the same cohort were investigating the molecular bacterial load
assay as an early bactericidal.21 Much work, including previously in our group has been
conducted in a specific location or ethnic group in Cape Town, South Africa, so this
project gave us the opportunity to not only determine whether our results were repro-
ducible in HIV-positive patients, but also in a different geographical location, ethnicity
and different prevalence of M. tb strains.
I hypothesised that coinfection does not confound TB induced blood transcriptomes
before and during treatment, enabling coinfected patients to be combined with TB-only
patients in treatment-response based biomarkers. A transcriptomic signature generated
from TB patients would be effective when analysing HIV/TB patient data.
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2.2 Aims and Objectives
Aims
I To investigate whether peripheral blood transcriptomic changes are de-
tectable during TB treatment in HIV coinfected patients.
Objectives
I Perform microarray analysis on whole blood samples from active TB
patients with and without HIV-1 coinfection.
II Compare the early and late transcriptomic changes in HIV-negative and
HIV-positive patients.
III Compare the transcriptomic changes in the early and late phases of TB
treatment.
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2.3 Methods
2.3.1 Sample processing
Twenty five pulmonary tuberculosis patients were recruited from primary care clinics
in Mbeya (NIMR-MMRP in Mbeya Referral Hospital), Tanzania in affiliation with the
PanACEA consortium. The study design was originally 20 HIV-positive TB patients and
20 HIV-negative TB patients, but problems arose with the shipment of the samples.
Patients were sputum smear positive for acid fast bacilli pulmonary TB, 18-65 years
old, and weighed 31-90kg. Patient exclusions were: diabetics, pregnant women and
other serious lung conditions. All patients received standard TB treatment from day
one onwards, with daily doses adjusted to weight range, following the guidelines of the
Tanzanian National TB and Leprosy Programme (NTLP). Of these 25 patients, 15 were
HIV-negative and 10 were HIV-positive. HIV-positive patients were all on HAART.
Three millilitres of venous blood were collected at TB diagnosis, and at three time
points after the initiation of TB treatment; week two, week four and week eight. The
blood was collected into Tempus Blood RNA Tubes (Applied Biosystems) and frozen at
−80◦C and shipped to the London School of Hygiene & Tropical Medicine.
Total RNA was extracted using the TempusTM mRNA kit (Ambion). Samples were
DNase treated and the globin transcripts were depleted using AmbionTM GlobinClear kit
(Life technologies), and RNA quantification wad performed using the Nanodrop. Fifty
nanograms of RNA was fluorescently labelled with Cy3 (Cyanine 3-CTP) or Cy5 (Cyanine
5-CTP) using the Two-Colour Low input Quick Amp Labelling Kit (Agilent). Sample
labelling followed a direct design, and were alternatively labelled between diagnosis and
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week 2, and week 4 and week 8. Often, microarray experiments involve a common
reference design, however, a direct design is one in which there is no single RNA source
which is hybridised to every array, but rather dye swaps between two conditions. This
design was chosen to detect the early and late responses in TB treatment, and it as seen
that the very early changes in anti-tuberculosis therapy are the most profound. cRNA was
hybridisated onto the SurePrint G3 Human Gene Expression 60K, Two-colour Microarray
Based Gene expression analysis Genechip (Aglient), and Genechips were scanned using
the SureScan Microarray Scanner at University College London.
2.3.2 Data processing and analysis
The Agilent Scanner creates a TIFF image. To extract the data, Agilent provides a
software for feature extraction, where it subtracts each feature from the background. Data
were then processed and analysed using the R (R v3.4.1 and RStudio v1.0.143) package
limma (linear models for microarray and RNA-seq data) (v3.28.21) and normalised using
the ’loess’ method. limma is a widely used package in microarray analysis; it fits a linear
model to the expression data for each transcript, and is capable of analysing multifactorial
experiments.92
Firstly, a two colour direct analysis was done, and then a separate channel analysis was
performed. The direct analysis was done because of the way the samples were labelled in
two pairs, and is the traditional and most commonly used method. The analysis directly
compared diagnosis with week 2 (early) and week 4 with week 8 (late). This was to
investigate the early and late transcriptomic changes until two months of TB treatment.
A contrast matrix was then constructed which enables one to extract results for the
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second variable; HIV status. Fold change estimates were then estimated for each level
in the factorial design; early changes in HIV-negative, early changes in HIV-positive,
late changes in HIV-negative and finally late changes in HIV-positive. Extracting these
showed the effect of HIV-1 coinfection on the early and late transcriptomic changes seen
in the first two months of TB treatment.
The second analysis was a separate channel analysis. This method analyses the indi-
vidual channel intensities as separate observations, instead of the log ratio. This method
allows one to compare conditions that are not connected in a two-colour experimental
design. For instance, loop designs, and designs that use a reference are connected, but
direct designs are not always. In this particular experimental design, it was unconnected,
with samples from early and late time points unlinked by hybridisation to the same ar-
ray, creating ’islands’ of arrays. Therefore it means that one can maximise the use of the
information generated, and in this case estimate the difference between early and late
samples.93
Modular analysis was performed using R package tmod (v0.31), using the modules
outlined by Chaussabel et al94 and by Li et al.95 An adjusted p-value of < 0.05 was
deemed to be significant.
A previously published TB signature, was also analysed to test whether its resolution
at week 8 was confounded by HIV coinfection. The Zak signature76 was chosen for reasons
outlined in Chapter 4.The differential expression at week 8 compared to diagnosis was
extracted for the 16 genes in both HIV-negative and HIV-positive patients.
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2.4 Results
2.4.1 Quality control of RNA extraction
Two different RNA extraction kits were available for TempusTM blood collection tubes.
The first was column based and collected total RNA including mRNA, and the second
was magnetic bead bases and collected total RNA including mRNA and miRNA. For
optimisation, whole blood was collected in TempusTM tubes from healthy LSHTM donors
by Carolyn Stanley, and RNA was extracted using either of the two kits. Figure 2.3 shows
the RNA quality obtained from the two kits. The Spin Column kit consistently extracted
good quality RNA, with all RINs over 7.5. On the other hand, RNA quality yielded from
the MagMAX extraction kit was highly variable and often of poor quality, with a median
RIN of 4. Because of the MagMAX’s inconsistency and sub-par quality yield, it was
decided the samples from Mbeya should be extracted with the Spin Column kit.
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Figure 2.3: RNA extraction from whole blood collected in TempusTM tubes, using
either MagMAX or Spin Column method. Whole blood was collected from healthy
donors from LSHTM (n=9). RNA quality(RIN) was obtained from the BioAnalyser (Agilent).
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2.4.2 Microarray two-colour direct analysis
Firstly, in microarray data, normalisation needs to be performed, so that the different in-
tensities of sample labelling are comparable. Systemic variation occurs in gene expression
microarray experiments due to technical factors, like differential labelling efficiency and
mRNA concentration. So, the purpose of normalisation is to eliminate such variation,
leading to appropriate comparison of the biological signal.
Figure 2.4 shows before and after normalisation within the arrays. In Figure 2.4B,
the green and red channels overlap, which means the loess normalisation achieved in
marrying the two channels within an array together. The normalisation has aligned the
two channels so the distributions become the same. Whereas prior to normalisation there
is more variability between arrays and also variability between the red and green channels
corresponding to Cy3 and Cy5 labelling.
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Figure 2.4: All arrays before (A) and after normalisation (B) in direct-design anal-
ysis. Agilent arrays were normalised using method ’loess’. Red (Cy5) and green (Cy3) are the
different channels corresponding to the sample labelling.
Initially, the overall early and late transcriptomic changes in HIV-negative and HIV-
positive patients combined were investigated, shown in Figure 2.5. In the early stages
of TB treatment, there is a change in the expression of a large number of genes with
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3113 statistically significantly expressed. Genes were mainly down-regulated at week two
relative to diagnosis, coupled with some up-regulation as well. At week eight compared
to week four (late stages), there was very little differential expression, with the expression
of only 82 genes significantly changing over this period.
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Figure 2.5: Early (A) and late (B) transcriptomic changes in TB treatment in both
HIV-negative and HIV-positive patients combined. Early changes were the up-regulated
and down-regulated genes at diagnosis compared to week 2, and late changes were the up- and
down-regulated genes at week four relative to week eight. Red are statistically significantly
differentially expressed genes after multiple testing correction, grey are not significant. An
adjusted p-value of < 0.05 was deemed significant. The most differentially expressed genes are
labelled.
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Early and late changes in HIV-negative and HIV-positive samples were extracted.
In HIV-negative patients, 3297 genes were significantly differentially expressed between
diagnosis and week two. In HIV-positive patients, 2581 genes were significantly differen-
tially expressed between diagnosis and week two. Figure 2.6 shows the top significantly
differentially expressed genes at diagnosis compared to week two. Both HIV-positive
and HIV-negative patients exhibit a similar expression profile in the early phase of TB
treatment, with HIV-positive patients having slightly less down-regulation. In the late
phase of TB treatment, between week four and week eight, there were no significantly
differentially expressed genes. In Figure 2.5B it appears there are significant genes, but
once the data are separated by HIV-status, these disappear.
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Figure 2.6: The 1000 most significantly differentially expressed genes in the early
stages of treatment in HIV-negative and HIV-positive patients. Log2 fold change of
genes at diagnosis compared to week two. Red are up-regulated genes at diagnosis compared
to week 2 and blue are down-regulated at diagnosis compared to week 2. An adjusted p-value
of < 0.05 was deemed significant.
These results show that the largest transcriptomic changes in TB treatment occur at
the very beginning; between diagnosis and week two, and there is subsequently relatively
little changes happening later on. In addition, it appears HIV-1 coinfection has little effect
on these changes. To further this, modular analysis was performed on the early changes
in both HIV-negative and HIV-positive combined. So, Figure 2.7 shows the modular
expression of HIV-infected and HIV-uninfected patients together at diagnosis compared
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to two weeks after the initiation of TB treatment. The modular analysis looked markedly
similar to what we would have expected; an up-regulation of inflammation, dendritic cells
and monocytes at diagnosis, and a down-regulation of T-cell modules. It shows that the
TB biosignature is still valid even when including HIV-positive patients.
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Figure 2.7: Significantly differentially
expressed transcriptional modules at
diagnosis compared to two weeks af-
ter the initiation of TB treatment in
HIV-positive and HIV-negative pa-
tients. Up-regulated (red) and down-
regulated (blue). The colour saturation is
relative to adjusted p-value, and length of
bars is relative to effect size. The amount
of colour corresponds to the proportion of
genes differentially expressed within that
module. Modules were deemed significant
with an adjusted p-value of < 0.05.
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2.4.3 Microarray separate channel analysis
A second analysis was done on the same data; using the separate channel method, which
looked at the individual log intensities of each sample. This allowed the comparison of
all four time-points for each patient. Figure 2.8 shows the result of loess normalisation
between the arrays. This does not necessarily marry the two channels together, but scales
the intensities so they have the same distribution across the arrays.
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Figure 2.8: All arrays before (A) and after normalisation (B) in separate channel
analysis. Agilent arrays were normalised using method ’loess’. Red (Cy5) and green (Cy3)
are the different channels corresponding to the sample labelling.
The fold changes between each time point were calculated; diagnosis−week two, week
two−week four, and week four−week eight in HIV-negative and HIV-positive patients.
From this differential expression analysis, 215 genes were found to be significantly dif-
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ferentially expressed at all of the time-point comparisons, Figure 2.9. Most of the genes
were up-regulated at diagnosis compared to week two, which were then strongly down-
regulated compared to the gene expression between week two and week four. The gene
expression ended up just over 0log2 fold change at eight weeks after initiation of TB
treatment. There does seem to be a slight difference between HIV-negative and HIV-
positive at the later time-points; HIV-positive patients were more up-regulated at week
4 compared to week 8 than in HIV-negative patients.
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Figure 2.9: Dynamics of gene expression changes through TB treatment in HIV-
negative (grey) and HIV-positive (red) patients. The differential expression changes of
the 215 statistically significant genes between; diagnosis and week two, week two and week four,
and between week four and week eight in the separate channel analysis. A p-value of < 0.05
was deemed significant.
A previously published TB signature was analysed at week 8 relative to diagnosis in
HIV-negative and HIV-positive patients. Only 14 out of the 16 genes could be analysed
(Figure 2.10). In HIV-negative patients, there was mainly down-regulation of the TB
signature, which was to be expected. In HIV-positive patients there was a larger down-
regulation of these genes. However, none of the genes were statistically significant in
either group.
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Figure 2.10: Fold changes of the Zak signature at week 8 compared to diagnosis
in HIV-positive and HIV-negative patients. The differential expression of the 14 genes
were extracted (from the separate channel analysis) at week 8 compared to diagnosis. Red is
up-regulated, blue is down-regulated.
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2.5 Discussion
2.5.1 Findings
Most of the transcriptomic changes in TB treatment occurred at the beginning of TB
treatment; within two weeks of treatment initiation. HIV-positive co-infected patients ex-
hibited similar changes. However, there does seem to be a difference in HIV-negative and
HIV-positive patients between week four and week eight post initiation of TB treatment,
which needs to be further investigated.
The biological interpretation of the microarray data showed that there was an up-
regulation of inflammation at TB diagnosis in both HIV-infected and HIV-uninfected TB
patients. By week 2, these was an increase in T-cell transcripts. These data show the
pattern of magnitude of innate and then adaptive immune responses through treatment.
When analysing a previously published blood TB signature at week 8 compared to
diagnosis, one would expect general down-regulation (as before treatment is associated
with heightened inflammation), which is seen in both HIV-negative and HIV-positive
patients. However, this was more so in HIV-positive patients. It would be interesting to
see if this remained the case at the end of treatment.
Overall, the TB transcriptomic signature and the changes during the treatment re-
sponse could still be observed with HIV coinfection. These data demonstrate that it
is possible to derive transcriptomic signatures which will work in a mixture of different
disease statuses, which is highly valuable for biomarker and diagnostic development.
So far, not many studies have included HIV co-infected patients which is not ideal
considering there are so many HIV/TB cases. The key study that did however, was by
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Kaforou et el;69 they included adult TB patients from different populations and that were
HIV-infected and HIV-uninfected. The signature that was developed had high sensitivity
and specificity (over 90%) when differentiating TB from LTBI and also TB from OD.
When the analysis was split by HIV status, the same signature had reduced specificity
in detecting TB from LTBI and OD. The 393- (TB versus LTBI) and 86- (TB versus
OD) gene signatures developed by Berry et al67 were applied to their data set where
it performed poorly; the sensitivity and specificity in differentiating TB from OD in
HIV-positive patients was below 70%.
A study by Anderson et al investigated the possibility of a diagnostic for TB in
HIV-positive and HIV-negative children using transcriptomics. This study also included
patients from multiple countries and they developed a disease risk score which was able
to distinguish TB from LTBI (sensitivity 94%, specificity 100%) and TB from OD (sensi-
tivity 82.9%, specificity 83.6%).75 These two studies show that HIV status can be mixed
in gene expression studies and it actually produces a more powerful gene signature.
There have been other studies that have investigated the transcriptome between HIV-
negative and HIV-positive TB patients using the multiplex ligation probe assay (MLPA).
This technique measures the gene expression of approximately 80 genes in many samples
at once, the gene probes are typically based on previous literature. Two separate studies,
one which included patients from four sub-saharan countries found expression of the
Fc-γ Receptor I A1 (FCGR1A) genes were the most consistent classifier for TB.96,97
Gene expression data are able to distinguish TB regardless of HIV status or geo-genetic
differences.
Data do show early changes in gene expression that are typically seen in TB patients
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are also clearly seen in HIV-infected individuals. It shows that biomarkers for early
treatment response could be developed to use in this population. This is probably because
these changes relate to innate, inflammatory immune responses, rather than to adaptive
responses.
2.5.2 Limitations of study
Ultimately, there were too few samples in this study, as we had aimed for over 20 samples
in each group. Also, we did not have later time-points through the continuation phase
until the end of treatment. End of treatment time-points would have been favourable
to see whether the gene expression signature had completely resolved in HIV-positive
patients as it would have in HIV-negative patients. However, both of these were outside
of our control, but should certainly be addressed in future studies.
This study was performed in part as preparation for the subsequent analysis in
TB/DM patients, discussed in Chapters 4 and 5. However, a decision was taken early
on to perform the latter work using RNA-seq rather than microarray as first intended.
Nonetheless, this preliminary study showed that limma was a good statistical approach
for measurement of TB treatment response via the blood transcriptome and that there
is still a place for microarrays.
To conclude, HIV and ART do not prevent transcriptomics from being a useful tool
for measuring TB drug-induced cure, especially in the early phase of treatment.
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3Transcriptional effect of Metformin
3.1 Introduction
3.1.1 Type 2 diabetes mellitus (T2D)
It is estimated in global reports there are 382 million people currently living with diabetes.
By cause of urbanisation and the ever hiking obesity problem, projections expect this to
rise to 592 million by 2035.36 Type 2 diabetes, or non-insulin dependent diabetes mellitus
(NIDDM) accounts for 90% of diabetes cases in adults. It manifests as hyperglycaemia,
in turn caused by insulin resistance, and/or impaired insulin secretion. Type 2 diabetes
has a complex aetiology, combining genetic and environmental factors.
Glucose is the primary fuel for the brain and is used to produce ATP through aerobic
or anaerobic respiration. It is used for a number of processes, including glycogen syn-
thesis for storage or also oxidisation to pyruvate via glycolysis to provide ATP. Plasma
glucose concentrations are tightly regulated. A drop in blood glucose levels manifests
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as discomfort and mental confusion. Further reductions lead to coma, convulsion and
sometimes brain damage and death. Elevated glucose also has serious physiological con-
sequences. High blood glucose levels can cause kidney failure, cardiovascular disease,
nerve damage and blindness. Therefore, maintaining normal blood glucose concentration
is a high priority.42
A variety of mechanisms have evolved to regulate glucose levels. The most important
regulators are the hormones insulin and glucagon, both produced by the pancreas in
clusters known as the islets of Langerhans. Insulin is produced by the β- cells, and is
released into the blood stream in response to changes in blood glucose. Insulin’s role in
the body is primarily directed at metabolism, with it’s most imperative being the use
of glucose as energy. Insulin stimulates glucose uptake, where it can be converted to
glucose-6-phosphate, and later glycogen. It also stimulates the storage of this excess fuel
as fat in adipose tissue.42
When there is persistently excessive glucose in the blood stream, is can cause the
body to become de-sensitised to insulin leading to a decrease in insulin stimulated glucose
transport and metabolism. This is called insulin resistance, and is a precursor state of
type 2 diabetes. The body then compensates by releasing even more insulin in order to
bring about the appropriate biological effects. Eventually, the β-cells fail, and the lack
of insulin transpires to the inability to regulate blood glucose.42
Medications are used to regulate blood glucose levels, where the body fails on its
own. Typically, type 2 diabetes patients are given oral medication, of which metformin
is the most commonly issued worldwide. Other medication includes sulphonylureas, like
glibenclamide, which increase the amount of insulin produced by the pancreas. Some-
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times injectable insulin is prescribed, but it can cause dangerously low blood sugar levels.
3.1.2 Metformin
Metformin first appeared in herbal guides from the 17th century, derived from the plant
Galega officinalis (French lilac). The ancient herbal remedy was described as having
abilities suitable for treating what we now know as diabetes.98 The metformin compound
itself was synthesised in 1922. Despite this, it was overshadowed by the synthesis of
insulin in the same decade. It was not until the 1950s that it received notoriety after
demonstrating cardiovascular benefits. Now, it is the most widely administered T2DM
medication.99 It has been recommended as the first line of defence based on the UK
Prospective Diabetes Study (UKPDS) in 1998.100 One of the advantages of metformin is
that it reduces blood glucose levels without inducing hypoglycaemia. Together with its
mild side effect profile and ease of administration, it has become a favourable treatment
for T2DM patients.101
The effects of metformin are profuse. Mainly, metformin has glucose reducing proper-
ties, but also improves insulin sensitivity and reduces inflammation. It’s exact mechanism
of action is largely unknown, but some studies have pointed to the role of AMP-activated
protein kinase (AMPK), a cellular regulator of glucose and lipid metabolism. A promi-
nent study in rats by Zhou et al demonstrated that metformin’s mechanism of action
starts with the activation of AMPK. When AMPK was inhibited, metformin was un-
able to induce its inhibitory effect on glucose production, showing a crucial role in the
metformin cascade.102 This cascade is then thought to result in the modulation of circu-
lating lipids and is also known to increase glucose uptake in the skeletal muscle during
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exercise,103 showing a mechanism in which metformin augments its insulin action.
In a study by Cho et al, metformin was administered to healthy subjects, in which
their urine underwent metabolic profiling. They found that there was a clear discrim-
ination between the control and the metformin-treated group. Metabolites like cortisol
were reduced after metformin administration. To further their results, the group admin-
istered metformin to rats and performed in vitro and in vivo experiments showing that
the protein expression of p-AMPK increased after metformin treatment, and also AMPK
phosphorylation was induced in the pituitary gland,104 therefore confirming the AMPK
pathway induction by metformin.
Prior to AMPK activation, metformin is thought to inhibit complex 1 of the mitro-
chondrial respiratory chain. El-Mir et al isolated mitochondria from the liver of rats pre-
viously treated with metformin, or untreated. They found that electron transfer through
complex I was inhibited in the liver mitochondria treated with metformin compared to
the control. The change in energy state could then activate AMPK.105
3.1.3 Unconventional uses for an old drug
Metformin has gained popularity in other avenues of research besides diabetes. It has
been reported that metformin has anti-cancer, immunoregulatory and anti-ageing ef-
fects. Diabetes patients taking metformin live longer, in the form of experiencing fewer
cardiovascular events and fewer cases of cancer. Epidemiological studies have peaked the
interest in the use of metformin as an adjuvant in cancer therapy, noting that metformin
reduces cancer incidence and also mortality. A meta-analysis by Gandini et al established
that metformin reduced the incidence of cancer by 31% and reduced the mortality by
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34% in diabetes patients, compared to patients on other medication.106
The mechanism is thought to be two-fold. Firstly, metformin activates AMPK, which
in turn reduces insulin resistance, and secondly due to the anti-inflammatory effects of
metformin. High insulin levels are thought to promote tumourigenesis through mod-
ulators like insulin growth factors. Insulin resistance is known to affect breast cancer
prognosis and increase breast cancer risk. This partly explains the association between
obesity and breast cancer. A study by DeCensi and colleagues conducted a trial of met-
formin versus placebo, and found that cancer proliferation was lower in the metformin
treated group.107
In other cancers, metformin has been shown to inhibit cancer growth of colon, lung,
pancreatic and prostate cancer cells. This was by directly modulating the inflamma-
tory processes that play an important role in tumour progression, blocking NFκB and
subduing the pro-inflammatory response.108–110
However, in one study in pancreatic cancer patients who were administered metformin
showed no improvement in mortality compared to patients without metformin.111 There
seems to be some heterogeneity in the effects of metformin, and more research needs to
be done in its beneficial effects in cancer patients, perhaps in the chronic treatment with
metformin. Regardless, data are promising.
In addition to the beneficial effects on cancer, the UKPDS illustrated that treatment of
patients with T2DM with metformin showed decreased risk of myocardial infarction and
subsequent death. The group analysed the effect of metformin and other anti-diabetes
drugs in T2DM patients. The metformin treated group had improved cardiovascular
benefits; a reduction in risk of CVD by 20%, together with a 42% lower risk of diabetes-
72
CHAPTER 3. METFORMIN
related death. The metformin treated group had better overall health outcomes and
metformin had a greater effect than other anti-diabetes drugs, like glibenclamide.100
There is an ongoing clinical trial in the preventative effect of metformin in CVD, named
The Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT).
Metformin has recently become a trendy research topic. In the mainstream media
it has been reported as an ’anti-ageing drug’. Not that it is able to combat wrinkles,
but rather delay the onset of age-related diseases, like cancer, CVD and Alzheimer’s
disease. There is currently a novel clinical trial, aptly named TAME; Targeting Ageing
with Metformin, in the U.S which aims for metformin to become the world’s first FDA-
approved anti-ageing drug.108
The suggestion of metformin having longevity benefits was voiced in a study by
Martin-Montalvo et al, in which middle-aged mice were administered metformin. The
mice that were treated with metformin lived longer compared to the standard mice, how-
ever, at higher concentrations, it was toxic. In addition to this, the metformin treated
mice exhibited better physical performance and also reduced inflammation. These in
vivo experiments demonstrate that chronic exposure to metformin has beneficial effects,
but why metformin manifests these pleiotropic effects is still unclear.112
A retrospective observational study by Bannister et al investigated diabetes patients
administered metformin compared to non-diabetic controls. This study included 180,000
subjects, and found that diabetes patients that were initiated with metformin mono-
therapy had longer survival than the non-diabetes subjects. However, the validity of
the study design was questioned, by whether the diabetic cohort had selectively retained
healthier individuals. During follow-up, if a diabetes patient needed treatment alter-
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ations, i.e. intensification of treatment, they were excluded from the cohort. Also, ad-
herent patients were only chosen in the diabetes cohort, but good adherence by itself has
been shown to reduce mortality.113 Regardless, data have shown that there are beneficial
effects of metformin in combating diseases other than diabetes.
More research is going on in the beneficial effects of metformin in infectious diseases,
in particular in TB. Epidemiological studies have shown that T2DM confers a three fold
increased risk of active tuberculosis. Given that the incidence of T2DM in TB endemic
areas is set to increase in the upcoming decades, studying the effects of metformin on the
immune response to tuberculosis is an integral part in understanding the link between
the two diseases.59
A case control study in India investigated the protective effect of metformin against
active TB in diabetes patients. They found that metformin had a 3.9 fold protective effect
against TB. However, it is unclear whether the improved glycaemic control induced by
metformin was responsible for the reduced susceptibility to TB, rather than metformin
directly inducing protection against TB.114
A recent study by Singhal et al demonstrated that metformin may be beneficial in
the context of TB. Firstly they showed in vitro that metformin reduced the survival
of M. tb in treated cells. In vivo experiments then demonstrated the beneficial effects
of metformin; mice were infected with M.tb and were administered isoniazid with and
without metformin. They found the group administered combination therapy had lower
bacillary loads in the lung than those that were administered mono-therapy. These same
metformin treated mice also exhibited less pathology in the lung tissue and enhanced im-
mune responses once the lung tissue was stimulated with M. tb. RNA was also isolated
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from the mice lungs infected with M. tb that were treated and untreated with metformin,
and microarray analysis was performed. Gene-set analysis of these data revealed met-
formin down-regulated gene-sets involved in inflammation like interferon signalling and
antigen presentation, compared to samples from untreated mice. It seems that metformin
is able to augment the hosts own immune response in response to M. tb that favours the
host, which is a potentially new therapeutic approach.115
3.1.4 Background of study
Our collaborators Ekta Lachmandas, Reinout van Crevel, and Mihai Netea at Radboud
University Nijmegen Medical College have investigated previously the effect of metformin
in vitro on PBMCs from healthy volunteers in the context of M. tb on the cytokine
response. Metformin increased glycolysis, and phagocytosis, whilst reducing the M.tb
induced production of TNF-α, IFN-γ, and IL-1β. A complementary study was then
initiated, in the form of a pilot trial. The study involved the administration of metformin
in healthy human donors for six days. Whole blood was taken and collected in PAXgene
tubes, in addition to a sample for harvesting peripheral blood mononuclear cells (PBMCs)
before and after administration of metformin. PBMCs were stimulated with 5 µg/mL
of M. tb lysate or unstimulated with RPMI before and after metformin administration.
The frozen samples were shipped to the London School of Hygiene & Tropical Medicine
for analysis.
Samples included whole blood, and also PBMCs under different stimulation condi-
tions, which underwent transcriptomic analysis using RNA-seq technology. This dif-
ferential expression analysis of healthy donors administered with metformin allowed an
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unbiased approach in investigating the effect of the anti-diabetic drug on gene expres-
sion in whole blood and also in PBMCs. This would uncover the effect of metformin in
absence of any stimulation on biological pathways like cellular metabolism. Half of the
PBMC samples were stimulated with M. tb lysate, which considers the potential effect
of metformin in the context of M. tb infection.
In vitro work has shown metformin increases ROS production, AMP activation and
phagocytosis, so one would expect the gene expression data to account for these changes.
Metformin administration has also shown anti-inflammatory effects in M.tb infected mice,
and therefore one would expect similar changes in human ex vivo blood and PBMC tran-
scriptomes. I hypothesised that metformin would affect the expression of genes related to
ROS production and cytokine production in response to mycobacteria in healthy donors.
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3.2 Aims and Objectives
Aim
I To determine the effects of metformin administration on leukocyte func-
tion particularly in response to M. tuberculosis.
Objectives
I Perform RNA-seq analysis of ex vivo samples collected before and af-
ter metformin administration in healthy volunteers to determine global
transcript changes.
II Perform RNA-seq on PBMC samples unstimulated or stimulated with
M. tuberculosis lysate for 4 hours before and after metformin adminis-
tration.
III To determine biological pathways in the immune response to M. tuber-
culosis which are affected by metformin.
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3.3 Methods
3.3.1 Sample Processing
Eleven healthy Caucasian male subjects were administered daily doses of metformin for
six days. The dose rose by 500mg each day until day five, where 2000mg metformin was
administered, and then on day six the subjects received a smaller dose of 1000mg. A
schematic of the daily dosage is shown in Figure 3.1.
Figure 3.1: Schematic of dosing of metformin during the pilot trial. Stars indicate when
blood samples were taken at day one, before administration, and at day six, after administration
of metformin.
Whole blood (2.5ml) was taken before administration of metformin on day one, and
after administration on day six and stored in PAXgene tubes. These were frozen at−80◦C
and shipped to LSHTM for RNA extraction (n=22). In addition, the peripheral blood
mononuclear cells (PBMCs) were harvested (total number of cells per sample; 5 million)
from the eleven donors before and after metformin administration. The harvested PBMC
were split and subjected to two different stimulation conditions, either unstimulated with
RPMI, or stimulated with M. tb lysate (n=44).
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Of the PBMC samples taken before metformin administration (n=22), 11 were un-
stimulated with RPMI-1640 (Gibco) and cultured in growth medium, supplemented with
10mM L-glutamine (Life Technologies), and 11 were stimulated with M. tb lysate for four
hours at 37◦C. The 22 samples harvested after metformin administration were also un-
stimulated (n=11) or stimulated with M. tb lysate (n=11) for four hours. The PBMCs
were then stored in RNA protect (Qiagen), frozen at −80◦C, and shipped to LSHTM
for RNA extraction. This was done at Radbound University Nijmegen by collaborators
Ekta Lachmandas, Reinout van Crevel, and Mihai Netea.
After receiving the 22 frozen whole blood PAXgene samples and the 44 frozen PBMC
samples, I extracted the RNA from whole blood samples using the PAXgene blood
miRNA kit (Qiagen) and stored at -80C. RNA from the PBMC samples was extracted
using the RNeasy Mini Kit (Qiagen) with the total RNA plus miRNA extraction method.
The whole blood RNA samples were globin-reduced using GLOBINclearTM (Invitrogen)
All 66 RNA samples were then processed and sequenced at University College London,
Institute of Child Health (UCL). The whole blood samples were processd using the Ribo-
Zero TruSeq stranded total RNA library preparation method (Illumina), whereas the
cultured PBMC RNA samples were processed using the TruSeq stranded mRNA Library
prep kit (Illumina). All samples were seqenced on the NextSeq500, generating ∼36-45
million 43bp paired-end reads per sample.
3.3.2 Data processing
I obtained raw RNA-seq data for each of the 66 samples in the form of FASTQ files from
UCL, which I then processed and analysed. FASTQ files were aligned to the human
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genome (version Human g1k v37) using STAR aligner (Spliced Transcripts Alignment
to Reference)116 (v2.5.2b). The STAR alignment algorithm was used because it is fast,
robust, and reliable (Personal communication, Yang). Engstrom et al published an eval-
uation of the current RNA-seq alignment methods, in which STAR aligner was one of
the top performers.117 Alignment generates SAM files, which contain the the number of
reads that overlap with 63,677 features. These reads were counted using HTSeq-count118
(v0.6.1) using the ensembl annotation file version Homosapiens.GRCh37.75.gtf and with
the settings described below.
-f sam format of the input data
-r name how the input data have been sorted
-s reverse whether the data is from a strand specific assay
-m union mode to handle reads overlapping more than one feature
-i gene id what attribute to be used as feature ID
HT-seq count produced a data frame of positive integer numbers for each feature or
transcript, for each of the 66 samples. The data frame, or count data was then imported
into the statistical programming language R (R v3.3.3 and RStudio v1.0.136) for differ-
ential expression analysis using the package DESeq2119 (v 1.12.4). There are a number of
R packages available for differential expression analysis of RNA-seq data. These packages
include DESeq2, edgeR120 and limma-voom.121 DESeq2 and edgeR use the negative bino-
mial as their reference distribution, and provide their own normalisation methods. The
negative binomial distribution (also known as the gamma-Poisson distribution) allows for
additional variance, or overdispersion characteristic of RNA-seq data. DESeq2 and edgeR
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both perform similarly in gene ranking results.122 limma-voom applies a normal-based
microarray-like statistical method using weights to RNA-seq analysis. The packages
DESeq2, edgeR and limma all use linear modelling as their method for statistical analysis.
This method is powerful as it enables multiple variables to be analysed at the same time.
In the differential expression analyses, a linear model was constructed for each transcript
across all equivalent samples.
3.3.3 Differential expression analysis
The two cell sample types; PBMC and whole blood, were analysed separately. Be-
fore statistical analysis, the count data were filtered for transcript rows that were non-
informative. Transcript rows that had an overall sum of less than 50 counts across all
samples were removed. This can improve statistical power of the downstream differential
expression analysis.123
In order to deduce the effect of metformin, the expression at day 6 (after metformin
administration) was compared with the expression at day 1 (before metformin adminis-
tration). The linear model constructed for the differential expression of the whole blood
samples is summarised in Equation 3.1. This includes both before and after metformin
as a variable. Next, Equations 3.2 and 3.3 show how a linear model was constructed
for the effect of metformin in cultured PBMCs, and also the effect of metformin in the
context of different stimulation conditions.
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y = (β1effect of metformin) +  (3.1)
y = (β1effect of metformin) +  (3.2)
y = (β1effect of metformin + β2stimulation condition) +  (3.3)
During differential expression analysis, a statistical test has been performed for each
transcript. Thousands of transcripts equate to thousands of tests, which all have a 5%
chance of being a false positive. If a straightforward approach to significance is taken, i.e.
p < 0.05 is taken as a cut off. This would lead to the risk of many false positive results,
and so correction for multiple testing must be performed. Multiple testing correction was
done using the Benjamini & Hochberg false discovery rate method. An adjusted p-value
of < 0.05 was determined to be significant.
3.3.4 Gene-set analysis
Gene-set analysis is an analysis method that groups genes into collections according to
biological function or processes. It is advantageous as gene level analysis can leave few
genes that meet the significance threshold, or, conversely, one can be left with a lengthy
gene list without a unifying biological theme. Gene-set analysis eliminates such issues by
finding genes with consistent but slight changes whilst introducing biological knowledge.
Furthermore, gene-set analysis reduces the multiple testing load as it allows one to test
collections of genes in a single step, therefore minimising the number of t-tests that are
calculated.
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Gene-set analysis was performed using the ’R’ package piano124(v1.12.1). The gene-
sets used were KEGG pathways (Kyoto Encyclopedia of Genes and Genomes) and Hall-
mark collections, both downloaded from the MSigDB (http://software.broadinstitute.org
/gsea/msigdb). Hallmark sets were generated by computational methodology and sum-
marise well-defined biological states or processes.
To consolidate the gene-set analysis, it was done again with a second package, gage125
(v2.22.0). This package uses the Kolmogorov-Smirnov statistic as in Gene Set Enrichment
Analysis (GSEA) from the Broad Institute (http://software.broad- institute.org/gsea/
index.jsp). It is a sensitive method, but there is evidence it has a tendency to produce
false positives.126
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3.4 Results
3.4.1 Assessment of RNA quality
The RNA extraction protocol for cultured PBMCs was optimised. This was because
there were two ways of doing it. One extracted total RNA including mRNA (mRNA
method), but the other extracted total RNA including mRNA and miRNA (miRNA
method). Five blood samples were obtained from LSHTM healthy donors, which then
underwent PBMC separation. The same sample was split into two, and underwent the
two different extraction methods. Figure 3.2 shows the results of the two methods; there
was no significant difference in the quality of the RNA (p-value 0.468) as determined
using the BioAnalyser (Agilent), but there was in the concentration of RNA (p-value
0.0165).
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Figure 3.2: RNA extraction from PBMCs using two different methods; mRNA and
miRNA. Five samples were split into two and underwent the two different extraction methods,
the Qiagen mRNA and miRNA RNeasy kits. A: RNA concentration from the Nanodrop using
both methods, B: RNA quality, shown as the RNA Integrity Number, from the BioAnalyser
using both methods. A paired t-test was performed and a p-value of < 0.05 was deemed
significant. total RNA was eluted into 30µl of RNase-free water
The miRNA method was chosen to extract the PBMC samples, as the quality was
not compromised, and yield was sufficient, but it would allow us to keep the miRNA.
I performed the extractions, and all 66 RNA samples had their quality assessed using
the LabChip GX (PerkinElmer) prior to library preparation. Figure 3.3 shows the RIN
values and the concentration of each of the whole blood and cultured PBMC samples.
All the RNA from the cultured PBMCs was of very high quality. A RIN of above seven
is ideal for RNA-seq, but the three whole blood samples that were below the threshold
were very close so were processed anyway.
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Figure 3.3: RNA quality and concentration of all 66 samples assessed using the
LabChip GX. A: Whole blood samples, B: PBMC samples. Red dashed line at RIN = 7
indicates the threshold of ideal RIN values for downstream RNA-seq analysis.
3.4.2 The effect of metformin whole blood gene expression
Ex vivo blood was collected in PAXgene tubes from eleven healthy donors before ad-
ministration of metformin (day 1) and after six days of daily metformin doses (day 6).
The gene expression in the whole blood samples at day 6 was compared to day 1 in
order to deduce the effect of metformin on transcription in healthy donors. A global
approach was initially taken, looking at differential expression changes at the gene level.
Initial principal component analysis showed that there was little variation between the
two groups, before and after metformin administration (Figure 3.4). Figure 3.5 shows
the global effect of metformin in the form of a p-value frequency histogram. Because
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the distribution of p-values resembles a uniform distribution, it means that there is no
global gene-level effect of metformin administration. As all p-values have equal chance
of occurring by chance, after multiple testing correction, any seemingly significant result
disappears. On the gene-level, there were was one significantly differentially expressed
gene after multiple testing correction, Required For Meiotic Nuclear Division 5 Homolog
A (RMND5A) (Figure 3.6). This is potentially because the relevant biological differences
were relatively modest.
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Figure 3.4: Principal component analysis of ex vivo samples before and after six
days of metformin administration.
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Figure 3.5: The frequency of p-values generated from differential expression analysis
in ex vivo samples before and after six days of metformin administration. Lists of
transcript counts were compared between before and after metformin using DESeq2.
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Figure 3.6: The effect of six days of metformin administration of healthy donors
on whole blood gene expression. Grey dots show which were not statistically significantly
differentially expressed, and blue dots show significant differential expression, after multiple
testing correction (Adjusted p-value < 0.05).
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This gene-level analysis may have missed important effects on pathways. Gene-set
analysis interprets gene expression data by focusing on groups of genes that share bio-
logical functions. Studying gene-sets allows one to find consistent but small effects in
collections of genes, whilst introducing biological knowledge. Gene-set analysis was per-
formed using the R package piano. The KEGG pathway database from MSigDB was
used for gene-set definitions. Within the whole blood samples, the differential expression
of KEGG pathways after six days of metformin treatment was compared with that be-
fore administration. This demonstrated the effect of metformin intake on gene expression
in whole blood. Analysis revealed several pathways that were significantly differentially
expressed (Figure 3.7). The most significantly differentially expressed pathway was ri-
bosome, which was down-regulated in response to metformin treatment. Only one other
pathway, oxidative phosphorylation, was down-regulated, while a further remaining ten
pathways were up-regulated. The up-regulated pathways included endocytosis, phagocy-
tosis and insulin signalling. These changes were of a small magnitude, but nevertheless,
consistent. A pathview image of the oxidative phosphorylation pathway, Figure 3.8 was
generated, where the differentially expressed genes can be seen, where complex I was
down-regulated in response to metformin.
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Figure 3.7: Significantly differentially expressed KEGG pathway gene-sets in whole
blood before and after metformin administration. Data were analysed using R package
piano and an adjusted p-value < 0.05 was deemed significant.
To extend the KEGG pathway analysis using piano, a second collection of gene-sets
was investigated, annotated as Hallmark gene-sets. Again, gene-sets were identified which
were differentially expressed in whole blood after metformin administration compared
to before intake. In agreement with the previous results, of the gene collections that
were significantly differentially expressed, the majority were up-regulated in response to
metformin, Table 3.1. These consisted of metabolism related collections, like oxidative
phosphorylation, and cell division gene-sets like mitotic spindle. In short, in whole blood,
metformin had a small but significant effect on gene expression of endocytic-like pathways.
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Figure 3.8: The genes differentially expressed in the oxidative phosphorylation path-
way in whole blood due to metformin administration. Gene-set analysis found oxida-
tive phosphorylation to be a statistically differentially expressed pathway. Green shows down-
regulated and red shows up-regulated genes following metformin.
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Hallmark gene-set Adjusted p-value
TNF-α signalling via NF-κB 0
Hypoxia 0
Mitotic spindle 0
G2M Checkpoint 0
Complement 0
Inflammatory response 0
Apoptosis 0.000556
PI3K AKT mTOR signalling 0.000556
Glycolysis 0.00167
mTORC1 signalling 0.003
IL-6 JAK-STAT3 signalling 0.00523
Reactive oxygen species 0.0056
TGF-β signalling 0.00617
Oxidative phosphorylation 0.02
Table 3.1: Hallmark gene-sets that were significantly differentially expressed in
whole blood in response to metformin. One pathway was down-regulated, seen in blue,
and the rest were up-regulated, coloured in red.
To consolidate this, gene-set analysis was done with a second package, gage. Once
more, the gene expression in whole blood after six days of metformin treatment was
compared to before administration (Table 3.2). Similarly with piano, gage revealed
that in whole blood, metformin up-regulates several pathways, the most significant being
endocytosis, along with the only significantly down-regulated pathway; ribosome.
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KEGG pathway q-value
Ribosome 3.15e−16
Endocytosis 7.54e−10
Chemokine signalling pathway 2.21e−08
Regulation of actin skeleton 3.23e−08
Phagosome 5.19e−08
MAPK signalling pathway 1.86e−07
Osteoclast differentiation 1.36e−06
Neurotrophin signalling pathway 3.88e−06
Fc gamma R-mediated phagocytosis 5.62e−06
Complement and coagulation cascades 1.18e−05
Leukocyte transendothelian migration 2.10e−05
Protein processing in endoplasmic reticulum 1.74e−04
Cell cycle 4.86e−04
Vascular smooth muscle contraction 6.14e−04
Carbohydrate digestion and absorption 6.14e−04
Insulin signalling pathway 6.14e−04
Toll like receptor signalling pathway 6.14e−04
Fc epsilon RI signalling pathway 6.14e−04
Porphyrin and chlorophyll metabolism 6.14e−04
Table 3.2: KEGG pathways that were the most significantly differentially expressed
in whole blood after metformin administration using R package gage. Blue indi-
cates the pathway was down-regulated in response to metformin, and red denotes up-regulated
pathways. q-value is the adjusted p-value, where a value of < 0.05 was deemed significant.
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3.4.3 The effect of metformin on stimulated and unstimulated
PBMC samples
PBMC samples from the same eleven healthy donors before and after six days of met-
formin administration were incubated in vitro for 4 hours under two different stimulation
conditions; stimulation with M. tb lysate, or left unstimulated in culture medium. Firstly,
the global difference across all samples was investigated. Further from this, the data were
then divided into the four variable groups for individual comparisons.
For the global analysis, the gene expression of all PBMC samples after metformin
administration (day 6) was compared with all samples before metformin administration
(day 1). This was also with and without a second covariate of M. tb lysate stimulation
(Equations 3.2 and 3.3). Initial PCA analysis across all the PBMC samples revealed that
the largest variance was due to the different stimulation conditions (Figure 3.9). The
first model was generated (Equation 3.2) looking at all PBMC samples before and after
metformin administration without regard for the different stimulation condition. The
second model using Equation 3.3 was generated. This model compared after metformin
with before metformin administration. This was done on the single gene-level and also
gene-set level.
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Figure 3.9: Principal component analysis of cultured PBMCs. PBMCs were isolated
from eleven healthy donors before or after metformin administration and stimulated for four
hours with M. tb lysate or cultured in growth medium alone. The shape of the point is equivalent
to whether the sample was unstimulated with RPMI or stimulated with M. tb lysate. The
colour represents either before administration of metformin or after six days of administration
in healthy subjects.
In Figure 3.10 p-value frequency histograms revealed that in PBMC stimulated sam-
ples, there is an effect of metformin on gene expression when comparing all samples at
day 6 to day 1, which slightly increases after adding a second covariate controlling for
M. tb lysate stimulation. Volcano plots summarise the gene expression profiles for the
global analysis of the effect of metformin (Figure 3.11). Both models show an effect of
metformin, however, the adjusted model shows an increased gene differential expression
profile. It can be summarised that metformin has a different effect depending on whether
or not the PBMCs have been stimulated with M. tb lysate.
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Figure 3.10: P-value frequencies of the global effect of six days of metformin ad-
ministration in PBMCs A: before correction, B: after correcting for stimulation
condition.
If there was no difference between the stimulation conditions, the gene expression
profile would remain the same after correction. After adjustment for M. tb lysate stim-
ulation, 926 genes were statistically differentially expressed due to metformin (adjusted
p-value < 0.05). These 926 genes were imported into the online functional annotation tool
DAVID, where the gene list’s biological themes were identified. The most significantly
differentially expressed KEGG pathway using this tool was ribosome.
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Figure 3.11: Global effect of six days of metformin administration in healthy donors
on gene expression in PBMCs, controlling for stimulation condition. Grey dots show
which genes were not statistically signifcantly differentially expressed, and purple dots show
significant differential expression, after multiple testing correction (Adjusted p-value < 0.05).
Gene-set analysis was performed on the adjusted model, similarly to the whole blood
samples, using two different R packages. Results from piano are shown in Figure 3.12.
The columns of the heatmap represent the different methods of ranking the gene-sets,
based on whether they were up- or down-regulated. The Hallmark gene-sets that were
most statistically significantly down-regulated were interferon-α response, oxidative phos-
phorylation and interferon-γ response. The most significantly up-regulated gene-sets in-
cluded mitotic spindle and G2M checkpoint, showing metformin promoted cell division.
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Figure 3.12: Global effect of metformin in PBMCs from Hallmark gene-set analysis.
Significantly differentially expressed Hallmark gene-sets in three directionality classes; distinct,
mixed and non. Non-directional are based on the absolute values of the gene statistics, so are
independent of direction. Mixed directional uses subset up- and down- gene statistics. Distinct
p-values are calculated with sign information, meaning up- and down- regulated genes cancel
each other out. Numbers are the adjusted p-values, and colour saturation is equivalent to
significance.
The same analysis was performed with ’R’ package gage, with the results summarised
in Table 3.3. The pathways shown were all down-regulated, as no up-regulated pathways
were statistically significant. The most statistically significant pathway was ribosome.
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Pathway p-value q-value
Ribosome 9.03e−25 1.42e−22
Oxidative phosphorylation 1.28e−08 1.01e−06
Splicesome 2.64e−08 1.38e−06
Proteasome 8.56e−06 3.37e−04
RNA transport 7.05e−05 2.12e−03
Ribosome biogenesis in eukaryotes 8.09e−05 2.12e−03
Cardiac muscle contraction 1.18e−04 2.66e−03
Intestinal Immune network for IgA production 1.86e−03 3.66e−02
Table 3.3: Global effect of metformin in PBMCs in a gene-set analysis using package
gage. KEGG pathways were all down-regulated. Samples were adjusted for M. tb lysate
stimulation. p.val was the global p-value result, of which the q.val is the FDR adjustment using
the Benjamini & Hochberg procedure. Statistics were performed using the non-parametric
Komogorov-Smirnov test, with a q-value of < 0.05 deemed significant.
A second analysis was done to extract specifically what was different between the two
stimulation conditions. This consisted of separating the samples by stimulation condition.
Firstly, the RPMI unstimulated samples were investigated by comparing the differential
expression profile after six days of metformin treatment with before administration. This
infers the effect of metformin in PBMCs, in which 103 genes were differentially expressed
after metformin than before administration (Figure 3.13A).
Next, the PBMC samples stimulated with M. tb lysate after metformin treatment
were compared with the cells that were M. tb lysate-stimulated before metformin treat-
ment. This reveals the effect of metformin in the context of M. tb, in which 13 genes
were differentially expressed after metformin compared to before administration (Figure
3.13B).
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Figure 3.13: Global gene expression before and after six days of metformin adminis-
tration in PBMC samples A: unstimulated with RPMI and B: stimulated with M.
tb lysate for 4 hours. Coloured points are statistically significantly differentially expressed
genes after multiple testing correction, and grey is not significant. An adjusted p-value of < 0.05
was deemed significant.
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As above, gene-set analysis was performed using piano, investigating the Hallmark
collections, to identify the small but consistent effects in changes in a biological context.
The effect of metformin in un-stimulated PBMCs was up-regulation of sets involved in
cell division, like mitotic spindle and G2M checkpoint. The gene collections that were
differentially down-regulated included oxidative phosphorylation. This is shown in a
network plot in Figure 3.14.
Figure 3.14: Gene-set analysis of PBMC samples unstimulated with RPMI. Red are
up-regulated gene-sets, blue are down-regulated gene-sets. The saturation of colour is equivalent
to the adjusted p-value. Stouffer method, adjusted p-value of < 0.05 was deemed significant.
The affects of metformin in PBMCs stimulated with M. tb lysate were down-regulation
of gene collections involved in inflammation, shown in Figure 3.15. In particular, interferon-
γ response genes, and TNF-α signalling via NFκB genes. This is striking as it is known
IFN-γ is a critical component of the immune response to M. tb. It appears that in the
context of M. tb lysate, metformin had an anti-inflammatory effect in PBMCs.
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Figure 3.15: Gene-set analysis of PBMC samples stimulated with M. tb lysate. Red
are up-regulated gene-sets, blue are down-regulated gene-sets. The saturation of colour is
equivalent to the adjusted p-value. Stouffer method, adjusted p-value of < 0.05 was deemed
significant.
Each gene-set has up to 200 genes within it. In order to see which genes were chang-
ing the most in response to metformin, genes with a 2-fold different expression were
extracted. Within the IFN-γ response gene-set, 10 genes were 2-fold differentially ex-
pressed due to metformin, shown in Figure 3.16. The most differentially expressed genes
were Interferon Induced Protein With Tetratricopeptide Repeats 1 and 3 (IFIT1, IFIT3),
MX Dynamin Like GTPase 1 (MX1) and Radical S-Adenosyl Methionine Domain Con-
taining 1 (RSAD1). This complements the findings using the Hallmark collections. Met-
formin appears to have an anti-inflammatory effect in M. tb lysate stimulated PBMCs,
in particular on interferon response genes.
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Figure 3.16: Genes within the interferon-γ response gene-set that were ≥ 2 fold
change differentially expressed before and after six days of metformin administra-
tion in either stimulation condition of PBMCs. PBMCs taken from healthy donors were
unstimulated in RPMI (blue) or stimulated with M. tb lysate (pink) before (day 1) and after
six days (day 6) of metformin administration.
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To confirm these gene-set findings, gene-set analysis with gene ontology terms was
done. The differential expression of gene ontology terms in M. tb lysate stimulated
PBMCs after metformin intake were compared to before intake. GO terms such as
innate immune response, NFκB signalling and response to type I interferon were down-
regulated in response to metformin. Type I interferons have been seen to be associated
with disease progression in M. tb infected individuals, so the ontology term was further
investigated. On the gene-level, the genes in the type I interferon set would not reach
significance. But, the adjusted p-values of the genes within this GO set are significantly
lower in comparison to the adjusted p-values of all the genes together (Figure 3.17).
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Figure 3.17: Gene ontology analysis of the M. tb lysate stimulated PBMC samples.
Adjusted p-values of all the genes, the genes within the type I interferon response GO-set, and
the genes within the regulation of dopamine metabolic processes, as an irrelevant control gene-
set. Statistics were performed using the R package piano, with an adjusted p-value of < 0.05
deemed significant.
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3.5 Discussion
3.5.1 Findings
In this study, a modest effect of metformin on the transcriptome in whole blood and in
PBMC samples has been demonstrated. The effect of metformin seems to be primarily
on cellular metabolism. In the context of M. tb however, metformin appears to have an
anti-inflammatory effect, in the form of a reduction in the interferon response genes.
In ex vivo samples, metformin only has a significant effect on the gene-set level,
not the gene-level. Such sets, in the form of pathways, were mainly up-regulated, like
endocytosis and phagocytosis. If cells have an enhanced propensity for phagocytosis due
to metformin, it can be envisaged that alveolar macrophages would more readily take
up and kill the M. tb bacilli. Future work could include investigating the phagocytic
capacity of antigen presenting cells, like macrophages and dendritic cells post metformin
treatment to see whether metformin does improve their phagocytic ability.
In whole blood, oxidative phosphorylation was down-regulated, which fits with cur-
rent literature. Studies have previously shown that complex 1 in the respiratory transport
chain is directly inhibited by metformin in mice and human hepatocytes. This inhibi-
tion elevates the levels of AMP, which is then a potential cause of AMPK activation by
metformin.127 AMPK activation has been shown to enhance neutrophil chemotaxis and
facilitate bacterial eradication, indicating a mechanism by which metformin exerts its
beneficial immunomodulatory effects.128 In addition, a reduction in oxidative phosphory-
lation means a switch towards glycolysis, also known as the Warburg effect observed in
tumour cells,129 which rapidly provides ATP as energy for phagocytosis, oxidative burst
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and cytokine production in macrophages.130
It is worth noting that the ex vivo samples were whole blood, meaning the majority
of the transcripts were likely derived from neutrophils. It is possible that the overall
transcriptome signal was somewhat swamped by the overwhelming neutrophil signal,
which explain why only modest effects could be detected.
In the PBMC samples, the effect of metformin was more pronounced. In the un-
stimulated samples as well, metformin was found to down-regulate oxidative phospho-
rylation. There was also with a down-regulation of interferon-γ response genes. This
anti-inflammatory effect was a lot more evident in response to M. tb lysate stimulation,
where interferon-γ response, interferon-α response, TNF-α signalling via NF-κB and
inflammatory response were all strongly down-regulated. Of course, there was a large
overlap in all these gene-sets. Genes that they did all have in common were the IFIT
genes; IFIT1, IFIT2, IFIT3 and MX1. These genes play roles in regulating inflamma-
tory cytokine mRNA stability, cell proliferation and apoptosis. They are mainly induced
by type I interferons. The results show a novel mechanism through which metformin
mediates its protective effect.
3.5.2 Interferons and metformin
The IFN signature has proven important in the response to TB, the magnitude of which
correlates with disease severity.67 A recent decisive study by Zak and colleagues found a
correlate of risk transcriptomic signature for the progression to active TB disease. This
signature was able to predict which latently infected individuals would progress to ac-
tive disease 180 days before disease diagnosis. This correlate of risk signature comprised
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of interferon genes, which was the only module to be over-represented in the signature
and appeared relatively rapidly in the months leading up to diagnosis. Because of met-
formin’s anti-inflammatory effects targeted at interferon, this could mean that it may
reduce the chance of active disease progression.76 On top of this, a study by Gideon et
al in Macaques demonstrated that the degree of lung inflammation correlates with the
blood transcriptional changes, which again included interferon genes. Interestingly, the
interferon response modules were significantly higher in animals that would develop ac-
tive disease and remained higher at later time points than animals that developed latent
infection. It does appear that the interferon response modules play an important role
in the progression to active disease, pointing to the option for host-directed therapy to
modulate the hosts immune response.131
Another study by Mayer-Barber et al investigated the prospect of a host-directed
therapeutic agent by targeting the type I IFN response in a mouse model. Zileuton, an
arachidonic acid metabolism modulator was administered to IL1 knockout mice together
with a control which were then infected with M. tb. They found that zileuton significantly
reduced bacillary loads and the IFN-associated pathology and enhanced survival. It shows
that modulating the hosts immune response with another type of host-directed therapy
is beneficial in M. tb infection outcomes, by again targeting the type I IFNs.132
The unconventional use of metformin is still a relatively new research topic, but it is
gaining track as data are identifying beneficial effects of metformin. Often however, the
beneficial effects of metformin seem to be in chronic treatment rather than short-term
administration. Regardless, it is indeed becoming an option for host-directed therapy,
especially for patients with TB and diabetes, as it may improve clinical outcomes. This
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was shown in the clinical arm of the Singhal study, where TB/DM patients administered
metformin had better treatment outcomes, in the form of increased survival than TB/DM
patients not on metformin.115 Therefore, this study reveals a potential mechanism for the
protective effect of metformin via suppression of an inappropriate IFN response. In more
detail, metformin could be able to dull the pathological inflammatory response associated
with TB lung lesions and disease severity, and also the progression into active disease.
Metformin’s potential is exciting because the WHO is very keen to drive immunomod-
ulatory agents that could boost the efficacy of antibiotic regimens especially in the era
of increasing concern of antimicrobial resistance. There are no known drug-drug inter-
actions between anti-TB drugs and metformin, but more studies need to be formally
performed that explore the relationship between them in order to advance the potential
adjuvant therapy.
It is a possibility that metformin could be given as an adjunctive treatment, along with
regular anti-TB therapy to TB patients. Alternatively, it could be given with prophylactic
treatment to latently infected M. tb patients to prevent progression. However, the study
by Singhal et al that presented this hypothesis has limitations. In their mouse work,
where metformin was shown to improve survival in conjunction with antibiotic therapy,
the difference between metformin treated and untreated animals, although significant,
was of a very low magnitude. The sample numbers of this experiment were very few, so
it would be interesting if this still stands with increased sample numbers. In addition to
this, the gene-set analysis tool used in the transcriptional data for this study, PAGE, is
notorious for false positives. When Luo et al compared PAGE with GAGE, they reported
that PAGE made a large number of false positive calls.115,125 So, whether metformin is
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the new wonder drug should be taken with a pinch of salt until more research is done to
validate the effect of metformin as a possible adjuvant.
3.5.3 Limitations and future work
Other diabetes drugs, like glibenclamide, also have been shown to possess anti-inflammatory
effects in response to bacterial infection. Glibenclamide strongly reduced pro-inflammatory
cytokine production in response to Burkholderia pseudomallei. Diabetes patients are
more susceptible to the bacterial infection, but treatment with glibenclamide reduces the
mortality of melioidosis by reducing the hyper-inflammation occurring in sepsis.133,134
It shows that other anti-diabetes drugs besides metformin have promise outside their
intended use, and should also be investigated for their beneficial effects in response for
example to M. tb infection.
What would have been ideal, would be to have performed the PBMC stimulations
with live M. tb than with M. tb lysate. Evidence has shown that more genes are signifi-
cantly differentially expressed when stimulated with live M. tb compared to stimulation
with irradiated M. tb.135 Also, these current data are only for 4 hours of stimulation,
and it would be valuable to investigate over further time-points. In this study, PBMCs
stimulated with M. tb lysate for 24 hours were collected and qRT-PCR was performed
on the IFN-response genes. The RNA-seq results for the 4 hour M. tb lysate stimulation
were validated in that the IFN-response genes were down-regulated after metformin ad-
ministration. At 24 hours however, the effect had dwindled, and a down-regulation of
a much smaller magnitude was witnessed in response to metformin. However, this was
only on a selection of genes, so it would be of value to perform genome-wide analysis on
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later time-points. In addition to this, in would be helpful to have stimulated the whole
blood samples with M. tb in order to see the difference in the immune response before
and after metformin administration.
A further limitation is in the classification for the gene-sets. The Hallmark gene-sets
were used, in which there are sometimes 200 genes within each set, and there are large
overlaps between the sets. Because of this it is questionable as to whether the enrichment
of the gene-set is truly reflective of its association. There is also variability in the gene-
set analysis tools. A comparative study found that the R package gage was one of the
worst performers, demonstrating poor specificity with a high false positive rate,126 albeit,
not as bad as PAGE which is why a second tool; piano was used. These kinds of tools
inherently rely on pre-existing pathways and associations and therefore limits the scope
of the analysis.
To conclude, these results do support a role of metformin in TB generally, and TB/DM
specifically. Research in metformin is blossoming and it is becoming clear its beneficial
properties are not just restricted to diabetes. It provides exciting avenues for research,
and the positive association in TB is promising.
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4Tuberculosis and diabetes in TANDEM:
cross-sectional study
4.1 Introduction
4.1.1 Tuberculosis and Diabetes: the collision of two epidemics
A link between type 2 diabetes (T2DM) and tuberculosis (TB) has been known for
centuries, initially when the Persian philosopher, Avicenna described the symptoms of
T2DM as including TB.32 During the 20th century, TB was a leading cause of death
among diabetic patients. Of course, the synthesis of insulin in the 1920s, and then
the discovery of streptomycin and other antibiotics in the 1940s led to the comorbidity
to somewhat dwindle. But, now T2DM has become a global epidemic in itself, as a
consequence of rising obesity, lifestyle changes, and an ageing population. Coupled with
TB, which has recently been classed the number one cause of death worldwide by an
infection, they now represent a threat to global health.6
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The TB/DM problem is exacerbated by the development of T2DM in countries where
TB is also endemic, like Indonesia and India. It has been estimated that 70% of diabetics
live in TB endemic countries. Indonesia has the third highest burden of TB globally, and
the fourth highest burden for diabetes.36 Countries like Romania and Peru also have a
high prevalence of both diabetes and TB,136 causing cause for concern. In a prospective
cohort study, the prevalence of diabetes among newly diagnosed TB patients in Indonesia
is 14.8% compared with 3.2% of the general population,137 which is projected to rise. The
increase in the prevalence of both diseases will potentially affect global TB control (Figure
4.1)
Figure 4.1: Projected prevalent diabetes cases and current worldwide tuberculosis
incidence. Estimated number and percent of individuals with diabetes mellitus in 2010 com-
pared with 2030 projections are shown. Tuberculosis incidence per 100 000 population data for
2007 are shown. Data from International Diabetes Foundation and WHO.
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Along with HIV-1, smoking and malnutrition, T2DM has also been recorded as a risk
factor for active TB disease. Even though the risk at the individual level is considerably
lower than, for example, AIDS, T2DM presents a substantial effect at the population
level due to the number of diabetic people.
To assess the likelihood of diabetic patients progressing to active TB disease, a sys-
tematic review of 13 observational studies and meta-analysis was performed. There was
large heterogeneity between studies, potentially due to the population differences in di-
abetes. Overall though, diabetes does increase the risk of TB; it estimated that T2DM
patients are 3.1 times more likely to develop active TB disease than non-diabetic indi-
viduals.59 Considering an estimated quarter of the world’s population is latently infected
with M. tb, and the number of T2DM cases are projected to be 552 million by 2030,36
it represents a huge reservoir of potential active TB disease. However, the causative link
between T2DM and TB remains largely elusive.
4.1.2 Clinical presentation of TB/DM
Evidence for diabetes patients to exhibit different clinical presentation of TB is incon-
clusive. Alisjahbana et al reported in a prospective cohort study that diabetes patients
were associated with more TB symptoms than those without diabetes. But, there was
not an increase in the severity of TB disease.137 Largely however, compared to TB pa-
tients without diabetes, diabetes patients are more likely to be sputum smear positive
at diagnosis and also delayed in culture conversion.138,139 Regarding diagnosis, screening
of TB patients has shown promise in diagnosing diabetes patients by using RPG as an
initial screen and then HbA1c testing (TANDEM, unpublished).
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4.1.3 Pre-diabetes
Pre-diabetes, or intermediate hyperglycaemia, is on the rise as well. Current projections
estimate the prevalence of pre-diabetes to be 470 million people worldwide by 2030. Pre-
diabetes is defined by having glucose levels that are higher than normal, but lower than
official diabetic thresholds, typically HbA1c values of 5.7%− 6.5%. It can be considered
a contentious category as not everyone with pre-diabetes progresses to diabetes, and the
term ’intermediate hyperglycaemia’ is sometimes used instead. It has been estimated
that 5− 10% of pre-diabetes subjects progress to diabetes annually, although this varies
considerably between populations.140 By proxy, pre-diabetes must also be associated with
insulin resistance and β-cell dysfunction, because if there were sufficient insulin sensitiv-
ity, elevated glucose levels would not be observed.140
The question of whether pre-diabetes leads to increased susceptibility of TB was
raised when susceptibility was strongly linked to glycaemic control.141 So, could patients
have an increased susceptibility even at intermediate levels of hyperglycaemia? Such
an association was shown by Viswanathan et al, who outlined that, in a cohort of TB
patients in India, the prevalence of pre-diabetes was 24.5%.142 However, it is unknown
whether it is a cause or effect of TB disease. From an immunological perspective, Kumar
et al wanted to find out if pre-diabetes also correlated with abnormal cytokine profiles in
TB patients. They found that TB pre-diabetes patients were associated with increased
circulating levels of Type I and Type 17 cytokines. Principally IFN-γ, TNF-α and IL-2
were significantly higher than TB without diabetes. This was also seen in response to
stimulation with M. tb antigens, showing that in the context of TB, pre-diabetes causes
a dysfunction in the immune response.143
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4.1.4 TB/DM immunology: a dysfunction
The way type 2 diabetes influences the immune system could have a relevant effect on
the body’s defence to M. tuberculosis. There have been studies that investigate the effect
of T2DM in the context of active TB disease. These include mouse experiments and
clinical investigations, both of which demonstrate T2DM increases susceptibility to TB.
The immunological basis of TB susceptibility in T2DM was recognised some decades
ago in streptozotocin (STZ)- treated mice. These mice have had their insulin producing
cells depleted, causing hyperglycaemia, so they are a good mouse model for studying
diabetes. When these diabetic mice were challenged with M. tb, more than 90% of them
died, compared to 10% of the challenged non-diabetic mice.144 Using the same model,
another study found that post M. tb challenge, diabetic mice had a higher bacterial bur-
den in the lung than non-diabetic controls. Martens et al demonstrated similar findings;
that the M. tb growth phase plateaued significantly later in chronic diabetic mice than
control mice, meaning a higher CFU weeks after infection.145 In addition to when these
STZ- treated mice were M. tb challenged, the diabetic mice produced less IFN-γ in the
lung in the early stages of infection than in control mice. However, after 2 months post
infection, the chronic diabetes mice had higher pro-inflammatory cytokine levels than in
non-diabetic mice.144 This could potentially indicate that diabetes delays the immune
response to M. tb, meaning repercussions in the control and confinement of the bacteria.
Studies in cytokine profiles in TB/DM patients are mixed. Some report altered cy-
tokine profiles in diabetic patients, whereas others report no differences. Restrepo et al
reported TB patients with diabetes were associated with higher levels of pro-inflammatory
cytokines like IFN-γand IL-2 than in patients with uncomplicated TB. This was posi-
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tively correlated with poor glycaemic control (HbA1c values > 6.2%), in which even more
cytokines like IL-6 and TNF were at higher levels.146 To contribute to this, Kumar et
al investigated the circulating levels of cytokines in TB/DM patients compared to TB
patients without diabetes. They found heightened levels of Th1 and Th17 inflammatory
cytokines in TB/DM patients than in uncomplicated TB. Such cytokines included IFN-
γ, TNF-α and IL-17A, but also increased levels of IL-10 were detected. This was also
the case in tuberculosis antigen (ESAT-6) stimulations of diabetic individuals.147,148 In
contrast, Stelenhoef et al found that IFN-γ cytokine production in TB/DM patients was
not different when compared to TB patients without DM. However, diabetes patients
without TB showed reduced levels of non-specific IFN-γ production,149 and in a sepa-
rate study, increased IL-6, which was positively correlated with HbA1c values.49 They
argue that it could mean defective non-specific immunity in diabetes that could cause
susceptibility to TB.
The dysfunction of the immune system in diabetes patients expands to the function
of immune cells. In vivo experiments have shown that diabetic mice display higher
absolute numbers of CD4 and CD8 T-cells, macrophages and neutrophils.145 This was
also seen in humans; diabetic patients had elevated absolute counts of neutrophils in
whole blood than in healthy controls. Not only are the number of immune cells higher,
but the cell’s immune function is also impaired. In general, it has been reported that
T2DM patients show consistent defects in neutrophils. For example, they exhibit reduced
migration,150 reduction of phagocytic ability,151 and also their antimicrobial activity.152
This is especially the case in diabetic patients with poor glycaemic control. In the context
of another infectious disease, this neutrophil impairment is seen in melioidosis, caused
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by the bacterium, Burkholderia pseudomallei, where diabetes causes an impairment in
migration and apoptosis, leading to a susceptibility of disease.153
Studies have shown that the immune cell’s phagocytic capacity is also awry in response
to M. tb infection. Restrepo et al showed that in T2DM patients, monocytes had overall
lower complement receptor mediated phagocytosis, and also lower phagocytosis efficacy.
Fc-γ Receptor mediated phagocytosis was also compromised in monocytes in T2DM pa-
tients, even after adjusting for age and BMI. Again, these impairments were associated
with hyperglycaemia.154 More recently, Raposo et al illustrated that phagocytosis is also
inhibited in neutrophils in diabetic patients compared to non-diabetic controls.155 Be-
cause neutrophils and monocytes are instrumental in the host defence against bacterial
infection, a dysfunction would mean implications in the control of M. tb infection.
In short, the immune dysfunctions identified in T2DM are suggestive that these could
render patients susceptible to infections, like M. tb where cell mediated immunity is
important. It is clear that this impairment is exaggerated in diabetic patients with poor
glycaemic control. However, the exact mechanism of susceptibility still remains unclear.
4.1.5 The TANDEM consortium
TANDEM (Tuberculosis and Diabetes Mellitus) is a four-year collaborative project funded
by the EU. It is a multi-national consortium that aims to unravel the casual link and to
improve care of concurrent tuberculosis disease and Type 2 Diabetes. The consortium
partners have expertise in clinical studies, epidemiology, genetics and immunology, with
leading laboratories in the United Kingdom and the Netherlands. TANDEM involves
four field sites; South Africa, Indonesia, Peru and Romania (Figure 4.2).
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Principally, TANDEM’s objectives were:
i To identify feasible, accurate and cost effective ways of screening TB patients for
diabetes and determine the prevalence of DM among TB patients and of TB in DM
in different geographical locations.
ii Determine the level of DM management required during and after TB treatment,
and the effect of glucose control on TB treatment outcomes.
iii To identify key pathways which may account for enhanced susceptibility to, and
poorer treatment outcomes of TB/DM by comparing gene expression and biomarker
profiles in TB patients with, compared to those without DM.
iv To establish the cellular and molecular basis responsible for the causal link between
diabetes and TB, and in particular to determine the effect of hyperglycaemia and
genetic variation on the host protective response to M. tb.
Figure 4.2: The TANDEM consortium is comprised of multi disciplinary partners all over the
world, with field sites in South Africa, Peru, Indonesia and Romania. Their aim is to unravel
the causal link between TB and type 2 diabetes, and improve care.
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Currently, data are lacking to improve care of TB/DM patients, and the association is
not mentioned in international and national treatment guidelines. However, screening of
TB in DM and vice versa could improve case detection and ensure appropriate treatment.
TANDEM involved determining the prevalence of TB/DM in the four fields; two (South
Africa and Indonesia) of which are the top TB incidence countries.
Of the many facets of TANDEM, The London School of Hygiene & Tropical Medicine
was the lead in the bioprofiling/gene expression study arm (Figure 4.3). The main
objective was to establish gene expression profiles of TB/DM comorbidity versus un-
complicated TB. Gene expression technology is a powerful tool in looking at biological
differences between two conditions. Because the biological mechanisms responsible for the
increased TB incidence in T2DM are unknown, transcriptomic analysis had the potential
to uncover such mechanisms. RNA-seq technology enabled us to perform an unbiased
approach in finding out whether diabetes causes intrinsically different gene expression.
This led onto performing a cross sectional study; of TB/DM, TB and TB preDM patients,
to determine blood biomarker profiles of each.
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Figure 4.3: The TANDEM consortium
4.1.6 Current transcriptomic findings
Gene expression analysis could uncover some of the underlying biological mechanisms
responsible for the increased susceptibility to TB disease in T2DM patients. The RNA
expression pattern in TB patients has been well described, in which active TB patients
are distinct from healthy controls, and also distinct from other diseases. The TB specific
signature included a neutrophil driven Type I interferon response.67 Since then, microar-
ray studies have extensively investigated the TB transcriptome, in PBMCs, and whole
blood in different settings.66,74,75,156 In comparison, transcriptomic studies in T2DM are
few. Manoel-caetano et al measured the gene expression in PBMCs of T2DM patients,
and found there is a distinct profile of from non-diabetic subjects. The profile included
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up-regulated genes involved in inflammation, and responses to oxidative stress and fatty
acid processing. The TB transcriptomic studies have only included uncomplicated TB
patients, which is not always reflective of the typical high TB burden population.
A study by Kaforou et al investigated the transcriptomic signature of mixed TB pa-
tients in order to generate a more inclusive result. In more detail, different populations
and different disease statuses (including HIV-1 infection) were all combined. They found
that when combining patients together, the signature generated was more powerful, com-
pared to analysing the groups separately.69 It is important to get a comprehensive analysis
of the TB signature which is relevant and can be used in different settings.
So far however, T2DM patients have been excluded from such TB gene expression
studies. It can be hypothesised that diabetes would modulate the effect of TB, as diabetes
is itself an immune dysfunction disorder. Of course, in what way is uncertain, but because
T2DM patients are more susceptible to active TB, it is presumably a detrimental effect.
Therefore, investigating the gene expression profile of patients with TB and T2DM will
divulge why they exhibit this increased susceptibility. We hypothesised if there were
changes in common in both disease which were synergistic when combined, the expression
profile of the two disease ’added together’.
Considering the pro-inflammatory profile of TB patients, and as diabetes is considered
as an inflammatory condition, I hypothesised that TB/DM co-morbidity patients would
have an enhanced inflammatory state to that of TB-only, which would be detectable
in blood transcriptomes. Further, I hypothesied that preDM would have similar blood
transcriptome to TB-only and the extent of a TB signature would correlate with extend
of diabetes progression.
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4.2 Aims and Objectives
Aims
I Determine whether there were any differences of gene expression in pa-
tients with uncomplicated TB and patients with type 2 diabetes comor-
bidity, and to characterise any difference identified.
II Determine the effect of intermediate hyperglycaemia levels on the gene
expression of uncomplicated TB
Objectives
I Perform RNA-seq analysis on whole blood samples from 4 different sites
and compare the differential expression profiles of TB, TB/DM and TB
preDM using an unbiased approach
II Compare the differential expression profile between the 4 different sites
III Compare the differential expression profile of TB, TB/DM, TB preDM
each with healthy controls
IV Compare the differential expression profile of TB/DM and TB preDM
each with TB
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4.3 Methods
4.3.1 Sample collection and processing
Newly diagnosed adult pulmonary TB patients with and without diabetes were recruited
into the study. Untreated TB patients were bacteriologically confirmed (culture, mi-
croscopy and/or Gene Xpert depending on whether facilities were available at the field
site). Informed consent was obtained and signed. Patients were excluded if they were
already taking TB treatment, had MDR-TB, were HIV-positive, pregnant, taking corti-
costeroids, or had other serious comorbidity. TB patients previously diagnosed T2DM
on anti diabetic drugs were included.
Whole blood samples were collected from four different field sites; South Africa, In-
donesia, Peru and Romania. The study locations were: Stellenbosch University in Cape
Town, Universidad Peruana Cayetano Heredia in Lima, University Padjadjaran in Ban-
dung and Universitatea de Medicina si Farmacie in Craiova.
Diabetes was diagnosed by laboratory test of glycated haemoglobin (HbA1c) as ≥
6.5%, according to the WHO recommendations and the American Diabetes Association.
The intermediate hyperglycaemia patients were characterised with an HbA1c reading of
≥ 5.7% and < 6.5%. Patients without diabetes, including healthy controls, had HbA1c
values of < 5.7%.
Two and a half millilitres of venous blood were collected at TB diagnosis, before
initiation of TB treatment, into PAXgene Blood RNA Tubes (PreAnalytiX) and frozen
at −80◦C, to then undergo RNA-seq, using the polyA tail library prep method, and single
read sequencing.
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Whole blood PAXgene samples (n=504) were received on dry ice by LSHTM from all
four field sites; South Africa, Indonesia, Peru and Romania (Table 4.1). The PAXgene
blood RNA tubes contain an additive that immediately stabilises the intracellular RNA
at collection, which reduces RNA degradation. These 504 samples were from patients
with TB with T2DM comorbidity, TB patients with pre-diabetes (intermediate levels of
hyperglycaemia), uncomplicated TB, T2DM with no TB, and healthy controls. Sample
collection was done at TB diagnosis, before the initiation of any treatment. In addition,
patients with TB/DM, TB preDM and TB-only had samples collected at three other
time points post initiation of TB treatment; week 2, month 2 and month 6 (discussed in
Chapter 5).
Field site Total Cross sectional study only
Indonesia 124 38
Peru 32 32
Romania 122 70
South Africa 197 109
Table 4.1: Total number of RNA samples from each field site that underwent differential ex-
pression analysis (after any exclusions), and total number of RNA samples from each field site
included in the cross sectional study.
All of the samples that underwent RNA-seq analysis were randomised using Excel,
mixing all field sites, disease group and time-points. Then, each sample was assigned a
new RSEQ label. This was to reduce potential batch effects, and prevent the introduction
of technological bias. The 504 samples were then shipped to the Department of Genetics,
University Medical Centre Groningen, University of Groningen in the Netherlands (in
collaboration with Vinod Kumar and Cisca Wijmenga) where I performed the RNA-seq
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lab work with Bahram Sanjabi and Desiree Brandenburg-Weening.
Total RNA (which includes mRNA, tRNA, rRNA and miRNA) was extracted using
PAXgene blood miRNA kit (Qiagen) using the semi-automated QIAcube (Qiagen). RNA
was quantified using the LabChip GX HiSens RNA system (PerkinElmer). The LabChip
GX is a highly multiplex electrophoresis system that can analyse size and purity of RNA
and DNA samples.
RNA-seq libraries were prepared using the Bioscientific NEXTflex-Rapid-Directional
mRNA-seq sample preparation with the Caliper SciClone (for Illumina platform). With
this kit, there were 48 different adapters available. These unique adapter barcodes were
6 bases long and used to tag the sample reads, in order to identify each sample after
demultiplexing. This allows for multiple samples to be pooled and sequenced at the
same time. The input RNA used for the library preparation was 1µg. The output
was then measured using Caliper GX HiSens DNA kit (PerkinElmer), samples plated in
triplicate into a 384 well plate. Sample pools for sequencing were made up of 24 samples,
the total final concentration of which was 10mM. The samples were sequenced using the
NextSeq500 High Output kit V2 (Illumina) for 75 cycles. In each flow cell, there were 24
samples, producing an average depth of 16 million reads per sample.
In total, 497 samples were sequenced. Of these, 481 were unique samples and the
remaining were three ’internal normalisers’ included 6 times each. These samples were
included for verification of consistency in the library prep, throughout all of the plates.
These 3 internal normalisers were chosen as they had high concentration and high RIN
values.
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4.3.2 Data processing and analysis
Patient characteristic variables were tested for normality using the Shapiro-Wilk test. If
deemed normally distributed, a pairwise t-test was performed, if not, a non-parametric
Wilcoxon Rank Sum Test was performed. This was done using the statistical program-
ming language R.
RNA-seq samples were demultiplexed by Gerban van der Vries at the University
of Groningen, Genetics Department. Twenty four samples were run on one flow cell,
and because each flow cell had four lanes, 4 FASTQ files were generated for each sam-
ple. I obtained the 1,988 FASTQ files, which I then processed and analysed. FASTQ
files were aligned to the human genome (version Human g1k v37) using STAR aligner
(Spliced Transcripts Alignment to Reference)116 (v2.5.1b). The 1,988 SAM files were
then converted to BAM files, and the 4 BAM files for each sample were merged using
SAMtools157 (v1.2), creating 497 complete BAM files. This was done in Unix in the ter-
minal using the GCC cluster (Genomics Coordination Centre in Groningen University).
Reads were quantified using HTSeq-count118 (v0.6.1) using the ensembl annotation file
version Homosapiens.GRCh37.75.gtf with the settings described below.
-f bam format of the input data
-r name how the input data have been sorted
-s no whether the data is from a strand specific assay
-m union mode to handle reads overlapping more than one feature
-i gene id what attribute to be used as feature ID
Quality control of FASTQ data was done using the program FastQC (Babraham
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Bioinformatics, v0.11.5). Count data generated by HTSeq-count, in the form of txt files
were then imported into the statistical programming language R v3.3.3 and RStudio
v1.0.136. Non-informative rows were removed and differential expression analysis was
performed using DESeq2 (v 1.12.4). Data were normalised using the default settings as
per the metformin study in Chapter 3. Multiple testing was corrected using the Benjamini
& Hochberg false discovery rate method. We had two different study designs, which are
summarised in Figure 4.4.
Figure 4.4: RNA-seq cross-sectional study design. The cross sectional analysis comprised
of two study designs. The first compared all disease phenotypes with healthy controls, as
in South Africa and Romania. The second used TB-only as the control, and was done for
Indonesia, Peru and also when combining all 4 of the field sites.
The first study design applied to South Africa and Romania because the field sites
127
CHAPTER 4. TB/DM: CROSS-SECTIONAL
had collected healthy control and type 2 diabetes patients without TB. The field sites
were normalised separately, and all of the disease phenotypes, TB-only, TB/DM, TB
preDM and DM-only were in turn compared to their matching healthy controls.
The second study design was performed in the Indonesia and Peru populations, and
later when all the field sites were combined and analysed together. This is because In-
donesia and Peru only collected samples from TB/DM, TB preDM and TB-only patients.
Here, TB-only was used as the control, where TB/DM and TB preDM were compared
against TB-only patients. This was conducive to find out how diabetes impacts the TB
gene expression profile. Another cross sectional analysis was done using this study design;
combining all the TB/DM, TB preDM and TB-only samples from all 4 field sites. This
substantially increased the sample numbers in the 3 disease groups, and also means any
differences found would be applicable across different populations.
The two different study designs existed because in the original TANDEM consortium
plan, only samples from South Africa were intended to be analysed using microarrays.
The opportunity to perform RNA-seq analysis on a larger sample set became available
during the course of the consortium project, and it was then decided to include samples
from the other three sites in order to make any differences relevant in different popula-
tions, but we were restricted to what had been collected.
Of the combined analysis, two sub-analyses were done. One included a population
correction term in the design formula (Equation 4.2), and one did not (Equation 4.1).
Incorporating a second covariate can control the (unwanted) variation caused by popu-
lation, and therefore further uncover the actual biological variation due to disease.
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y = (β1disease category + ) (4.1)
y = (β1disease category + β2population + ) (4.2)
4.3.3 Modular analysis
Modular analysis is a technique that analyses groups of genes together as a means to iden-
tify immunological mechanisms. These gene groups are genes that tend to be expressed
together, formulated from transcriptional data sets. It can provide a framework for visu-
alisation and function interpretation and a means to identify immunological mechanisms.
It was done using R package tmod (v0.31). This package uses the modules outlined by
Chaussabel et al94 and by Li et al.95
Module enrichment is calculated by ranking the genes by p-value that belong to the
module, and genes that do not belong to the module using the CERNO test, described
by Yamaguchi et al.158 An adjusted p-value of < 0.05 was deemed to be significant.
4.3.4 Previously published signature analysis
To test the effect of diabetes and pre-diabetes on published TB signatures, the Zak et
al7616 gene signature was analysed in the differential expression results (disease category
versus healthy controls). This specific signature was selected for analysis as literature
is moving forward with smaller signatures and it has received the most critical acclaim.
Also, it used more sophisticated and robust methods based on machine learning algo-
rithms, rather than for example just a list of significantly differentially expressed genes.
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The log fold changes for these 16 genes were extracted from the comparisons; TB/DM,
TB preDM, and TB-only versus healthy controls. These fold change values were summed
as per the Disease Risk Score formula from Kaforou et al.69 The normalised count for
these genes was also extracted for each patient and summed in order to stratify by HbA1c.
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4.4 Results
4.4.1 Patient characterisation
The patients from the four field sites (Indonesia, South Africa, Peru and Romania) were
age and sex matched. This was deliberate so there was no age or gender bias between
the groups. For example, in South Africa, TB patients were selected so that they were
not significantly different from the TB/DM patients. However, in the cases of the other
field sites, there were no extra patients so all of them were analysed, Figure 4.5 and 4.6.
Age was normally distributed, and pairwise t-test revealed no significant difference in age
between any of the groups, after multiple testing correction (p-value < 0.05).
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Figure 4.5: Age of patients of all the patients groups before the initiation of TB
treatment in the four field sites. A: Indonesia, B: South Africa, C: Peru, D: Romania.
Lines show the median, and the first and third quartile. Points outside the lines represent
outliers, calculated by Q1− 1.5 ∗ IQR and Q3− 1.5 ∗ IQR. Pairwise t-test was performed and
a p-value < 0.05 was deemed statistically significant.
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Figure 4.6: Gender of the patients in each of the groups, in the four field sites. A:
Indonesia, B: South Africa, C: Peru, D: Romania.
In all the populations, Indonesia, South Africa, Peru and Romania, patients with
TB/DM had generally higher body max index, although not statistically different from
TB-only or TB preDM (Figure 4.7). In South Africa, BMI tended to be higher in diabetes
patients, this was especially the case patients that were not diagnosed with TB. DM-
only, preDM and Healthy Controls were all statistically significantly different from the
TB disease groups; TB/DM, TB-only, and TB preDM (pairwise Wilcoxon Rank Sum
Test, p-value < 0.05), results shown in Table 4.2. This is expected as TB patients
have characteristic weight loss. In Romania, the BMI of the DM-only control group was
statistically significant from TB/DM, TB-only and TB preDM, results shown in Table
4.3.
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Figure 4.7: Body mass index (BMI) of all the patient groups before the initiation
of TB treatment in the 4 field sites A: Indonesia, B: South Africa, C: Peru, D: Romania.
Lines show the median, and the first and third quartile. Points outside the lines represent
outliers, calculated by Q1− 1.5 ∗ IQR and Q3− 1.5 ∗ IQR. Groups were tested for normality
and a non-parametric Wilcoxon Rank Sum Test was performed.
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DM-only Healthy controls pre DM TB/DM TB-only
Healthy controls 0.083 - - - -
pre DM 1 0.839 - - -
TB/DM 0.0041 0.617 0.152 - -
TB-only 2.4e−05 0.152 0.0931 1 -
TB preDM 3.8e−07 0.0034 0.0153 0.617 1
Table 4.2: Significance of Body Mass Index between each patient group in South
Africa. Results from a non-parametric Wilcoxon Rank Sum Test. Colour indicates a significant
p-value (< 0.05)
DM-only TB/DM TB-only
TB/DM 0.121 - -
TB-only 0.021 0.663 -
TB preDM 0.014 0.635 0.663
Table 4.3: Significance of Body Mass Index between each patient group in Romania.
Results from a non-parametric Wilcoxon Rank Sum Test. Colour indicates a significant p-value
(< 0.05)
Figure 4.8 shows the HbA1c values in all the populations and groups. In all of the
populations, the HbA1c values of the patient groups were all significantly different from
one another, particularly in TB/DM patients than in TB-only or TB preDM, results
shown in Tables 4.4, 4.5, 4.6 and 4.7 (non-parametric Wilcoxon Rank Sum Test, p-value
< 0.05). In Romania and South Africa, there were also DM-only patients, which consisted
of newly diagnosed, and previously diagnosed DM, some of which had well controlled
diabetes. Here, DM-only was also significantly different from the other groups. The
populations exhibit different patterns of glucose control. For instance, in Indonesia, the
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TB/DM patients were more defined, as they had a considerably smaller IQR of HbA1c
values, and also have a higher mean average than in the other populations. On the other
hand, South African and Romanian diabetes patients have a much larger variability in
glucose control, with lower average means.
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Figure 4.8: Laboratory HbA1c values, taken before the the initiation of TB treatment
of all the patients groups in the 4 field sites. A: Indonesia, B: South Africa, C: Peru,
D: Romania. Dashed red lines indicate the threshold cut offs for pre-diabetes (intermediate
hyperglycaemia) (HbA1c 5.7%− 6.5%) and diabetes (HbA1c ≥ 6.5%). Lines show the median,
and the first and third quartile. Points outside the lines represent outliers, calculated by Q1−
1.5 ∗ IQR and Q3− 1.5 ∗ IQR.
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TB/DM TB-only
TB-only 4e−06 -
TB preDM 0.0017 0.0017
Table 4.4: Significance of HbA1c values between each patient group in Indonesia.
Results from a non-parametric Wilcoxon Rank Sum Test. Colour indicates a significant p-value
(< 0.05)
DM-only Healthy controls pre DM TB/DM TB-only
Healthy controls 9.0e−08 - - - -
pre DM 0.00378 0.00136 - - -
TB/DM 1 2.5e−06 0.00315 - -
TB-only 8.7e−05 1 0.008 0.00016 -
TB preDM 1.4e−06 2.1e−07 1 6.3e−06 8.7e−05
Table 4.5: Significance of HbA1c values between each patient group in South Africa.
Results from a non-parametric Wilcoxon Rank Sum Test. Colour indicates a significant p-value
(< 0.05)
TB/DM TB-only
TB-only 0.00016 -
TB preDM 0.00027 0.00027
Table 4.6: Significance of HbA1c values between each patient group in Peru. Results
from a non-parametric Wilcoxon Rank Sum Test. Colour indicates a significant p-value (< 0.05)
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DM-only Healthy controls pre DM TB/DM TB-only
Healthy controls 5.8e−05 - - - -
pre DM 0.0163 0.0189 - - -
TB/DM 1 0.00016 0.0189 - -
TB-only 0.00018 1 0.0189 0.00037 -
TB preDM 0.00018 0.00067 1 0.00037 0.00147
Table 4.7: Significance of HbA1c values between each patient group in Romania.
Results from a non-parametric Wilcoxon Rank Sum Test. Colour indicates a significant p-value
(< 0.05)
The TB/DM patients within the different field sites were receiving anti-diabetes med-
ication (Figure 4.9). They were on either insulin, metformin, a combination of the two,
in combination with other diabetes drugs, or no medication at all. The patients on no
medication were mostly newly diagnosed cases. The majority of previously diagnosed
diabetes patients in Romania were on insulin. But, in the other three field sites, diabetes
medication was mixed, with most on metformin or metformin in combination with other
oral diabetes medication (like glibenclamide).
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Figure 4.9: Proportion of TB/DM patients on anti diabetic medication in the four
different field sites.
4.4.2 Assessment of RNA quality
In total (cross sectional and longitudinal study), 504 PAXgene tube samples were isolated
and underwent quality assessment. Of these, 436 had a RNA integrity number (RIN) of
≥ 7, and 46 had a RIN of ≤ 7 ≥ 4. It was decided that these 482 samples would proceed
to the library preparation stage. This was because although some samples that had
varying degrees of quality, clear 18S and 28S RNA peaks were still seen in the LabChip
GX (Figure 4.10). In 22 cases, the samples had to be excluded due to either absence of
RNA or complete degradation. The field site with the poorest quality RNA was Peru,
which has significantly lower RIN values than in South Africa, Romania or Indonesia
(Figure 4.11).
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A B
C
Figure 4.10: Examples of variations of RNA quality. RNA integrity number (RIN) was
used as a measure for RNA quality. RIN is calculated from the ratio of 28S and 18S peaks,
generated by the LabChip GX. The clearer the two peaks, the higher the quality of RNA. A:
good quality RNA samples (RIN=8), B: partially degraded RNA sample (RIN = 4), C: sample
with no RNA yield (RIN=0)
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Figure 4.11: Relationship between RNA quality (RIN) and field site. RIN was calcu-
lated using the LabChip GX. Samples shown red, had very poor RNA quality and had to be
excluded. The majority of exclusion occurred in Indonesia and Peru. Pairwise t-test revealed
RIN values of samples from Peru were significantly different from the other 3 populations (p-
value 1× 10−7).
A total of 482 unique samples were sequenced, after which, 3 samples had to be
excluded due to poor number of aligned reads (Figure 4.12). The RIN values and number
of aligned reads appear to have a positive association, with a higher RIN value, an
increased number of reads aligning to the reference. However, 1 of the samples with poor
read alignment had a RIN of 8. During cleaning of the meta data, 4 further samples had
to be excluded. This brought the sum of samples for downstream analysis to 475.
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Figure 4.12: Relationship between RNA quality (RIN) and read alignment. Number
of reads aligned to the reference human genome in each of the 481 whole blood RNA samples.
RNA quality was assessed using LabChip GX. Three samples had fewer than 8,000,000 reads,
and had to be excluded for down stream analysis, shown in red.
The cross-sectional study consisted of 249 samples from all 4 field sites and 6 disease
categories; TB/DM comorbidity, TB preDM, TB-only, DM-only, pre-DM and healthy
controls. The 3 categories; TB/DM, TB preDM and TB-only were the only groups
consistent across all 4 populations, in which there were 151 samples in total. (Table
4.10)
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Field site TB/DM TB preDM TB-only
Peru 12 9 11
Indonesia 19 5 14
Table 4.8: RNA sample numbers that underwent differential expression analysis in
the different patient groups within the cross sectional study in Peru and Indonesia.
Field site TB/DM TB preDM TB-only DM-only preDM Healthy Controls
Romania 15 10 10 19 4 12
South Africa 15 20 11 33 6 24
Table 4.9: RNA sample numbers that underwent differential expression analysis in
the different patient groups within the cross sectional study in South Africa and
Romania.
TB/DM 61
TB preDM 44
TB-only 46
total 151
Table 4.10: RNA sample numbers of the three groups that were consistent across
all the field sites within the cross sectional study.
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4.4.3 Gene expression in TB/DM patients in South Africa
The South African cohort consisted of 109 samples for 6 groups; TB/DM comorbidity,
TB-preDM, TB-only, DM-only, pre-DM and healthy controls (Table 4.9). All 109 samples
were normalised together, and a PCA was done to observe any clustering (Figure 4.13).
The PCA plot revealed two main clusters. Healthy controls and people with type 2
diabetes (and pre diabetes) clustered together. The second main cluster comprised of
TB/DM comorbidity and TB pre diabetes patients. Uncomplicated TB patients spread
across these two clusters. The PCA revealed that the TB pre DM patients were more
similar to TB/DM patients.
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Figure 4.13: Blood global transcriptome differences between patients groups in South
Africa. Principal component analysis of all the patient groups in South Africa before the
initiation of TB treatment.
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Each disease group was compared to healthy controls, to obtain a differential ex-
pression profile of each phenotype. Volcano plots in Figure 4.14 summarise the gene
expression profiles for each disease category. As expected, when comparing TB-only pa-
tients to healthy controls, there is a large asymmetrical up-regulation of many genes,
mirroring previous literature.67,68 In DM patients, the expression profile was more sym-
metrical, with a lower magnitude of fold change. Unexpectedly however, the TB/DM and
TB preDM differential expression profiles were very similar to each other, but also to-
gether very different from the expression profiles of TB-only and DM-only versus healthy
controls. The two groups; TB/DM and TB preDM exhibited a comparable amplitude of
gene expression, with many of the same genes up- and down-regulated.
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Figure 4.14: Differential expression analysis of all the disease phenotypes in South
Africa compared to healthy controls before the initiation of TB treatment. Gene ex-
pression profiles of A: TB-only (n=11); B: DM-only (n=33), C: TB/DM (n=15), D: TB preDM
(n=20), each relative to healthy controls (n=24). Genes that were deemed statistically signifi-
cant had an adjusted p-value of < 0.05 after multiple testing correction (method=Benjamini &
Hochberg). Purple corresponds to the genes that were significant, grey is genes that were not
significant. The most differentially expressed genes were labelled.
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Venn diagrams in Figures 4.15 and 4.16 encapsulate the number of genes differen-
tially expressed when each phenotype was compared with healthy controls. Interestingly,
the genes differentially expressed in diabetes are not the same as those differentially ex-
pressed in TB-only. This is curious because T2DM is seen as an inflammatory disorder,
and TB stimulates a large pro inflammatory response, so one would expect there to be
similarities. The genes differentially expressed in TB/DM and TB preDM overlapped
considerably with DM and TB-only, but also included a large number of genes which
were not differentially expressed in these two groups compared to healthy controls.
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Figure 4.15: The number of statistically significantly differentially expressed genes
in TB/DM, TB-only and DM-only relative to healthy controls in South Africa. All
samples in South Africa taken before initiation of TB treatment were normalised together, and
differential expression performed. An adjusted p-value of < 0.05 was deemed significant.
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Figure 4.16: The number of statistically significantly differentially expressed genes in
TB/DM, TB preDM, TB-only and DM-only relative to healthy controls in South
Africa. All samples in South Africa taken before initiation of TB treatment were normalised
together, and differential expression performed. An adjusted p-value of < 0.05 was deemed
significant.
Modular analysis was performed in order to introduce biological knowledge to the
groups of genes that were expressed together, shown in Figure 4.17. This was con-
densed into a panel plot, which shows the statistically significant modules in each of the
four disease categories compared to healthy controls. In TB-only, modules that were
up-regulated, included type I interferon response, complement and activated dendritic
cells. In contrast, in diabetes patients, mainly respiration modules were up-regulated,
that are not present in the comorbidity groups. The TB/DM and TB preDM patients
exhibited similar module expression. Of the differentially expressed modules, most were
up-regulated. The modules differentially expressed in TB-only were also expressed in
the TB/DM and TB preDM groups. This was in addition to increased down-regulation
of modules, in particular; adaptive immune response modules such as T-cell activation,
differentiation and B-cells.
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Figure 4.17: Transcriptional modules
that were significantly differentially
expressed in TB-only, TB/DM, TB-
preDM and DM-only compared to
healthy controls in South Africa be-
fore initiation of TB treatment. Tran-
scripts were evaluated using a pre existing
modular framework. Up-regulated (red)
and down-regulated (blue) modules. The
length of each bar corresponds to effect size
of that module, and the colour saturation
represents the adjusted p-value (< 0.05).
The amount of colour represents the pro-
portion of genes within that module that
are differentially expressed.
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4.4.4 Gene expression in TB/DM patients in Romania
The Romanian analysis consisted of 70 samples and was the second field site that also
obtained healthy controls (Table 4.9). Again, during differential expression analysis, each
disease phenotype was compared to healthy controls to get a gene expression profile of
each disease group (Figure 4.4). PCA analysis in Figure 4.18 revealed some clustering of
healthy controls and diabetes patients together. Also, TB/DM and TB preDM clustered
primarily together.
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Figure 4.18: Blood global transcriptome differences between patients groups in Ro-
mania. Principal component analysis of all the patient groups in Romania before the initiation
of TB treatment.
To demonstrate the gene expression profiles of each disease category versus healthy
controls, volcano plots were generated (Figure 4.19). In the other control group; DM-
only, there was a pattern of up-regulation. The gene Carbonic Anhydrase 1 (CA1) had
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the largest statistically significant fold change, and has a role in respiration.
Complement C1q B Chain (C1QB) and interferon response genes, Interferon Induced
Protein With Tetratricopeptide Repeats 1 and 3 (IFIT1 and IFIT3) were the top signifi-
cantly differentially expressed genes in TB-only relative to healthy controls. This mirrors
previous literature. Complement and interferon related genes are frequently noted as up-
regulated in response to active TB disease. In this population, TB-only against healthy
controls were different from in the South African population in that there was more
down-regulation as well as the expected up-regulation.
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Figure 4.19: Differential expression profiles of disease categories compared to healthy
controls in Romania before initiation of TB treatment. Blood transcriptome of; A:
TB-only (n=10), B: DM-only (n=19), C: TB/DM (n=15), D: TB preDM (n=10) relative to
healthy controls (n=12). Orange points represent genes that were statistically significant after
multiple testing correction (adjusted p-value < 0.05), grey were genes that were not statistically
significant. The most differentially expressed genes were labelled.
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TB/DM and TB preDM versus healthy controls had similar expression profiles to one
another, but were different to the TB-only comparison. This is alike the result from the
same group comparisons in the South African population. Both disease categories had
a similar magnitude of expression, with many genes over 2log2 fold change differentially
expressed. With the large up-regulation, there was also considerable down-regulation.
The genes C1QB and C1QC were highly up-regulated in both TB/DM and TB preDM
than in healthy controls.
The number of statistically significant genes were plotted in Venn diagrams, Figures
4.20 and 4.21. The genes differentially expressed in TB-only or DM-only had a small
overlap. The genes differentially expressed in TB/DM or TB preDM have a large overlap,
but are in turn both very different from the other group comparisons.
166
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Figure 4.20: The number of statistically significantly differentially expressed genes in
TB/DM, TB-only and DM-only relative to healthy controls in Romania. All samples
in Romania taken before initiation of TB treatment were normalised together, and differential
expression performed. An adjusted p-value of < 0.05 was deemed significant.
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Figure 4.21: The number of statistically significantly differentially expressed genes in
TB/DM, TB preDM, TB-only and DM-only relative to healthy controls in Roma-
nia. All samples in Romania taken before initiation of TB treatment were normalised together,
and differential expression performed. An adjusted p-value of < 0.05 was deemed significant.
Figure 4.22 shows the modular analysis of the four Romanian patient groups versus
healthy controls. In TB-only, as in its corresponding volcano plot, there was a large
up-regulation of modules, but also reasonable down-regulation. The most statistically
significant differentially expressed module was interferon. The genes within the particular
interferon module are involved in IFN-γ signalling and transcriptional regulators of type
I interferons. Along with interferon, monocytes, dendritic cells and inflammation were
also up-regulated. Together with this, adaptive immune response modules were mostly
down-regulated. These include T-cell differentiation and activation.
When comparing DM-only to healthy controls, modules were largely up-regulated.
This comprised of modules involved in respiration, like the electron transport chain, but
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also inflammation modules. This is contrasting to the DM-only patients in South Africa,
which saw slight down-regulation of inflammation modules.
The modular expression profiles of TB/DM and TB preDM were again very similar,
with considerable up-regulation. The top significantly differentially expressed modules (in
both) were enriched in monocytes and inflammation. Together with this, there was also
down-regulation of B-cells and T-cell activation modules. The module expression profile
of these two groups in Romania was analogous to the same groups in South Africa. In
both, the modules were was widely up-regulated, particularly type I interferon response
and inflammation modules.
155
CHAPTER 4. TB/DM: CROSS-SECTIONAL
enriched in B cells (VI)
Mitochondrial Respiration
transcription elongation, RNA polymerase II
respiratory electron transport chain (mitochondrion)
respiratory electron transport chain (mitochondrion)
nuclear pore complex
translation initiation factor 3 complex
enriched in cell cycle
heme biosynthesis (II)
erythrocyte differentiation
Protein Synthesis
heme biosynthesis (I)
Protein Synthesis
Erythrocytes
Erythrocytes
Cell Cycle
enriched in membrane proteins
Cell Cycle
spliceosome
Erythrocytes
intracellular transport
Mitochondrial Stress / Proteasome
Protein Synthesis
enriched in monocytes (I)
Monocytes
Resting dendritic cell surface signature
platelet activation & blood coagulation
DC surface signature
cell adhesion
platelet activation − actin binding
lysosome
cell movement, Adhesion & Platelet activation
endoplasmic reticulum
enriched in dendritic cells
signaling in T cells (I)
T cell activation and signaling
cell adhesion (lymphocyte homing)
NK cell surface signature
cell junction (GO)
Platelets
transcription regulation in cell development
Inflammation
respiratory electron transport chain (mitochondrion)
Mitochondrial Respiration
respiratory electron transport chain (mitochondrion)
enriched in T cells (I)
receptors, cell migration
TLR and inflammatory signaling
Cytotoxic/NK Cell
activated dendritic cells
T cell activation (III)
inflammatory response
T cell differentiation via ITK and PKC
regulation of antigen presentation and immune response
innate antiviral response
viral sensing & immunity; IRF2 targets network (II)
enriched in NK cells (I)
Monocyte surface signature
viral sensing & immunity; IRF2 targets network (I)
enriched in neutrophils (I)
type I interferon response
enriched in activated dendritic cells (II)
antiviral IFN signature
Interferon
Interferon
Inflammation
Interferon
Cell Cycle
Inflammation
Inflammation
immune activation − generic cluster
Inflammation
enriched in monocytes (II)
Apoptosis / Survival
Inflammation
cell cycle and transcription
myeloid cell enriched receptors and transporters
T cell
T cell activation (I)
enriched in monocytes (IV)
T cells
Cell Death
Inflammation
T cell differentiation
innate activation by cytosolic DNA sensing
formyl peptide receptor mediated neutrophil response
cell adhesion (GO)
chemokines and inflammatory molecules in myeloid cells
enriched in neutrophils (II)
nucleotide metabolism
transmembrane transport (I)
enriched in antigen presentation (II)
MHC−TLR7−TLR8 cluster
RIG−1 like receptor signaling
enriched in myeloid cells and monocytes
Activated (LPS) dendritic cell surface signature
enriched in antigen presentation (III)
T cell activation (II)
T cell signaling and costimulation
B cell
enriched in B cells (I)
enriched in B cells (II)
blood coagulation
suppression of MAPK signaling
enriched in monocytes (surface)
complement activation (I)
complement and other receptors in DCs
enriched in NK cells (receptor activation)
TLR8−BAFF network
cell cycle and growth arrest
enriched in T cells (II)
T cell activation (IV)
regulation of signal transduction
enriched in activated dendritic cells/monocytes
enriched in B cells (III)
lysosomal/endosomal proteins
enriched in NK cells (II)
extracellular matrix (II)
integrins and cell adhesion
TB
−o
nl
y
TB
/D
M
TB
−p
re
DM
D
M
−o
nl
y
Effect size:
P value:
0.5 0.98
0.01 0.001 10−4 10−5 10−6
Figure 4.22: Modular analysis of TB-
only, TB/DM, TB preDM and DM-
only compared to healthy controls be-
fore the initiation of TB treatment in
Romania. Up-regulated (red) and down-
regulated (blue) relative to TB-only. The
colour saturation is relative to adjusted p-
value, and length of bars is relative to ef-
fect size. The amount of colour corre-
sponds to the proportion of genes differen-
tially expressed within that module. Mod-
ules were deemed significant with an ad-
justed p-value of < 0.05
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4.4.5 Gene expression in TB/DM patients in Indonesia
The Indonesian cohort consisted of 38 samples from only three groups; TB/DM, TB
preDM and TB-only (Table 4.8). As no healthy controls were collected in Indonesia, it
meant that a different study design was used, in which TB-only was used as the control
(Figure 4.4. TB/DM and TB preDM were each compared to TB-only, and volcano plots
show the results of this. Because of the few samples in the TB preDM group, 0 genes were
statistically significantly differentially expressed. In TB/DM, 24 genes were significantly
differentially expressed versus TB-only. All of these except one were up-regulated. The
most differentially expressed gene was a ribosomal protein (RLPL13P12) .
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Figure 4.23: Gene expression profile of TB/DM (A) and TB preDM (B) relative to
TB-only patients from Indonesia before the initiation of TB treatment. Navy blue
points represent the genes that were significantly differentially expressed after multiple testing
correction (adjusted p-value < 0.05). Grey was not significant. The genes that were most
differentially expressed were labelled.
4.4.6 Gene expression in TB/DM patients in Peru
In the Peru population, 32 samples comprised of 3 groups; TB/DM, TB preDM and
TB-only (Table 4.8). This cohort followed the same study design as in the Indonesian
population, whereby TB-only acted as the denominator.
Volcano plots show TB/DM and TB preDM against TB-only. Statistically significant
genes were mostly up-regulated in both instances. In TB/DM versus TB-only, 22 genes
were statistically differentially expressed, the most up-regulated being IFI27. IFI27 is an
158
CHAPTER 4. TB/DM: CROSS-SECTIONAL
alpha interferon protein involved in interferon-γ signalling. When comparing TB preDM
and TB-only, 39 genes were found to be significantly differentially expressed.
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Figure 4.24: Gene expression profiles of TB/DM (A) and TB preDM (B) compared
to TB-only in Peru before the initiation of TB treatment. Green points represent the
statistically significantly differentially expressed genes after multiple testing correction (p-value
< 0.05), grey was not significant. The most differentially expressed genes were labelled.
4.4.7 Gene expression in TB/DM in field sites combined
All of the TB/DM, TB preDM and TB-only groups from the four different field sites were
combined. This was to increase the sample size of each of the three groups to dissect what
impact diabetes has on the gene expression profile of active TB infection (Table 4.10).
Because these three groups were the only ones present through the four populations, the
TB-only group was used as the control.
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Two analyses were run in parallel; with and without a population correction. Adding
a population variable in the design can correct for some of the unwanted variation caused
by the differences across the populations, thus, leaving the biological variation from the
different disease conditions (Equation 4.2).
An initial PCA plot showed no clustering, Figure 4.25. This meant the disease groups
from each population were not too different from one another that they could not be
combined.
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Figure 4.25: Principal component analysis of all the samples before the initiation of
treatment, in all four field sites.
The two analyses produced slightly different results, in that without a population
correction, fewer genes were found to be statistically differentially expressed. This was
the case in both TB/DM and TB preDM. As the two designs produced slightly different
160
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results, there was a small effect of population present. The population corrected model
was chosen for downstream analysis.
In the population corrected design, differential expression analysis revealed 422 sig-
nificantly differentially expressed genes in TB/DM against TB-only. In TB preDM, 558
genes were significantly differentially expressed. Figure 4.26 demonstrate that there was
a definite effect, but of a relatively small magnitude. The pattern was quite symmetrical,
but genes that were up-regulated were of a higher fold change.
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Figure 4.26: The gene expression profile of TB/DM (A) and TB preDM (B) relative
to TB-only when combining all four field sites (Indonesia, South Africa, Romania
and Peru) before the initiation of TB treatment. Genes statistically significantly differ-
entially expressed after multiple testing correction are seen in pink (p-value< 0.05). Grey are
not statistically significant. The most differentially expressed genes are labelled.
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CHAPTER 4. TB/DM: CROSS-SECTIONAL
To detect differences in biological mechanisms between uncomplicated TB-only and
the diabetes phenotypes, modular analysis was performed on the population corrected
data. A panel plot illustrates the modules that were significantly differentially expressed
in the diabetes and pre-diabetes groups when comparing against TB-only.
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tially expressed transcriptional mod-
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TB/DM and TB preDM show similar module expression patterns when compared
with TB-only. Both show a general trend of up-regulation, specifically of modules in-
volved in inflammation. Interestingly however, patients with TB/DM also exhibit down-
regulation of interferon modules compared to TB-only. The most statistically significant
modules revealed from modular analysis were inflammation, inflammatory response, neu-
trophils, interferon, antiviral interferon and type I interferon response. The differential
expression of the genes within the top modules were summarised in a heatmap, Figure
4.28. The overriding pattern is that fold change increased from TB preDM to TB/DM. In
addition, whilst inflammation and neutrophils were up-regulated in both diabetes groups
than in TB-only, type I interferon response was down-regulated. The greatest fold change
difference was in the gene Ubiquitin Specific Peptidase 18 (USP18), which is thought to
have a role in down-regulating interferon responses. In brief, it appears patients with
active TB and clinically diagnosed T2DM have a reduced IFN response than uncompli-
cated TB. The genes within the interferon response modules that were 2 fold or greater
in TB/DM or TB preDM than in TB-only were HERC5, IFIT1, LAMP3, MX1, OTOF,
RSAD2 and USP18, Figure 4.29.
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Figure 4.29: Genes within the interferon response module that were 2 fold or greater
in TB/DM or TB preDM than in TB-only. The four populations were combined and
modular analysis revealed interferon response as one of the most significantly differentially
expressed in TB/DM or TB preDM and TB-only. Normalised counts for the differentially
expressed genes (≥ 2) in each disease category.
An existing signature was tested in the TANDEM data to see whether diabetes co-
morbidity affects the performance. When plugging in the Zak 16 gene signature to the
differential expression results versus healthy controls, TB/DM and TB preDM patients
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exhibited a more intense expression than TB-only (Figure 4.30).This also translated to
higher absolute values after summing the fold changes of all genes (Figure 4.31). All of
the 16 genes were statistically significant after multiple testing correction.
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Figure 4.30: Fold changes of the Zak signature in TB patients relative to healthy
controls in South Africa. Differential expression results of the 16 genes were extracted
from TB-only, TB preDM and TB/DM versus healthy controls at diagnosis. Red indicates
up-regulation.
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Figure 4.31: Sum of fold changes of Zak signature. The fold changes of the 16 genes from
the Zak signature were summed in TB-only, TB preDM and TB/DM versus healthy controls.
It was also investigated whether this signature correlated with HbA1c. The sum of the
normalised counts for the 16 genes for each patient was taken (Figure 4.32). Signature
performance generally increased with HbA1c values in TB-only and TB preDM groups.
Performance within the TB/DM group is higher than in TB-only, but with a negative
correlation with HbA1c.
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Figure 4.32: Sum of the normalised count of the Zak signature in each patient group.
The normalised count for the 16 genes were summed for each patient category, and stratified
against their HbA1c values.
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4.5 Discussion
4.5.1 Findings
This cross-sectional study showed that TB/DM patients can be discriminated from un-
complicated TB patients dependent on their blood transcriptomes at baseline. Also, in
contrast to expectations, the TB preDM patients were more similar to TB/DM than
to TB-only. The TB-only profile reflected previously literature; a large up-regulation of
inflammatory genes and modules. The TB/DM signature was of a larger magnitude than
TB-only, coupled with more down-regulation as well as a large up-regulation of genes and
modules. The two groups were very different from one another, indicating that diabetes
does indeed affect how the immune system responds to TB.
Importantly, the gene signature of TB preDM; was remarkably similar to the TB/DM
profile, than for example TB-only. Because TB/DM and TB preDM patients exhibit
similar transcriptomic signatures it means that patients with even intermediate levels
of hyperglycaemia, exhibit an immune dysfunction which could lead to an increase in
susceptibility to active TB disease. This is contrary to current thought, as diabetologists
would consider that enhanced risk of infectious disease, specifically TB, occurs at higher
HbA1c values, later on in the progression of diabetes. However, these current data show
there are already differences in pre-diabetes patients, which may be revealing in terms of
susceptibility mechanism.
The comorbidity groups were also differential from patients with diabetes without
TB. The gene expression profile of DM-only patients was of a lot smaller magnitude
compared to the comorbidity groups. I had hypothesised that maybe the gene signature
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of TB/DM would resemble DM-only, with further up-regulation owing to the TB. But,
as the results show, this was not the case, the comorbidity causes further differential
expression, beyond that of TB-only and DM-only. In addition to this, TB also seemed to
modulate the diabetes, as some modules that were differentially expressed in DM-only,
were then not differentially expressed in the comorbidity groups. such as the respiratory
modules. It appears both diseases affect the way the host responds to each of them.
When looking at the different field sites separately, TB/DM and TB preDM versus
TB-only, no genes or a small number of genes were found to be significantly differen-
tially expressed. However, when all four populations were combined, differences were
detectable, which were relatively small but consistent, between TB/DM and TB preDM
with TB-only. These main differences were that in TB preDM versus TB-only, the
inflammatory response was up-regulated, but interferon modules, including the type I
response genes, which was one of the top significantly differentially expressed modules,
were down-regulated. These differences were even greater in TB/DM versus TB-only,
demonstrating that it is a spectrum. This analysis also shows that combining different
populations yields more powerful and maybe more meaningful results.
The analysis of a previously published TB signature showed a larger expression in co-
morbidity patients than in TB-only. It was expected that an existing signature would can-
cel each other out, due to the down-regulated interferon, and inflammatory up-regulation,
or not be as effective in DM patients. But, because the Zak signature is comprised of
mainly inflammation genes, it’s performance is increased, revealing that it is potentially
valid for use in diabetes patients. It prompts the question that if the signature is detect-
ing a sign of disease, is it detected more severe disease? Again, the similarities between
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TB preDM and TB/DM were striking; both exhibited similar patterns of expression and
absolute absolute values. There was interesting positive correlation between TB signa-
ture and HbA1c in both TB-only and TB preDM. This was lost in TB/DM, possibly due
to counter-regulatory mechanisms or anti-diabetes medication.
It was speculated that the differences seen between TB/DM and TB-only might be
due to the anti-diabetes medication the patients were on, but it cannot be the case for two
reasons. Firstly, TB preDM patients have a similar gene and module profile to TB/DM,
and the pre-diabetic patients are not on anti-diabetes treatment. Secondly, as discussed
in Chapter 3 in the RNA-seq analysis of the effects of metformin in healthy donors,
negligible changes were seen on the gene level in the whole blood transcriptome after the
administration of metformin. Therefore, it can be concluded that these differences are
due to the biological variation between TB/DM and TB-only and not the anti-diabetes
medication.
4.5.2 The role of interferons
There are three groups of interferons; type I (IFN-α and IFN-β), type II (IFN-γ) and
type III (IFN-ε). The type I interferons all signal through the same receptor: IFNAR1
and IFNAR2, whereas the type II interferon (IFN-γ) has the distinct receptor IFNGR.
Interferons, especially the type II interferon IFN-γ are essential in the protection and
containment of M. tb.
The importance of IFN-γ was uncovered in mouse experiments, when IFNGR−/−
knockout mice were infected with M. tb and showed decreased survival. When IFN-
γ was then infused into the knock out mice to reconstitute the immune response, the
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mice had increased survival.159 In another study, in which the gene for IFN-γ had been
disrupted in mice and then infected with M. tb, there was widespread necrosis and huge
bacterium levels. These data showed that when IFN-γ is lacking, the immune system
struggles to contain and control M. tb infection.160 This is also the case in humans, where
patients with a mutation in IFNγR1 were totally susceptible to M .tb infection and also
BCG.161,162
Interferons have a protective effect against infections, and are important in the con-
tainment and pathogenesis of M. tb and other bacteria. Type I IFNs, IFN-α and IFN-β,
are particularly important in viral infections, as they activate anti-viral factors. Type I
IFNs and their response can vary, from anti-viral activity and the secretion of cytokines
to regulate the adaptive arm of the immune response. Type I IFNs mainly boost the
immune system, by activating dendritic cells, NK cells and directly acting on CD4+
and CD8+ T-cells to promote differentiation into IFN-γ producing TH1 cells.
163 Many
virus have evolved mechanisms to evade or hinder type I IFNs, and type I IFN-deficient
mice are more susceptible to viral infections. But, type I IFNs in bacteria are poten-
tially detrimental to the host, and there has been research into the pro-bacterial effect of
them. For example, the effect of type I IFNs has been validated in mouse experiments
using IFNAR−/− knockout mice, which blocks the signal of type I IFNs (but not type
II) through their receptor, IFNAR. The IFNAR−/− mouse model has been shown to be
highly resistant to Listeria monocytogenes,164 and also M. tb.
Type I interferons have been shown to be induced following M. tb infection, but the
evidence of the role of the type I IFNs during infection is somewhat conflicting. It has
been shown that type I IFNs can be harmful in the host’s response to M. tb infection. A
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study by Manca et al found that more virulent strains of M. tb were associated with the
induction of IFN-α and IFN-β. In addition, when mice were administered type I IFN
inducers, it resulted in higher bacterial loads in the lungs and exacerbated pathology.165
To further this, Dorhoi et al investigated the effect of M. tb infection in the IFNAR−/−
mouse model. They found that the knockout mice had improved mortality and harboured
fewer bacteria 21 days post infection than wild type (WT) mice, demonstrating that
blocking the signal of type I IFNs improves survival from M. tb.166
Type I IFNs have long been associated with active TB disease, particularly since
Berry et al found a distinct interferon based transcriptional signature, which correlated
with disease severity.67 This signature was primarily neutrophil driven, and included
the up-regulation of IFIT1, IFIT2, IFIT3, OAS1, OAS2, OAS3, RSAD2 and MX1 gene
expression in blood.167 Not only this, but type I IFNs have also been associated as a
correlate of risk; an up-regulation of IFNs before the onset of infection was correlated
with the progression to active disease in non-human primates,76,131 indicating the IFNs
are clearly key in the immune response to TB.
Another study by Mayer-Barber and colleagues investigated the effect of type I inter-
ferons in mice and the cross-talk that exists between type I IFNs and IL1. They found
that IFNAR1−/− mice had a reduced bacterial burden compared to wild type and in
the absence of type I IFN signalling, levels of IL-1β increased. Conversely, IL1R1−/−
mice had significantly elevated bacterial load, and much lower survival, but the double
knockout IL1R1, IFNAR−/− were significantly less susceptible to M. tb infection than
IL1R1−/− single deficient mice. Finally, they tested a therapeutic agent, an arachidonic
acid metabolism modulator which inhibited the type I IFN response pathway, which re-
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sulted in increased survival. They concluded that the balance between type I IFNs and
IL-1 is important in the disease presentation.132
Conversely, a study by Desvignes et al characterised the dynamics of type I and type
II, and found that type I IFNs play a non-redundant protective role, particularly in the
early stages of infection. They studied the double knockout mouse model; IFNGR−/−,
IFNAR−/−, where mice did not produce type I or type II IFN responses, and compared
it with the IFNGR−/−, where only type II responses were defective. They found that the
double knockout mice had significantly reduced survival, and higher lung bacillary loads
than the sole IFNGR−/− mice. In addition to this, the double knockout had dysfunctional
immune cell recruitment to the lungs and significantly different histopathology. The
IFNGR−/−, IFNAR−/− mice also exhibited more M. tb infected macrophages than in the
IFNGR−/− mice. All these data show that the combined effects of both type I and type
II IFNs contribute to a timely immune response to M. tb prior to the onset of adaptive
immunity.168
Evidence for the requirement of type I IFNs in the containment of M. tb was also
documented in Kuchtey et al. IFNR1−/− mice were infected with BCG, and their CFUs
were measured at points throughout infection. At 14 days after infection, bacterial growth
was significantly higher than in WT mice, but at 21 days post-infection, CFUs in both
phenotypes were comparable. This study shows that type I IFNs may have a role in the
early control of M. tb infection.169
Research is showing that IFN-α and IFN-β can exert different effects through the
same receptor; IFNAR. These disparities are due to subtle differences in receptor bind-
ing, signalling cascades and feedback mechanisms.170 The divergence of IFN-α and IFN-β
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is evident in autoimmune disorders like systemic lupus erythematosus (SLE) and multiple
sclerosis (MS). IN SLE, IFN-α is pathogenic, but in MS, IFN-β is used as an immunosup-
pressant treatment with success. MS patients administered IFN-β had reduced clinical
relapses, reduced brain disease activity and slower progression to disability, showing the
anti-inflammatory and tissue protective role of IFN-β.171,172 Whereas, IFN-α serum levels
are higher in SLE patients than healthy controls and is strongly associated with disease
severity.173 This is again seen in transcriptomic data, where there is a IFN-inducible gene
expression signature for SLE that is distinct from healthy controls.174 It seems that al-
though IFN-α and IFN-β share IFNAR, they interact in a different manner with the
receptor and activate the downstream pathways in a different way causing a dichotomy
in their immunoregulatory roles.
Type I IFNs became available as a therapy in the 1980s for their immune stimulating
and anti-viral properties, for example, in hepatitis B and C infection. Type I IFNs
exhibit their antiviral capabilities by suppressing viral replication and inducing apoptosis
in virally infected cells. But, type I IFN therapy in hepatitis patients increases the risk of
developing T1DM, which is also closely associated with the IFN response gene OAS1.175
There have been some studies using type I IFNs in adjunctive therapy with antibiotic
treatment in patients with active TB. When standard therapy was supplemented with
IFN-α, there was a positive effect on clinical TB outcomes, ranging from improvement in
clinical manifestations, and an increase in sputum smear negativity.176–180 These studies
were mainly performed on hard-to-treat-TB, like MDR-TB cases. However, when IFN-α
was administered without antibiotic treatment, for example in patients with hepatitis C,
there were more cases of latent TB reactivation.181 This reactivation of TB is reported
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after treatment with IFN-α therapy, but not IFN-β, however there is little known about
the separate effects of IFN-α and IFN-β in M. tb infection. The contradictory effects in
different situations reflects the heterogeneity of the type I IFN family and its downstream
targets.
In the literature, there are differences between the type I IFN cytokines action, as de-
scribed above, but these data and also previous TB signatures focus on the downstream
inducible genes. As discussed, it was found that type I interferon response genes were
down-regulated in TB/DM compared to TB-only, showing that the response of the in-
terferons in response to M. tb infection is different in diabetes. Considering the nuances
in the interferon responses, it is difficult to completely unravel the implications of the
aberrant type I IFN response and the elevated inflammatory response.
It could be hypothesised that the TB/DM patients have an enhanced clinical phe-
notype, characterised by the increased inflammatory response and aberrant type I IFN
response. But, in clinical studies between TB/DM and TB-only patients, there was no
significant difference in the presentation or pathology of TB disease, except in one study,
where TB/DM patients listed more symptoms.137 Other work in the TANDEM consor-
tium, yet uncompleted, involves performing unbiased computer-aided reading of digital
X-rays, to further determine whether there are any chest pathology differences. So far
however, there is little evidence suggesting the TB/DM have a heightened clinical TB
phenotype, suggesting the altered transcriptome is a mechanism of enhanced susceptibil-
ity.
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4.5.3 Limitations and future work
Of course, it would have been favourable to collect samples from healthy controls in all the
field sites in order to dissect the how each disease is different in more populations. But,
field sites had decided to join the RNA-seq analysis after the sample collection had been
initiated, so further collection of healthy controls was not available. So, this meant the
study designs were not consistent across populations which was not ideal. It would have
been desirable to dissect the differences of all the disease groups between their healthy
controls to see how each disease is different in each population.
Somewhat of a caveat of modular analysis is in the module classification. Sometimes
the genes within a gene-set or module may not truly reflect the biological association.
Module or gene-set classification can vary depending on who compiled them and by what
method. A study by Pollara et al evaluated the sensitivity and specificity of particular
cell-associated modules by looking at the overlapping content across different data sets.
They found that different modules of the same cell type vary somewhat, and came up with
a modular discrimination index (MDI) score as a predictor of module performance.182 It
would be an idea to use this tool in further analysis to validate the modular findings in
these data.
4.5.4 Implications in TB control
Indeed TB/DM and TB preDM patients are an increased risk of disease development and
of poor TB treatment-outcomes, including death, failure and relapse, meaning there are
implications in TB control. Our data could suggest that the threshold for diabetes is low-
ered, as an immune dysfunction clearly exists at intermediate levels of hyperglycaemia.
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Diabetes and pre-diabetes patients could be more closely followed, and undergo prophy-
lactic TB treatment if they were diagnosed with latent M. tb infection. The practicalities
of this may be challenging as high TB/DM burden countries are also low income, and
such a control strategy is more likely to be feasible in high income, low burden countries.
Diabetes clearly shapes the immune response in TB disease, so is likely to impact vaccines
that induce such a response in the host. This would cause implications if diabetes patients
do not respond accordingly to the vaccine, either causing an over- or under-stimulation,
meaning the vaccine would not work effectively. This needs to be considered in vaccine
development. This data also bring about the possibility of using host directed therapy in
TB disease, where the drug targets the host, rather than the bacteria themselves. This
would open new avenues of research as the immune abnormalities caused by TB/DM
could be modulated by a drug which then causes the host to respond appropriately.
In the main, we have found that diabetes does effect the TB gene expression profile,
and that this effect is also seen in pre-diabetes. If this transcriptomic change is indeed
evidence of a mechanism of TB susceptibility, then it has real implications on efforts of
TB control as pre-diabetes patients are often overlooked.
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5Tuberculosis and diabetes in TANDEM: longitudinal
study
5.1 Introduction
5.1.1 Diabetes effects TB treatment response
Not only has T2DM been recorded as a risk factor for active TB disease, but also causes
a greater severity of disease, and has a negative effect on treatment response. This
negative effect on treatment often transpires as treatment failure, slower rates of culture
conversion, higher rates of relapse and also death.183
There have been a few studies investigating treatment outcomes in TB patients with
diabetes. In a study in Egypt, it was found diabetes conferred a 3.9 times higher risk
of treatment failure. This was in patients receiving directly observed therapy so was not
due to poor adherence.184 Another study in Indonesia by Alisjahbana et al also concluded
that diabetes increases the risk of TB treatment failure. In more detail, they found that
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diabetes patients were at 7.65 times higher risk of being sputum culture positive after
six months of TB treatment. This same study also showed that a higher proportion
of diabetic patients were culture positive after two months and also six months of TB
treatment than in TB patients without diabetes.137 Results from other studies of sputum
culture conversion at two months are mixed, with most reporting no difference in TB/DM
and TB without diabetes. Yoon et al however reported that only uncontrolled diabetes
patients showed a higher instance of sputum culture positivity, and controlled diabetes
patients did not show any difference compared to non-diabetics.185 The overarching theme
however was that the mean time to culture conversion tended to be longer in TB/DM
than uncomplicated TB patients.183,186,187 Generally, it seems poor glycaemic control
is strongly associated with poor TB treatment outcomes. In a prospective study of
TB/DM patients, poor glycaemic control (HbA1c ≥ 7%) in particular was associated
with higher rates of treatment failure. Of the patients with poor glycaemic control, 23%
failed treatment, compared to only 4% of patients with optimal glycaemic control. These
patients were also at 2.83 times higher risk of relapse.188
Not only are diabetes patients more likely to fail TB treatment, but they also have a
higher risk of death. Retrospective cohort studies of patients with pulmonary TB have
shown that diabetes patients have 6.5 increased risk of death than non-diabetics.183,189
However, cause of death is not always recorded, so it is difficult to deduce whether it is
actually down to the comorbidity. Regardless, all of the studies in TB treatment outcomes
in diabetes patients point to an increased treatment failure and increased occurrence of
death. It raises the question as to whether diabetes patients’ immune system respond
differently during treatment compared to non-diabetics.
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As discussed previously, TB/DM patients exhibit altered immune system and cytokine
profile compared to TB patients without diabetes. This dysfunction includes monocytes
and neutrophils, and an altered expression of Th1 and Th17 cytokines, which are known
to influence the pathogenesis of pulmonary TB. A couple of studies by Kumar et al have
looked into the immunological changes of diabetes patients throughout TB treatment.
Firstly, they found that the ex vivo percentage of dendritic cell and monocyte subsets was
lower before TB treatment, and after two months of treatment. But, six months after
initiation of treatment, the dendritic and monocytes subsets are increased in TB/DM
patients than in TB patients without diabetes. Secondly, they found TB/DM patients
had significantly increased levels of effector memory CD8 and CD4 T-cell subsets two
months post treatment. At six months post initiation of TB treatment, TB/DM patients
had increased levels in naive CD4 and CD8 T-cells. This was coupled with a decrease
in the percentage of central memory CD4 and CD8 T-cells.190,191 These cell types are
important in the protective immunity against TB, and a dysregulation could be why
diabetes patients are more likely to fail TB treatment.
5.1.2 The TANDEM consortium
The TANDEM consortium also looked at treatment response of TB/DM patients com-
pared to uncomplicated TB, because diabetes is associated with increased TB treatment
failure, death and relapse. In another work package of the consortium, a randomised
control trial was performed in which TB/DM patients were randomly allocated to re-
ceive standard DM care or enhanced monitoring/adjustment of DM treatment through
TB treatment, to determine whether the poor treatment outcome could be reduced.
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In addition to this, we wanted to characterise TB treatment response of TB/DM
patients using bioprofiling, which led to the longitudinal study. This study investigated
the differences in gene expression in TB/DM, TB pre DM and TB-only patients over
their treatment in different populations (Romania, Indonesia and South Africa).
The studies looking at the transcriptomic changes throughout TB treatment are com-
paratively few compared to cross-sectional studies. Overall, any blood transcriptomic
signature present at diagnosis of TB, had diminished by two months of treatment, and
disappeared by twelve months after diagnosis. This paralleled with clinical improvement,
measured by chest X-ray. This signature included a type I interferon response, in which
the same was also found in neutrophil-depleted samples.73 Interestingly however, dynamic
changes in whole blood are seen throughout treatment, particularly within the first one
to two weeks, where there is a large down-regulation of differentially expressed genes.68,72
This down-regulation included complement genes like C1QB and other inflammatory
genes.
We wanted to see whether the same dynamic changes are seen in TB/DM patients,
or are there fundamental differences. As large scale changes are seen in gene expres-
sion through treatment which correlate with TB cure, perhaps the resolution of the TB
transcriptomic signature is delayed or altered by diabetes, which would correspond to
poor treatment outcomes. As seen in Chapter 4, there are differences between TB and
TB/DM at diagnosis, so it is likely that differences also exist at the end of treatment, if
the transcriptomes are still different at six months, it may indicate why TB/DM patients
are at enhanced risk of relapse, whilst also showing treatment failure. If this is indeed
the case, it will help in decision making regarding treatment for TB/DM patients.
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Considering diabetes comorbidity affects TB treatment outcomes in the form of in-
creased treatment failure and relapse, this would be reflected in altered blood transcrip-
tomes in TB/DM patients throughout and at the end of treatment compared to TB-only
patients. I hypothesised that preDM patients would behave similarly to TB-only pa-
tients. I also hypothesised that when analysing a blood TB signature, TB/DM patients
would have altered resolution at the end of treatment. Conversely, preDM patients would
be comparable to TB-only patients, as a worse TB signature would correlate with pro-
gression of DM.
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5.2 Aims and Objectives
Aims
I To determine whether the gene expression profile through TB treatment
is different in patients with TB/DM or TB preDM.
Objectives
I Perform RNA-seq analysis on whole blood samples from three differ-
ent sites at four time points throughout TB treatment in patients with
TB/DM, TB preDM and TB-only.
II Compare the gene expression profiles through treatment of TB/DM and
TB preDM each with TB in one closely defined population, namely In-
donesia.
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5.3 Methods
Whole blood samples for the longitudinal analysis were collected from uncomplicated TB
patients, TB preDM and TB/DM patients from Indonesia, Romania and South Africa.
Unlike in the TANDEM cross-sectional study, Peru was not included in the longitudinal
study. Samples from these three field sites were collected at four time points; diagnosis
(before the initiation of treatment), and at two weeks, two months and six months post
treatment. These three subsequent time points were chosen because previous literature
has shown dramatic changes within the first two weeks after initiation of TB treatment;
the month two time point is most TB patients have become should be sputum smear
or culture negative, and month six is at the end of TB treatment, when patients should
have reverted to ’healthy’ status. Table 5.1 shows the number of samples within each
patient group, at each time point, in each field site.
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Diagnosis Week 2 Month 2 Month 6
South Africa TB/DM 15 15 16 12
TB preDM 11 10 10 10
TB-only 6 4 6 5
Indonesia TB/DM 17 12 16 15
TB preDM 4 4 3 5
TB-only 12 10 10 11
Romania TB/DM 8 10 9 8
TB preDM 5 4 4 2
TB-only 5 5 5 5
total TB/DM 40 37 41 35
TB preDM 20 18 17 17
TB-only 23 19 21 21
Table 5.1: Number of samples in the longitudinal study. Samples of each patient group,
at each time point, in the three field sites and in total.
5.3.1 Sample processing and data analysis
Samples and data were processed with the rest of the TANDEM samples as described
in the previous chapter. Raw data were aligned and quantified with the cross-sectional
samples, as a whole, with the same tools and settings as discussed in the previous chapter.
Differential expression analysis was again performed using R (R v3.4.1 and RStudio
v1.0.143) package DESeq2 (v 1.16.1). Firstly, all the samples (Table 5.1) were normalised
together in a global analysis which included all three of field sites; South Africa, Romania
and Indonesia and population was corrected for. In this analysis, TB-only was used as
a control, with TB/DM and TB preDM compared against them. This was to determine
whether TB patients with diabetes or pre-diabetes share the same transcriptomic dynamic
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throughout treatment as uncomplicated TB patients. This was also because healthy
controls were not collected in Indonesia.
To find the genes that were differentially expressed through time and across pheno-
type, the likelihood ratio test was performed. This test allows you to test the difference
between two model curves, and measure ’the fit’ of the two models. In other words, it
creates a model curve through the time-points for each phenotype group, in which the
differences are the output. It pulls out genes that are differentially expressed at any
time-point but also differentially expressed across phenotype. So, the results yielded are
the genes that change through TB treatment but must also be different with and without
diabetes. This likelihood ratio method was done in TB/DM and TB preDM compared to
TB-only. Multiple testing was corrected using the Benjamini & Hochberg false discovery
rate method.
Another analysis was done; a more directed approach. This analysis involved segre-
gating the samples by field site. In Indonesia, only TB-only and TB/DM patients were
investigated because there were too few patients with TB preDM. TB-only patients were
again used as the control, to compare against TB/DM. Each time-point of TB-only was
compared to the same time point in TB/DM, i.e. diagnosis versus diagnosis, week 2
versus week 2 and so on. This was to dissect what was different at these crucial time
points through anti TB treatment when patients have T2DM co morbidity.
Modular analysis was done to add biological knowledge, and performed using the R
package tmod (v0.31), with the modules outlined by Chaussabel et al and Li et al.94,95 An
adjusted p-value of < 0.05 was deemed significant. From the modular analysis, module
activity can be calculated for the modules that were significantly differentially expressed
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in TB/DM compared to TB-only at any time-point. Equation 5.1 shows the formula
to calculate the module activity, where g is the expression value of each gene within a
module, and n is the number of genes within that module.
module activity =
∑
g
n
(5.1)
A published signature was also analysed to test the hypothesis of whether DM and
preDM patients resolve their transcriptome after completion of treatment as in uncom-
plicated TB. The Zak et al signature76 was chosen, as in Chapter 4. TB-only patients at
month 6 were compared with TB/DM and TB preDM patients as these patients would
be deemed ’healthy’.
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5.4 Results
5.4.1 Diabetes and tuberculosis treatment outcomes
The laboratory HbA1c values were taken in active TB patients, with and without dia-
betes, before initiation of TB treatment, and after completion of treatment (Figure 5.1).
The general pattern in all of the three field sites and across all patient groups was that
HbA1c values decreased after six months of TB treatment. This was even the case in
TB patients without diabetes. The most dramatic differences in HbA1c values were seen
in TB/DM patients, in all of the field sites, particularly in Indonesia. There were some
exceptions however, especially in South Africa, where HbA1c values in TB/DM patients
were increased at month six. This could be due to poor management of glucose control.
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Figure 5.1: HbA1c values in TB patients with and without diabetes or pre-diabetes
before initiation of treatment, and after completion. A: Indonesia, B: South Africa, C:
Romania
TB Treatment outcomes were summarised as good or poor. Poor outcomes included
treatment failure, death (due to TB) or relapse. Good outcomes included cure or treat-
ment completion. The relapse outcomes in South Africa were assessed by whether patients
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had clinically relapsed and were on treatment again alongside microbiological results. In
Indonesia, relapse was defined as only culture positive after completion of treatment. Fig-
ure 5.2 shows the proportion of good and poor treatment outcomes in active TB patients
with and without diabetes in the three field sites. Poor treatment outcomes in TB/DM
were consistently around 27% across field sites (Table 5.2). This was higher than TB-only
or TB preDM in Romania and South Africa. However, in Indonesia TB-only and TB
preDM patients both had a large proportion of poor treatment outcomes, which might
be due to the different definitions of poor treatment outcome.
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TB
 pr
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Figure 5.2: Treatment outcomes of TB patients with and without diabetes or pre-
diabetes from the three field sites. Poor outcomes in South Africa were defined as patients
that relapsed and had gone back onto treatment. In Indonesia, poor outcomes were based on
culture results.
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South Africa Romania Indonesia
TB/DM 26.7% 26.7% 27.8%
TB-only 10% 10% 38.5%
TB preDM 15% 10% 40%
Table 5.2: Percentage of poor treatment outcomes in each of the patient groups in
the 3 field sites.
5.4.2 Global analysis of TB/DM patients through TB treat-
ment
All three field sites were combined in a global analysis, to look at the effect of TB
treatment (time) in the different patient groups (phenotype). TB/DM, TB preDM and
TB-only patient groups were normalised together. Using the likelihood ratio test, 8258
genes were found to be differentially expressed over time and across phenotype.
Modular analysis was performed, and the top significantly differentially expressed
modules are shown in Table 5.3. These are the modules that were the most differen-
tial throughout TB treatment and across the patient groups. The most differentially
expressed modules were related to B-cells and T-cells. Figures 5.3 and 5.4 show the
dynamics of expression of the genes within the B-cell module in each patient group.
TB/DM and TB preDM both start with a higher normalised count than in TB-only.
The normalised count then decreased in all the patient groups at week two, especially in
TB preDM, then increases at month six.
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Module name AUC Adjusted p-value
Enriched in B cells (I) 0.919 5.29e−28
Mitochondrial Respiration 0.731 8.67e−19
B cell 0.919 3.48e−18
Immune activation - generic cluster 0.665 1.32e−16
Enriched in B cells (VI) 0.961 3.57e−15
Enriched in B cells (II) 0.899 1.04e−14
T cell 0.758 4.09e−12
Mitochondrial Respiration 0.705 8.14e−11
Plasma cells and B cells, immunoglobulins 0.808 2.09e−09
B cell surface signature 0.607 1.11e−08
T cell activation (I) 0.771 1.69e−08
Enriched in T cells (I) 0.742 4.20e−07
Enriched in monocytes (II) 0.647 4.56e−07
Protein Synthesis 0.781 7.33e−07
Inflammation 0.653 2.53e−06
T cell surface signature 0.736 9.11e−06
Respiratory electron transport chain (mitochondrion) 0.884 1.17e−05
Receptors, cell migration 0.779 3.26e−05
Enriched in B cells (III) 0.777 4.35e−05
Enriched in naive and memory B cells 0.821 6.32e−05
Apoptosis / Survival 0.705 6.33e−05
Enriched in activated dendritic cells (II) 0.739 7.71e−05
T cells 0.725 1.09e−04
Regulation of antigen presentation and immune response 0.677 1.09e−04
Interferon 0.856 1.12e−04
Inflammation 0.709 1.12e−04
Table 5.3: Modular analysis from the results of the likelihood ratio test in TB
patients with and without diabetes or pre-diabetes through TB treatment from all
three field sites. The top most significantly differentially expressed modules through time
and across phenotype. AUC is the area under the curve, a measure of the effect size. P-values
were adjusted using Benjamini-Hochberg correction.
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Figure 5.3: Normalised count of genes of the most significantly differentially ex-
pressed module; B-cell, at each time point through TB treatment. The different
colours represent the three patient groups. A Loess line of best fit was plotted for each group.
Data were taken from all three field sites and population corrected.
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Figure 5.4: The normalised count for all the genes from the B-cell module at each
time point through TB treatment. A loess line of best fit was fitted through all normalised
counts of all the genes. Data were taken from all three field sites and population corrected
In the T-cell module, the general pattern is that the normalised count in all the patient
groups increases through TB treatment. TB/DM patients have higher normalised count
of each of the genes throughout TB treatment than the other two groups (Figures 5.5
and 5.6).
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Figure 5.5: Normalised count of genes in the significantly differentially expressed
module; T-cell, at each time point through TB treatment. The different colours rep-
resent the three patient groups. A Loess line of best fit was plotted for each group. Data were
taken from all three field sites and population corrected.
197
CHAPTER 5. TB/DM: LONGITUDINAL
400
500
600
Di
ag
no
si
s
W
ee
k 
2
M
on
th
 2
M
on
th
 6
Timepoint
No
rm
al
is
ed
 c
ou
nt
TB/DM
TB−only
TB preDM
Figure 5.6: The normalised count for all the genes from the T-cell module at each
time point through TB treatment. A loess line of best fit was fitted through all normalised
counts of all the genes. Data were taken from all three field sites and population corrected
Figures 5.7 and 5.8 show the normalised counts of the genes within the interferon
module. Interferon modules have consistently been significantly differentially expressed
in TB/DM in the TANDEM study. The interferon genes have a similar pattern to one
another; they change dramatically though time. Many are down-regulated at week two
compared to diagnosis. The interferon genes in TB/DM and TB preDM behave similarly,
but together behave opposite to TB-only patients at both month two and month six. The
adjusted p-values from the gene-level differential analysis for each of these genes is shown
in Table 5.4.
198
CHAPTER 5. TB/DM: LONGITUDINAL
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
RSAD2 RTP4 SERPING1 TRIM6 XAF1
OAS1 OAS2 OAS3 OASL OTOF
IFITM3 ISG15 LAMP3 LY6E MX1
IFI44 IFI44L IFIT1 IFIT2 IFIT3
BATF2 CXCL10 EPSTI1 HERC5 HES4
Di
ag
no
si
s
W
ee
k 
2
M
on
th
 2
M
on
th
 6
Di
ag
no
si
s
W
ee
k 
2
M
on
th
 2
M
on
th
 6
Di
ag
no
si
s
W
ee
k 
2
M
on
th
 2
M
on
th
 6
Di
ag
no
si
s
W
ee
k 
2
M
on
th
 2
M
on
th
 6
Di
ag
no
si
s
W
ee
k 
2
M
on
th
 2
M
on
th
 6
1
10
100
1000
10000
1000
10000
10
1000
1000
10000
100
1000
10000
1e+03
1e+04
1e+05
1e+03
1e+04
1e+05
100
1000
10000
1
10
100
100
1000
100
1000
10000
10
1000
1000
10000
100
1000
10000
1
10
100
100
1000
10000
100
1000
10000
1000
10000
100
1000
100
1000
100
1000
1e+03
1e+04
1e+05
1000
10000
100
1000
10000
Timepoint
No
rm
al
is
ed
 c
ou
nt
l
l
l
TB/DM
TB−only
TB preDM
Figure 5.7: The normalised counts of the genes within the significantly differentially
expressed module; interferon. A loess line of best was plotted through each of the time
points. The colours represent the different patient groups. Data were taken from the three field
sites and population corrected.
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Figure 5.8: The normalised count from all the genes in the interferon module at each
time point through TB treatment. A loess line of best fit was plotted through all of the
counts of all the interferon genes. Data were taken from all three field sites and was population
corrected.
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Adjusted p-value Gene Symbol
0.0713 BATF2
0.00389 CXCL10
0.00211 EPSTI1
0.000437 HERC5
0.113 HES4
0.0119 IFI44
0.00226 IFI44L
0.00116 IFIT1
2.65e−05 IFIT2
0.00288 IFIT3
6.42e−06 IFITM3
0.00596 ISG15
1.12e−05 LAMP3
0.00130 LY6E
0.000231 MX1
0.00192 OAS1
0.000332 OAS2
1.47e−05 OAS3
0.124 OASL
5.49e−06 OTOF
4.04e−06 RSAD2
0.0495 RTP4
0.00315 SERPING1
0.00471 TRIM6
0.00707 XAF1
Table 5.4: Adjusted p-values for genes within interferon module produced from the
likelihood ratio test. TB/DM, TB preDM and TB-only patients groups included in the
normalisation
There has been evidence in the literature that the immunological altered state in
TB/DM is correlated with increasing HbA1c values. So, the sum of the normalised count
of each interferon gene was plotted against the patients’ HbA1c reading at diagnosis
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(Figure 5.9). There appears to be positive correlation in the TB-only patients; sum
of normalised count increases with HbA1c values. However, in TB/DM patients, there
appears to be slight negative correlation, in that the sum of the normalised count of
the interferon genes decreases with HbA1c readings. The TB preDM group is heavily
skewed by the Indonesian population because of the small sample size, but also have a
positive correlation, but less so than TB-only. When looking at the field sites combined,
the correlation is not statistically significant, but the pattern remains true (Figure 5.10).
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Figure 5.9: Sum of the normalised count of each patient for each gene in the in-
terferon module, against patient HbA1c levels taken at TB diagnosis separated by
population. Lm line of best fit was plotted for each patient group for each field site. Colour
represents the patient group, and line type represents the field site.
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Figure 5.10: Sum of the normalised count of each patient for each gene in the inter-
feron module, against patient HbA1c levels taken at TB diagnosis. Colour represents
the different patient groups. Lm line of best fit plotted with confidence intervals, with the field
sites combined. P-values of the correlation for each patient group are shown. A p-value of
< 0.05 was deemed significant.
The Zak et al signature was analysed in TB/DM and TB preDM patients at month 6
to determine whether diabetes co-morbidity affected the resolution of the transcriptome
after TB treatment. TB/DM and TB preDM at month 6 was compared to TB-only
at month 6, as they would be deemed ’healthy’. Figure 5.11 shows that the 16 gene
signature was down-regulated at the end of treatment in TB/DM and TB preDM patients
compared to TB-only. All of these genes were statistically significant. The sum of the log
fold changes of these genes in TB/DM and TB preDM were -11.38 and -10.88 respectively.
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Figure 5.11: Fold changes of Zak signature in TB/DM and TBpreDM relative to
TB-only at month 6. Differential expression results of the 16 gene signature were extracted
at the end of treatment in TB/DM and TB preDM patients versus TB-only. Blue indicates
down-regulation.
5.4.3 Directed analysis in closely defined population
In a directed approach, only the Indonesian samples were normalised together, and a
comparison of each time point was made between TB/DM and TB-only. This was in
order to look at what specifically happens at each time point in TB/DM compared to
TB-only. The Indonesian population was chosen as the patients are comparatively well
characterised, with two clear-cut groups; TB/DM and TB-only. The number of genes
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statistically significantly differentially expressed in TB/DM and TB-only between each
time-point are shown in Table 5.5. The greatest difference was at month two.
Time-point Number of genes
Diagnosis 2
Week 2 3
Month 2 239
Month 6 8
Table 5.5: Number of significantly differentially expressed genes in TB/DM patients
compared to TB-only, between each time point through TB treatment. A p-value of
< 0.05 was deemed significant.
Modular analysis of the Indonesian samples also showed that most of the differential
expression between TB/DM and TB-only was at month two (Figure 5.12). The modules
that were differentially expressed in TB/DM at any time point were selected for further
investigation into their module activity.
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Figure 5.12: Modules that were sig-
nificantly differentially expressed in
TB/DM relative to TB-only between
each time point in Indonesian pa-
tients. Time points were before, through-
out, and at the end of TB treatment. Up-
regulated modules in red, down-regulated
modules in blue. The length of the bar rep-
resents the effect size of the module, and
the saturation of colour represents the ad-
justed p-value (< 0.05)
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The module activity was calculated for the modules that were significantly differ-
entially expressed in TB/DM compared to TB-only at any time-point, using Equation
5.1. Figure 5.13 shows the module activity dynamics in TB/DM patients throughout
TB treatment. For example, the neutrophil module is up-regulated in TB/DM relative
to TB-only at diagnosis, and persists throughout treatment. Another module; inter-
feron displays a peculiar pattern. It is down-regulated in TB/DM relative to TB-only at
diagnosis, but is then up-regulated at month two, oscillating through treatment.
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Figure 5.13: Modules that were significantly differentially expressed between
TB/DM and TB-only at any time point throughout TB treatment in Indonesian
patients. Modular activity was calculated by summing the expression of all the genes within
a module at a time point and dividing by the number of genes within that module.
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To look on the gene level within the significant modules, Figure 5.14 shows the gene
expression levels of each gene in the neutrophil module through time in TB/DM patients
compared to uncomplicated TB-only. The saturation of the colour equates to the fold
change. For example, the genes within the neutrophil module are highly up-regulated;
up to 2log2 fold change, with the most occurring at week two and month two. In the
interferon module, the majority of the genes are down-regulated, as seen in the cross-
sectional study. These genes are highly down-regulated; especially otoferlin (OTOF),
which is over −2log2 fold change. Like in Figure 5.15, there is an up-regulation at month
two in a number of the genes, which then plateaus at the end of treatment at six months.
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Figure 5.14: The expression of the genes within the neutrophil module in Indonesian
TB/DM patients relative to TB-only. From the inside, outwards: diagnosis, week 2, month
2, month 6. The saturation of the colour is equivalent to the fold change.
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Figure 5.15: The expression of the genes within the interferon module in Indonesian
TB/DM patients relative to TB-only. From the inside, outwards: diagnosis, week 2,
month 2, month 6. The saturation of the colour is equivalent to the fold change.
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5.5 Discussion
5.5.1 Findings
The longitudinal study showed that, similarly to the cross-sectional study, interferon
response genes were down-regulated at diagnosis in TB/DM and TB preDM relative to
TB-only. Not only this, but it does seem diabetes affects the way the host responds to
TB treatment; there was something very different in the dynamic changes which occur in
response to the killing of M. tb. This correlates phenotypically at the end of treatment,
as TB/DM have increased rates of poor treatment outcomes.
Two months after the initiation of TB treatment was the critical point of contrast in
the dynamic changes. The type I IFN response genes showed an unexpected dynamic;
in TB/DM and TB preDM, the type I IFN response genes were up-regulated at month
two compared to TB-only, after being down-regulated at diagnosis.
When analysing the Zak signature at month 6, it was found that the resolution of the
signature in TB/DM and TB preDM had gone further, and dampened the inflammation
at the end of treatment compared to uncomplicated TB. This is quite paradoxical as the
comorbidity patients started with an increase of inflammation before the initiation of TB
treatment. Again, TB/DM and TB preDM patients were very similar to one another,
and together different from TB-only. It provokes interesting questions on the affect of
intermediate hyperglycaemia. As DM and preDM confound the resolution of the TB
blood signature, causing them to be different from ’normal’, it could have implications
in their capacity for relapse and also re-exposure. If they are starting from a lower level,
could they be more susceptible?
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This has implications for TB control, as diabetes affects the way one responds to TB
treatment, resulting in increased likelihood of treatment failure or relapse. If diabetes
patients are not successfully clearing M. tb, it can increase prevalence and peddle drug
resistance. Different treatment options should be considered for comorbidity patients.
Also, this same abnormal dynamic exists in TB preDM patients showing it is a continuum.
This is important because currently, patients with intermediate levels of hyperglycaemia
have been overlooked, as it was thought TB susceptibility was only apparent at higher
levels of hyperglycaemia. However, from these data, pre-diabetes patients also displayed
an altered response to TB treatment. Perhaps pre-diabetes patients should also have
re-consideration when it comes to appropriate TB treatment. As discussed in the cross-
sectional study in Chapter 4, it reiterates how important it is for TB patients to be
screened for (intermediate) hyperglycaemia.
A recent study in macaques nicely demonstrated time-specific transcriptional effects
before and through M. tb infection, albeit without anti-tuberculosis therapy. They com-
pared these time-specific changes of animals that developed active disease with animals
that remained latently infected, and also animals that had severe lung inflammation with
animals that had less inflammation.131 Animals that developed active TB had signifi-
cantly higher interferon response module expression at infection and at later time-points
post-infection. Interestingly, these transcripts were differentially expressed in the animals
that went onto develop active disease before M. tb infection. Genes in particular were
MX1 and IFIT1. The IFN response modules were also highly up-regulated in animals
that had more lung inflammation, indicating type I IFNs had a negative impact on dis-
ease outcome. This supports the study by Zak et al that found a correlate of risk for
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active TB disease that included a type I IFN signature.76 There is an argument that this
signature is less a reflection of the hosts’ response to infection, but a predisposition of
outcome. Considering that IFNs are recognised as a marker of susceptibility, the current
data initially appear paradoxical as IFNs are down-regulated in TB/DM relative to un-
complicated TB patients at diagnosis, even though epidemiological data show diabetes
patients are more susceptible to active TB. But, the patterns of type I IFN signatures
are different during treatment, it seems that the response is delayed, so diabetes causes a
prolonged persistence resulting in lack of resolution during the timeframe of conventional
treatment.
Our data contradicts the dogma that there is one blood transcriptomic signature of
TB which resolves uniformly during TB treatment, but rather an uncoupling of the im-
mune response occurs in TB/DM patients. Our data show that different components
within the TB signature are separately regulated; the neutrophil and inflammatory re-
sponse in TB/DM are controlled by TB treatment, but a different pattern is displayed
in the type I IFN response. This difference means that by the end of TB treatment, the
TB/DM patients’ immune status has not resolved to the same point as TB-only patients.
This demonstrates that there is a more complex regulation of gene expression occurring
through TB treatment than originally thought.
In this regard, a molecular distance to health single measure, based on prior TB
transcriptomic data, would not be sufficient to explain the increased risk of poor TB
treatment outcomes in TB/DM. It is likely that a new biosignature will be needed in
order to be inclusive and measure these differences.
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5.5.2 Implications on TB control
It would be beneficial to follow diabetes and pre-diabetes patients more closely in their
TB treatment. TB/DM patients may still not have their HbA1c under control after com-
pletion of TB treatment, and the enhanced risk of relapse could be because the diabetes
is still not managed, so intervening with glycaemic management is critical. Results from
the randomised control trial (RCT) performed in TANDEM have shown that TB/DM
patients had significantly improved glycaemic control when they had been intensively
monitored.
Seeing as TB/DM patients have an altered response to TB, different treatment al-
gorithms should be considered. Perhaps an extended intensive phase and/or extended
continuation phase would be beneficial: these options could be tested in a clinical trial,
measuring clinical outcome as the primary endpoint, with the resolution of the TB/DM
transcriptomic signature measured as secondary outcome. If the cure rate and relapse
rate improves, the transcriptome would be seen returning to normal. This would be
indicative of disease clearing, and would mean that the altered treatment was a success.
Again, the longitudinal study suggests the option of host-directed therapy, or adjunc-
tive treatment, including something that will re-calibrate the immune system after it
has been modulated by diabetes, so the host can respond effectively. It could be in the
form of a non-inappropriate boost to the immune system, or modulation in the middle
of treatment, like neutralising anti-type I IFN antibodies.
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5.5.3 Comments on the study and future work
A large limitation from this study was the sample size. There were too few samples for
each patient group at each time-point. In differential expression studies, this is crucial, so
when there are too few samples, fewer genes are statistically significant. To add to this,
Peru could not be included in the longitudinal study as the samples were not collected
in time. There was a deadline for all samples to be received by LSHTM, as the RNA-seq
experiments were on a tight time line and all the samples had to be processed together
to avoid unwanted batch effects.
The grouping of diabetes patients also proved challenging, particularly in the pre-
diabetes group. Some remained at intermediate HbA1c values at the end of treatment,
whereas some decreased to ’normal’ levels and some increase. The patients whose HbA1c
values lower to normal levels were likely experiencing TB-induced hyperglycaemia, so it
is difficult to understand which patients are truly pre-diabetic when they initially present
in the TB clinic. But, if a patient does experience transient hyperglycaemia, they are
still different from a patient who remains HbA1c < 5.7%, and are at a higher risk of
developing full diabetes later in life. Further work however could unravel the effect of
transient hyperglycaemia and pre-diabetes. But, the addition of more and more groups
runs the risk of losing resolution in the data and reducing the sample numbers in each
group even further.
There were also challenges in analysing longitudinal data. Each time-point sample
was from the same patient, so were highly correlated, and the linear modelling methods
treated each time-point as a separate, independent variable. This is slightly erroneous. It
means the relative variation between two time-points is dulled because as they were from
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the same patient, are already very similar to one another. In repeated measure data, a
mixed model approach is usually taken, which calculates the random effect, to calculate
the added variance between individuals. However, this method is not available in current
differential expression analysis tools.
Firstly, it is important to ascertain in Indonesia whether poor treatment outcomes
refer to a patients clinical symptoms, and if further treatment was taken, as at the
moment, poor treatment outcomes were defined on microbiological culture data. This
would establish whether diabetes led to poor treatment outcomes in Indonesia. Other
work in TANDEM involved investigating the pharmacokinetics of rifampicin and anti-
diabetes drugs. Diabetes patients have been associated with lower concentrations of
rifampicin, which could be associated with higher BMI commonly seen in T2DM patients.
It could simply mean that their TB treatment needs to be weight-based dosing to achieve
the desirable effects. However, these results are yet to be announced, but other drug-drug
interactions need to be considered.
Of course, a study with more sample numbers would be ideal, and validation of the
results of the current RNA-seq project using a larger sample set an alternative, more
high throughput assay, would be logical. This option is currently being investigated by
the TANDEM consortium. There was a plan to analyse a much larger set of samples
(∼800) from the whole cohort using the reverse transcriptase multiplex ligation probe
assay (RT-MLPA) to validate the results of the RNA-seq to dramatically expand this
work, but this has not yet been completed. This would also include more time-points;
month one, month four and month twelve (from South Africa). It would be of value
in order to validate the results so far and unravel mechanisms of susceptibility as more
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intensive points through treatment.
In conclusion we have found that TB/DM and TB preDM patient immune systems
behave differently in response to TB treatment which could be indicative of why diabetes
causes an increase in poor treatment outcomes. The TB treatment signature is more
complex than first considered; it appears different parts of the immune response are
regulated separately which has implications in biosignature development.
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6Final Discussion and Summary
Comorbidities do have an effect on the TB blood transcriptome. HIV coinfection had a
comparatively small effect, and diabetes had a large effect. The distinct TB biosignature
has been well described, and it is still detectable in HIV-positive patients. Diabetes
causes considerable alterations to the TB transcriptome. This is contrary to what I
initially expected, as HIV can be so devastating in TB patients, whereas diabetes is
not notoriously as overwhelming. This is because HIV primarily affects the adaptive
immune response, leaving the innate immune system relatively intact, and ART is very
successful in re-stabilising the adaptive response. On the other hand, diabetes affects
systemic metabolism, inflammation and the innate response, components that influence
the progression and prognosis of TB. Also, the control of diabetes is highly variable
within populations, so even with available treatment, sufficient management is not always
obtained and therefore not curbing these harmful effects.
These differences in TB/DM and TB preDM patients span an increase inflammation
and a decrease in type I IFN responses, which may reflect a mechanism of susceptibility
217
CHAPTER 6. SUMMARY
as diabetes affects the immune response to M. tb. To add, as pre-diabetes patients also
show dramatic differences, this may possibly indicate enhanced susceptibility even before
the clinical diagnosis of diabetes. It demonstrates that this susceptibility occurs even at
intermediate levels of hyperglycaemia, which was not previously considered. Usually these
harmful effects would be apparent at higher levels of hyperglycaemia, so it is debatable
that the threshold for diabetes should be lowered because changes are observed, meaning
the causative means (insulin resistance and chronic inflammation) are present as well.
Analysis of a TB blood signature revealed that the performance increased in DM and
preDM patients, showing biosignatures are still valid in comorbidity patients. What was
particularly surprising was its performance was positively correlated with HbA1c values,
even in TB-only, showing an interesting relationship between inflammation and HbA1c.
Resolution of the biosignature at the end of treatment was confounded by DM and also
preDM, again reiterating the substantial affect even intermediate hyperglycaemia has
on TB infection. Also, a divergence from ’healthy’ at the end of TB treatment could
cause implications in treatment outcome in the form of relapse. HIV coinfection also
partially confounded biosignature resolution (at week 8), however none of these genes
were statistically significant so it is difficult to make a conclusion. Further analysis at
the end of treatment and their treatment outcomes would need to be done, in order
to fully determine whether a treatment response biosignature would still be effective in
HIV-positive patients.
In regards to TB control, it should be recommended that TB patients are screened for
abnormal glycaemia levels, and diabetes and pre-diabetes patients should be more closely
monitored for TB symptoms. There were also differences in diabetes and pre-diabetes
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patients throughout TB treatment. TB/DM patients did not resolve to the same point
as uncomplicated TB patients. This could reflect a susceptibility mechanism of why
diabetes patients are more likely to suffer from poor treatment outcomes. This should be
taken into account when administering TB treatment to comorbidity patients in regards
to length of treatment, prophylaxis or host directed therapy. Host directed therapy is a
more attractive option for TB treatment rather than more antibiotics because of looming
drug resistance. It has been speculated that the anti-diabetes drug metformin has a
potential role here, and these data showed that it exhibits desirable anti-inflammatory
effects in response to M. tb infection.
The type I IFN response was highlighted as aberrant in TB/DM patients and has
been reported as an important component in the control of M. tb. The response elements
and subsequent inducible effects are pleiotropic which reflects in the literature which is
somewhat contradictory; an elevated type I IFN response is pathogenic and is positively
correlated with disease severity,67 but then type I IFNs have also been used as adju-
vant therapy. In these data, inflammation and the type I IFN response do not seem to
correlate, suggesting that they are regulated separately, and showing the downstream
IFN response is different in diabetes. It presents a challenge in unravelling IFNs’ role in
susceptibility.
IFNs are also a potential target of metformin which has been suggested as a candidate
for adjunctive therapy; these data suggest that it has beneficial anti-inflammatory effects
in the context of M. tb. Type I IFN response has been noted as a possible target for host
directed therapy in other studies, namely Mayer-Barber et al. They found that when
an arachidonic acid metabolism modulator, that works by inhibiting type I IFNs, was
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administered to susceptible mice, there was reduced pathology and increased survival.132
To add to the TANDEM data, functional studies would be required to validate the change
in type I IFNs and their inducible genes. Useful work with animal models of TB/DM
to validate biosignatures could be performed. A diabetes mouse model exists, and a
prospective study could be performed where the mice are subsequently infected with
M. tb and blood transcriptome analysis done through time to find a diabetes-associated
correlate of risk. This could then be translated to non-human primates that would give
more insight into TB human pathology.
Microarrays and RNA-seq are both valuable tools in investigating gene expression.
Microarrays are still cheaper and it can be argued the analysis is more reliable as it
is heavily peer-reviewed online and extensively optimised. On the other hand, with
RNA-seq; it is still expensive, the lab work is more laborious and finicky, and there is
no gold standard in the analysis. At each stage of data processing, assumptions need
to be made, and different tools produce slightly different results. For instance, during
alignment, the underlying algorithms of the software are different, in for example how
the reads overlap at exon boundaries. Plus, the data processing needs to be performed
in a cluster which is often impractical. There is a software that requires significantly
less computer memory, but it is more inaccurate.192 However, RNA-seq is able to detect
lower abundance transcripts that would otherwise be removed as background noise, so the
slight consistent changes that are seen in these data may or may not have been detected
if microarrays had been used instead of RNA-seq.
In gene-set and module analysis, the large caveat is it relies on already known gene
associations and known pathways. The analysis tools at the moment are good at re-
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proving existing knowledge, but do not seem to be extending our knowledge about all
the less well characterised genes. This is particularly the case for non-protein coding
genes like long non-coding RNAs (lncRNAs) which are not included in module or gene-
set groups. It means a loss of information that is a potentially crucial layer in biological
regulation, as many lncRNAs and other non-coding RNAs are differentially expressed
(another advantage of RNA-seq over microarray), but it is difficult to characterise and
interpret them appropriately.
So what does this mean for the development of a biosignature? It is still valid as a
treatment efficacy measurement; lack of resolution still correlates with poor treatment
outcomes. But, a single measure of disease risk may not be appropriate as they are
heavily based on up-regulated type I IFN genes. This is also the case in the correlate of
risk which includes type I IFN response genes.76
Moving forward, combining TB treatment response blood transcriptome datasets,
from TANDEM, PanACEA and other published studies, a biomarker signature of TB
treatment response could be developed which could be widely applicable to measure
treatment efficacy and outcome in a wide variety of settings and subjects. Such a biosig-
nature would need to be tested in a phase III clinical trial, with changes in the signature
correlated with treatment outcome and with relapse over a 2-year follow-up period. The
continued presence of an aberrant biosignature at the end of TB treatment might indicate
an increased risk of both relapse and reinfection, particularly in patients with diabetes
comorbidity.
In conclusion, comorbidities do need special consideration in regards to global TB
control in regards to screening and also treatment plans. Further work needs to be done
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to fully understand the susceptibility mechanism, which could then be targeted for host
directed therapy in the future.
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